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Abstract 
Chapter 1 presents a flexible synthesis of (-)-securinine in 18 steps and 16% 
overall isolated yield from the commercially available frvms-4-hydroxy-L-proline. 
Securinine is the major Securinega alkaloid isolated from the Securinega, which has been 
associated with a number of interesting biological activities. The key steps of the 
synthesis include the highly diastereoselective preparation of the spirocyclic a,P-
unsaturated y-lactone intermediate and the intramolecular Heck cyclization to complete 
the tetracyclic skeleton. We anticipate that the synthetic route can be readily modified to 
access other Securinega alkaloids {e.g. norsecurinine). In chapter 2 Acyclic 
Diaminocarbene (ADC) were studied as lignads in various C-C bond formation reactions 
(e.g. Suzuki-Miyaura, Sonogashira and Heck). ADCs are more basic than their 
counterpart NHCs and can be easily synthesized from the formamidinium salt precursors. 
The resulting coupling products obtained in good to excellent yields. Homoallylic 
amines are very useful synthons for numerous biologically active compounds. Chapter 3 
presents facile syntheses of homoallylic amines using an easily executable three 
component system of ketone, ammonia, and allylboronates. The resulting homoallylic 
amines were isolated in good to excellent yields through simple acid-base extraction. 
The crotylation of N-unsubstituted ketimines was also shown to be highly 
diastereoselective. 
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Chapter 1 Asymmetric Total Synthesis of Securinine 
1.1 Introduction 
The total synthesis of natural products has always fascinated synthetic organic 
chemists. Total synthesis plays a crucial role in organic and biological chemistry. 
Natural product chemistry thus stands on the brink of being re-embraced by the 
pharmaceutical community. Historically, the process of synthesizing natural products 
and their analogs has taken many years, a timescale which cannot satisfy the 
requirements of automated pharmaceutical screening. However, the application of 
improved, efficient chemical methods enabling rapid and scalable syntheses of these 
natural medicines (and non-natural analogues with improved efficacy), is now an aim that 
is within the grasp of the organic chemist. The past few decades have witnessed many 
elegant contributions to both the science and art of total synthesis.1"4 Many drugs were 
originally inspired by 'natural products' (i.e. molecules refined by Nature over millions of 
years) which can have potent, specific biological activity against human diseases.5 
Alkaloids are one of the largest components of natural products and often possess 
intereseting biological properties. Hence numerous systematic studies have been directed 
towards the synthesis of alkaloids. Several comprehensive reviews on alkaloid isolation 
and synthesis have been published in recent years.5 
Securinega is a genus of plant under the family Phyllanthaceae, which contains a 
group of about 20 or more structurally interesting alkaloids. Securinine (1) is the major 
Securinega alkaloid. It was the first isolated in 1956 by Ban'kovskii et al6 The 
structural ambiguity of (1) was cleared in 1962 by degradation and spectroscopic studies.7 
The structure of securinine was confirmed by X-ray crystallography in 1965.8 In addition 
to fascinating architecture of the four fused bridged rings, Securinega alkaloids have been 
associated with a number of interesting biological activities. 
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Figure 1.1 Structures of Various Securinega Alkaloids 
1 
(-) - securinine 
O 
allosecurinine 
O 
14 
ent-phyllantidine 
OC2H5 
15-ethoxy-14,15-dihydroallosecurinine 
(-) - norsecurinine (-) - allonorsecurinine 
7 8 
(-) - dihydronorsecurinine viroallosecurinine 
H3CO H3CO,, 
OH 
phyllantidine B 
O 
16 
securitinine 
18 
14,15-epoxynorsecurinine 
19 
secu'amamine A 
3 
phyllantine nirurine suffruticosine bicuculine 
1.1.1 Biological Studies 
The plant, securigena suffruticosa, from which the alkaloid securinine (1) has 
been isolated, was considered to be one of the fifty basic medical plants in Chinese folk 
medicine. It has been used for the treatment of many disorders such as rheumatic 
disorders, quadriplegia, paralysis following infectious disease, and psychiatric disorders. 
Later western medicine began to be interested in securinine and it was mentioned as a 
drug for the first time in the 10th Russian Pharmacopoeia in 1968.10 In Russia, securinine 
was popular as a CNS stimulant due to possessing similar effects as strychnine after i.p. 
or i.v. injections (i.e. clonic-tonic convulsions). However, research proved that both 
drugs have different pharmacological profiles as securinine antagonized the meprobamate 
and pentobarbitone induced loss of righting reflex in mice whereas strychnine had no 
effect in those cases. Securinine was also up to 20-fold weaker than strychnine in the test 
of antagonization of inhibition of flexor response induced by mephenesin, meprobamate, 
and urethane in rabbits.11 As the registration for securinine as a drug has already expired 
in Russia, currently the alkaloid is distributed through the Internet as a remedy for 
impotence, and this is the only current known use of securinine. 
In 1970s, there were also some limited use of securinine in the treatment of 
amyotropic lateral sclerosis (ALS) and chronicaplastic anemia in many parts of the world. 
However these approaches were only supported by scant clinical evidence, and were not 
followed by any rigorous clinical trials.'' 
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Despite the popularity of securinine as a CNS stimulant in Russia, the exact 
mechanism of its activity remained undiscovered until 1984 when Beutler et al. described 
(1) as a GABA competitive antagonist, with selective binding to the subtype-A GABA in 
a mammalian brain and spinal cord.12 Studies were conducted to compare convulsant 
activity and GABA receptor binding activity of securinine (1) with bicuculine (23) 
(another GABA receptor antagonist). Securinine, like bicuculine, contains both a lactone 
and a tertiary amine functional group. In addition, other alkaloids such as allosecurinine 
(2) (C-2 isomer of securinine), virosecurinine (6) (optical antipode), and 
dihydrosecurinine (5) (reduced analog of securinine) were studied. In the equilibrium 
binding assays, they found that these natural products inhibit GABA binding to rat brain 
membrane.12 The following results were reported as shown in Table 1.1: 
Table 1.1 Evaluation of the Effects of Securinine Alkaloids on GABA and GABA-
activated Benzodiazepine Binding and on Seizure Threshold 
Alkaloids 
Bicuculine (23) 
Securinine (1) 
Dihydrosecurinine (5) 
Allosecurinine (2) 
Virosecurinine (6) 
Receptor binding IC50 (MM> 
GABA binding 
7 ±0.4 
57 ± 7 
49 ±8 
>1000 
>1000 
GABA-activated 
benzodiazepine 
9 ± 1 
101 ±22 
79 ± 18 
Convulsant activity 
(CD50, mg/kg) 
8 ± 4 
28 ± 3 
11 ± 0.4 
39 ± 5 
87 ± 7 
It can be seen from the table that bicuculine inhibited GABA binding by 50% 
(IC50) at a concentration of 10 uM.12 The IC50 value for both securinine and 
dihydrosecurinine were found to be approximately 50 uM, while allosecurinine and 
virosecurinine were very weak in GABA binding with a value of more than 1 uM. A 
5 
similar study was done with the GABA-activated benzodiazepine receptor where 
bicuculine was more active as an inhibitor. Table 1.1 also shows the convulsant activity 
of other alkaloids. In these experiments, they found that bicuculine and dihyrosecurinine 
were most potent convulsant having CD5o values of 8 and 11 mg/kg respectively. 
Securinine and allosecurinine were found to be much weaker convulsant than 
dihydrosecurinine with virosecurinine being the least potent convulsant. It was 
previously assumed that securinine was a glycine receptor inhibitor but when it reversed 
the inhibitory effect of GABA on spinal neurons isolated from cat spinal cord, it was 
clear that securinine had no effect on the glycine receptor. Securinine-induced 
convulsion was blocked by diazepam, muscimol, and pentobarbital in mice, while 
beclofen showed no protection up to the lethal dose. These effects suggested that the 
GABA receptor could be the target of securinine's biological activity, specifically to the 
GABAA receptor. Other research also proved that GABA could antagonize convulsions 
induced by picrotoxin, but had no effect in those caused by securinine.13 Only the 
combination of GABA and diazepam inhibited securinine-induced seizure, but neither of 
them alone had any effect.13 There are also some reports that showed that securinine was 
inactive as an inhibitor of benzodiazepines, cholinergic muscarinic, and P-adrenergic 
receptor binding.12 In general, due to its specificity for GABAA receptor and various 
other advantages over bicuculine (e.g., securinine salts are very soluble in aqueous media; 
are stable at various physiological pH; and are easily able to cross the blood brain 
barrier), securinine could be useful substance for electrophysiological and biochemical 
examination of the GABA receptor.12 
There are also several isolated reports showing that securinine facilitates learning 
and memory, and improves alcohol induced amnesia by enhancing the amplitude of the 
population spike and inducing long term potentiation in the dentate gyrus of anesthetized 
rats.14 
In addition to acting as a convulsant, securinine demonstrates antibacterial15 and 
antimalarial activities. Research has revealed that securinine also induces Toll-like 
receptor (TLR) independent macrophage activation in vitro and in vivo against Coxiella 
burnetii, leading to interleukin-8 secrection, L-selectin down regulation and CD lib and 
6 
10,17 MHC Class II antigen up-regulation. ' Although the securinine alkaloid has similar 
effects as a TLR agonist, it does not act through known TLRs.17 
1.1.2 Previous Synthetic Studies on Securinine 
Due to the demonstration of important aforementioned 
biological/pharmacological/medicinal properties, many research groups have focused 
their attention on the total synthesis of the Securinega family alkaloids.18"22 These groups 
have also focused on the development of new synthetic technologies to overcome 
difficulties in their synthetic preparation. Securinega alkaloids contain a fused tetracyclic 
structure formed by a piperidine or pyrrolidine (ring A), an a,P-butenolide y-lactone (ring 
D), and a 6-azabicyclo[3.2.1]-octane (rings B and C). The size of ring A distinguishes 
the securigena alkaloids into two main groups: securinine and norsecurinine-like (Figure 
1.2). 
Figure 1.2 Ring Labeling of (-)-Securinine and (-)-Norsecurinine 
securinine (-) norsecurinine 
The first, nonstereoselective, low-yielding total synthesis of racemic securinine 
was reported by Horii and coworkers in 1966.18 Despite the impressive range of 
biological activities of Securinega alkaloids, there were no further reports of synthetic 
studies until 1983, when Heathcock et al. described the first total synthesis of 
norsecurinine. However, several other syntheses of racemic securinine have appeared 
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recently20 as well as the total syntheses of the natural enantiomer of (1) by Honda et al. 
and de March and coworkers.21'22 
In 2001, Spiros Liras et al. from Pfizer Global Research and Development 
reported the total synthesis of (±)-Securinine from silyloxyfuran (27). Liras' 
retrosynthetic analysis for racemic 1 is shown in Scheme 1.1. 
Scheme 1.1 Retrosynthetic Strategy of (±)-Securinine by Liras et al ,20a 
£ £ 
24 
: > 
A butenolide-intermediate would be synthesized by a stereoselective addition of 
silyloxyfuran (27) to an in situ generated iminium ion from substrate (26). The resulting 
product would be transformed to intermediate (25) via the 1,4 addition of allyl phenyl 
sulfoxide. Intermediate (25) would then undergo ring closing metathesis and subsequent 
installation of the butenolide double bond to yield compound (24). An amino-cyclization 
reaction of a dibromide intermediate stemming from compound (24) would then lead to 
the total synthesis of securinine. 
A detailed summary of Liras' approach is presented in Scheme 1.2. The allylation 
of commercially available silyloxyfuran (28), using BuLi and TMEDA at 0 °C in heptane 
followed by addition of allyl bromide afforded 5-allyl siloxyfuran (27). 
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Scheme 1.2 Total Synthesis of (±)-Securinine by Liras et al 20a 
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(a) sec-BuLi, TMEDA, allyl bromide, THF, 0 °C, 82%;(b) TIPSOTf, heptane, -78 °C, 78%; (c) Allyl 
phenyl sulfoxide, LiHMDS, THF, -78 to -45 °C, 71%; (d) Grubbs' 1st generation catalyst, C1CH2CH2C1, 70 
°C, 79%; (e) LiHMDS, THF, phenylselenylbromide, -78 °C to rt; (f) H202, dichloromethane, 0 °C, 43% for 
steps e and f; (g) TFA, CH2C12; (h) Br2, CHC13, -10 °C to rt; (i) K2C03, DMF, 70 °C, 78% for steps g-i. 
Reaction of 5-allyl siloxy furan (27) with an in situ generated iminium ion from 
substrate (26) using 0.1 equiv of TIPSOTf gave substrates 29 and 30 at -78 °C. This 
mixture was separated by flash chromatography affording 29 as the major product in 
62.5% yield. The compound 29 was converted to substrate 25 for subsequent ring 
closing metathesis via the 1,4-addition of the anion of allyl phenyl sulfoxide in 71 % 
yield. With compound 25 in hand RCM was performed using a full equivalent of 
Grubbs' first generation catalyst in refluxing 1,2-dichloroethane giving 31 in 79% yield. 
The next transformation in the synthetic pathway was the introduction of the butenolide 
double bond, which was carried out by treating 31 with LiHMDS and 
9 
phenylselenylbromide in THF at -78 °C. This was followed by oxidative elimination of 
an intermediate phenylselenide under the influence of H2O2 in dichloromethane at 0 °C 
providing 24 in 43% overall yield. The Boc protecting group was then removed and 
selective bromination of the nonconjugated olefin and finally tandem cyclization-
dehydrohalogenation using K2CO3 in DMF afforded racemic securinine (1) in 78% yield 
for the final three steps. Key steps of the synthesis included a stereoselective addition of 
a silyloxyfuran to an iminium ion, a stereoselective 1,4 addition of phenyl allyl sulfoxide 
to a butenolide moiety, and a novel ring closing metathesis reaction. 
In 2004, Honda and coworkers reported the first diastereoselective synthesis of 
(-)-securinine (1) from (+)-pipecolinic acid.21 The pre-existing stereocenter in piperidine 
derivative 34 influenced the formation of the quaternary carbon center of (-)-securinine as 
shown in Scheme 1.3. 3-(Z)-butenylmagnesium bromide then reacted with thioester 34 
to afford ketone 35 in 90% yield in THF at 0 °C. Tertiary alcohol 36 was subsequently 
synthesized by alkynylation of ketone 35 with lithium trimethylsilylacetylide in the 
presence of a stoichiometric amount of cerium(III) chloride. The addition of lithium 
trimethylsilylacetylide reagent occurred mainly on the si face of the ketone. The addition 
followed the Felkin-Anh model which showed a clear steric hindrance towards attack on 
the re face due to the orientation of the Boc group. Deprotection of the TMS group of 36 
followed by the O-allylation of 37 with allyl trichloroacetimidate gave the needed allyl 
ether 38 in 76% yield. Allyl ether 38 was then subjected to the tandem RCM with the 
highly active ruthenium catalyst 4124 in CH2CI2 at room temperature affording the 
cyclized compound 39 in 74% yield. The tandem RCM afforded the A, C, and D rings of 
securinine. The allylic position of diene 39 was subsequently oxidized with chromium 
trioxide and 3,5-dimethylpyrazole at -20 °C to provide lactone 40. Allylic bromination of 
40 was then effected with NBS and AIBN followed by removal of the protecting group 
with TFA and subsequent cyclization of the resulting amino bromide with potassium 
carbonate furnished (-)-securinine (1). The RCM reaction on a dienyne intermediate 38 
is the key step in the reported synthesis. The synthesis took 11 steps to complete with 
overall yield of 16.5%. 
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Scheme 1.3 Diastereoselective Chiral Synthesis of (-)-Securinine by Honda and 
coworkers 21 
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41 
(a) (Z)-3-hexenylmagnesium bromide.THF, 0 °C, 90%; (b) n-BuLi, CeCl3, trimethylsilylacetylene, THF -
78 °C, 97%; (c) TBAF, THF, 0 °C, quantitative; (d) CH2=CHCH20C(=NH)CC13, TfOH, CH2C12, rt, 76%; 
(e) catalyst 41, CH2C12, rt, 74%; (f) Cr03, 3,5-dimethylpyrazole, CH2C12, -20 °C, 77%; (g) NBS, AIBN, 
CCU, reflux; (h) TFA, CH2C12, rt; (i) K2C03, THF, 45% for steps g-i. 
The total synthesis of securinine and (-)-allonorsecurinine by Pedro de March and 
coworkers also appeared in 2004 as shown in Scheme 1.4 and utilized a similar strategy 
of Honda et al. {vide supra) to construct the ring D using ring closing metathesis (RCM) 
as the key C-C bond forming steps.22 The researchers started with the previously known 
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aldehyde 43 , synthesized from (i?)-(-)-JV-tert-butoxycarbonyl pipecolinic acid (42). 
Addition of the Grignard reagent 44 at -78 °C in THF to aldehyde 43 afforded the 
racemic alcohol 45 with 82% yield. Subsequent oxidation using Dess-Martin periodinane 
produced ketone 46 in 81 % yield. Addition of vinylmagnesium bromide and subsequent 
quenching of intermediate alkoxide with acryloyl chloride gave an inseparable mixture of 
acrylates 47 in a 6:1 diastereomeric ratio and overall yield of 57%. The stereochemistry 
of 47 was confirmed later on in the synthesis (i.e., the addition of the Grignard reagent 
occurred mainly on the re face of the piperidinyl ketone). The mode of addition follows 
the Felkin-Anh model for 46, in which the molecular models show a clear steric 
hindrance of the Boc group blocking attack on the si face. 
The mixture of aery late 47 was then subjected to ring closing metathesis (RCM) 
using Grubbs' 2n generation catalyst to afford mixture of butenolides 48 in 78% yield. 
The next important step for construction of the C ring was deprotection of cyclic acetal 
using DDQ and subsequent conversion of aldehyde to (Z)-iodoolefins using Wittig 
conditions, which gave 49 in 35% yield. At this stage, the diastereomers were separated 
with the more polar major product being obtained in 28% yield. The absolute 
configuration of major diastereomer could not confirmed at this stage using nOe (Nuclear 
Overhauser Effect) experiments, but it was later assigned as (2R,2S) according to the 
synthesized natural product. The product 49 then underwent intramolecular Heck 
reaction to afford tricyclic compound 50. Finally, the total synthesis of the securinine 
alkaloid was achieved by sequential allylic bromination of 50, removal of the Boc group, 
and basic treatment with potassium carbonate - a series of steps that were very similar to 
those reported by Honda et al. which yielded securinine, (1), in an overall yield of 2.5% 
(after total of 13 steps). 
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Scheme 1.4 Total Synthesis of Securinine by Pedro de March et al. 
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(a) BH3-THF, rt, 20 h, 96%; (b) Dess-Martin reagent, CH2C12, rt, 3 h, 76%; (c) THF -78 °C to rt, 14 h, 
82%; (d) Dess-Martin reagent, CH2C12, rt, 1 h, 81%; (e) BrMgCH=CH2, THF -40 to rt, 3.5 h; (f) 
C1C0CH=CH2 THF, rt, 1.5 h, 57%; (g) Grubb's 2nd generation catalyst, reflux, CH2C12, 10 h, 78%; (h) 
DDQ, CH3CN-H20, rt, 3 days; (i) Ph3P=CHI, THF -78, 2 h, 35%; 0) PdCl2(PPh3)2, DMF, 90 °C, 14 h, 
78%; (k) NBS, CC14, Reflux, 45 min; (1) TFA, CHC13, rt, 14 h; (m) K2C03, rt, 30 min, 53%. 
Weinreb and coworkers have also synthesized three securinega alkaloids, 
differing in the A ring size and functionality, from enantiopure 4-trans-hydroxy proline. 26 
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The synthesis was executed such that the common C and D rings were annulated 
first, allowing the manipulation of the A ring at a later stage in synthesis. First trans-4-
hydroxy-L-proline (51) was converted to ester sulfonamide (52) without any difficulty.27 
The secondary alcohol functionally was then protected as the TBS ether using TBSC1 in 
dichloromethane in 88% chemical yield. The ester was then completely reduced by 
DIBAL-H to the corresponding alcohol in 98% yield. The primary alcohol was subjected 
to Swern oxidation condition to afford aldehyde which was immediately subjected to 
Wittig reaction to give a,|3-unsaturated nitrile (53) as a mixture of E/Z isomers (E/Z 1:2). 
The isomeric ratio of the alkene at this stage was not an important issue considering the 
subsequent reduction of functionality using catalytic hydrogenation, which went in 98% 
yield using 1 atm hydrogen on 10% Pd/C. The TBS ether was then removed using 
B114NF in THF in almost quantitative yield. The secondary alcohol was subsequently 
oxidized by Jones reagent to afford the ketonitrile (54) in overall high yield. According 
to the procedure described by Wolfe et al, ketonitrile (54) was subjected to samarium 
diiodide followed by acidic hydrolysis, in order to effect cyclization to afford azabicyclic 
a-hydroxyketone (55) in 78% yield.28 
A series of protection and deprotection reactions were then performed in order to 
get desired derivative 59. Although these set of reaction were high yielding they did 
however lengthen the route to the desired securinine derivates. Compound 59 was 
reacted with NaNC^'HCl and CuCh in MeOH to effect a-oxidation. The actual result 
turned out messy and was poor yielding. However the mixture of (60a) and (60b) both 
subsequently generated N-acyliminium ions in the presence of BF3#Et20, which upon 
reaction with excess allylmagnesium bromide afforded the allylated product 61 as the de-
benzoylated derivative. The authors reported the simultaneous removal of the benzoyl 
protecting group, but the next step in the synthesis was the protection of free 2° amine 
with a Boc group. The alkene in 62 was then subjected to hydroboration followed by 
oxidation of the resulting organoboron derivative and finally tosylation of the primary 
alcohol to afford compound 63. Treatment of 63 with HC1 removed the Boc group, 
which led to in situ cyclization to tricyclic derivative 64. The removal of TBS and ketal 
groups from 64 then afforded tricyclic intermediate 65. Treatment of 65 with PhSeCl 
gave undesired product 66 in 60% yield.29 
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Scheme 1.5 Towards the Total Synthesis of (-)-Norsecurinine by Weinreb et al26 
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(a) TBSC1, imid., CH2C12, 88%; (b) DIBAL-H, PhMe, -78 °C to rt, 98%; (c) DMSO, (COCl)2, NEt3, 
CH2C12, -78°C/Ph3P=CHCN, CH2C12, -78 °C to rt, 90%; (d) 1 atm H2, 10% Pd/C, EtOAc, 98%; (e) Bu4NF, 
THF, rt, 100%; (f) Jones reagent, Me2CO, rt, 84%; (g) Sml2, MeOH, THF, -78 °C to rt; then H30+, 78%; 
(h) TBSOTf, i-Pr2NEt, CH2C12, 0 °C to rt, 91%; (i) (CH2OH)2, p-TsOH, PhH, A, 100%; (j) Na, naphthalene, 
DME, -78 °C; (k) isatoic anhydride, DMAP, MeCN, rt, 87% from 57; (1) NaN02, HCl, CuCl2, (100 mol 
%), MeOH, rt; (m) allylmagnesium bromide, BF3-Et20, THF, -78 to 0 °C; (n) (Boc)20, NEt3) CH2C12, 
reflux, 68% from 60; (o) disiamyl borane, THF, 0 °C to rt/H202, NaOH; (p) TsCl, DMAP, NEt3, CH2C12, 
71% from 62; (q) 0.8 N HCl, MeOH, 60 °C, 81%; (r) 3 N aqueous HCl, 95 °C, 74%. 
The final steps of the synthesis included the esterification of tricyclic selenide 
alcohol (66) with commercially available diethylphosphonoacetic acid to produce 
phosphonate (67) in high yield. The reaction of (67) with potassium carbonate/18-crown-
6 in toluene led to an efficient intramolecular Wadsworth-Horner-Emmons cyclization 
affording y butenolide (68) in 95% yield. In order to finish the total synthesis a selenide 
oxidation/elimination sequence were performed. The oxidation of the mixture of 
selenides (68) with dimethyldioxirane at -78 °C produced (-)-norsecurinine (3) in a 
moderate 39% yield. 
Scheme 1.6 The Completion of Total Synthesis of (-)-Norsecurinine by Weinreb et al 26 
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(s) PhSeCl, NEt3, EtOAc, reflux 60%; (t) (EtO)2POCH2C02H, CDC, CH2C12, 88%; (u) K2C03, 18-C-6, 
PhMe, 95%; (v) DMDO, Me2CO, CH2C12, -78 °C, 39%. 
Ph3P=C=C=0 \ N T ^ . 
12kbar, P h M e * H O \ T Equation 1.1 
CH2CI2, 89% V ^ 
O 
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Weinreb has also successfully synthesized other securinega alkaloid such as (-)-
dihydronorsecurinine (Equation l.l).30 
T 1 
Kerr et al. very recently reported total synthesis of (-)-Allosecurinine , whose 
biological properties have not been investigated in detail. They started the synthesis with 
the construction of ring B, using their previous methodology that allowed for easy 
construction of both 2,5-cis-substituted and 2,5-trans-substituted pyrrolidines (Scheme 
1.7).32 
Cyclopropane 69 was synthesized via a series of transformations from 
commercially available homoallylic alcohol.31 Ethanolic hydrazine easily deprotected 
cyclopropane 69 in order to get free cyclopropane 70. Ytterbium triflate mediated 
cyclization afforded the isoxazole framework, which upon reaction with aldehyde 71, 
lead to the construction of 2,5-cis pyrroloisoxazolidine 72 in excellent yield (88%). 
Pyrroloisoxazolidine 72 was then easily reduced with hydrogen and Pd(OH)2/C 
(Pearlman's catalyst). The resulting free amine was protected using di-tert-
butyldicarbonate to provide 2,5-c/5,-substituted pyrrolidine 73 in 85% yield, which was 
then subjected to Krapcho decarboxylation in order to produce the required monoester 
74a. Alternatively, microwave irradiation also lead to the formation of monoacid 74b 
which upon reaction with TMSCHN2 gave monoester 74a. The primary alcohol in 
pyrrolidine derivative 75 was then subjected to dehydration through the use of a 
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procedure by Grieco (i.e. treatment with o-nitrophenylselenocyanate and B113P followed 
by oxidation with hydrogen peroxide) to provide the required alkene 75.33 
The next step in the synthesis involved the deprotonation of 75 by KHMDS at -78 
°C and treatment of the resulting enolate 76 with Davis' oxaziridine to afford an 
intermediate a-hydroxy ester. The ester was reduced with NaBPLi in the presence of 
CaCh to provide diol 77. Diol 77 was then subjected to oxidation by IBX to provide 
aldehyde 78. Vinylmagnesium bromide was subsequetly added to 78 to yield the 
corresponding allylic alcohols as a mixture of diastereomers, which were oxidized with 
IBX in DMSO to afford <x,P unsaturated ketone 79. 
The final steps of the synthesis were to form the requisite y-lactone by 
intramolecular Horner-Emmons (HE) reaction. Ketone 79 was converted to phosponate 
80 by reaction with diethylphosphonoacetic acid and DCC. Phosphonate 80 was easily 
cyclized via the Horner-Emmons reaction to afford y-lactone 81. Butenolide 81 was taken 
further without purification due to its instability on silica gel. In the next reaction the 
Hoveyda-Grubbs' 2nd generation catalyst was used to effect RCM and afford 82 in 40% 
yield. At this stage the researchers had synthesized the B, C, and D ring framework of 
allosecurinine. All that remained at was to construct the remaining ring A. Towards this 
end, the PMB group in 82 was deprotected with DDQ and converted to corresponding 
mesylate derivative 83. The Boc protecting group in 83 was then removed by TFA in 
CH2CI2 which resulted in cyclization to afford allosecurinine (2) in 65% yield. The 
synthesis took 15 steps from homochiral cyclopropane 69 to complete in an overall yield 
of 5%. 
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Scheme 1.7 Total Synthesis of (-)-Allosecurinine by Leduc and Kerr 31 
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a) hydrazine hydrate, 3:1 EtOH/CH2Cl2 ; b) ytterbium(III) trifluoromethanesulfonate hydrate (5 mol%), 
CH2C12, 30 min, then aldehyde 71 (88%); c) Pd(OH)2/C (30 wt%), Boc20, H2, MeOH (85%); d) NaCN, wet 
DMSO, 140 °C, 12 min.; e) TMSCHN2, 2:1 benzene/MeOH (86% from 73 and re-esterified 74b); f) Bu3P, 
o-nitrophenylselenocyanate, THF then H202, THF (94%, 2 steps); g) KHMDS, THF, -78 °C, 1.5 h then 
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Davis oxaziridine 76, -78 °C; h) CaCl2, NaBH4, 1:1 THF/EtOH (73%, 2 steps); i) IBX, DMSO (86%); j) 
vinylmagnesium bromide, THF, 0 °C-+rt (76%); k) IBX, DMSO (69%); 1) DCC, diethylphosphonoacetic 
acid, CH2C12 (90%); m) LiBr, NEt3, THF; n) Hoveyda-Grubbs' 2nd generation catalyst, THF, reflux (40%, 
2 steps); o) DDQ, 9:1 CH2C12/H20; p) MsCl, NEt3, THF (83%, 2 steps); q) TFA/CH2C12 then silica 
gel/acetone (65%). 
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1.2 Results and Discussion 
1.2.1 Retrosynthesis and an Early Approach 
Our original retrosynthetic approach to (-)-securinine (1) consisted of two key 
steps: (i) an intramolecular Heck cyclization to construct the C ring, 4 and (ii) addition of 
functionalized boronates to N-acyliminium ions based on the methodology developed by 
Batey et al. to form Ring A.35 
Scheme 1.8 First-generation Retrosynthetic Approach of (-)-Securinine 
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Compound 84 could theoretically be accessed by the spontaneous intramolecular 
lactonization of 85 upon workup of the Grignard addition on indolizinone 86, which will 
be derived from aminal 87. The aminal 87 would in turn be synthesized from L-hydroxy 
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proline (51). The A ring would be synthesized via the addition of functionalized boronic 
ester 88 to the N-acyliminium ion generated from 87, followed by hydrogenation of the 
alkene and subsequent cyclization. The hydrogenation and cyclization steps could 
conceivably occur in the same pot and is based on previous precedence from Batey's 
work.35 It was also envisioned that the addition of the appropriate boronate to N-
acyliminium species could also lead to the synthesis of (-)-norsecurinine (3) and 
phyllanthine (20). The overall route for the synthesis hinges on the flexibility of 
introducing the A ring in the skeleton. A proposed synthesis of (-)-securinine (1) in a 
forward direction using the above approach is shown in Scheme 1.9. 
Scheme 1.9 Proposed Synthesis of Securinine 
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The proposed synthesis would start with the known hydroxyl proline derivative 
90, which would then subject to anodic oxidation in the presence of MeOH to afford 
T O 
functionalized aminal 91. The stereoselective addition of boronate 92 to the N-
acyliminium species derived from aminal 91 would then be expected to lead to alkene 
93.35 The addition of the boronate could be directed by the hydroxyl group at the C-9 
position thereby setting the relative stereochemistry at C-2.35 Subsequent hydrogenation 
of alkene 93 with concomitant deprotection of the CBZ protecting group should lead to 
free 2° amine 94. The amine should then displace the tosyl leaving group, thereby 
forming the AB ring system in intermediate 95. The subsequent hydrogenation and 
cyclization steps could be carried out in the same vessel. 5 The ester moiety in 95 would 
then be reduced by DIBAL to the corresponding aldehyde and immediately subjected to a 
Wittig reaction to form Z-bromo alkene as the predominant diastereomer.40 Protection of 
the free hydroxy group in 95 should not be necessary based on prior precedent in the 
literature.41 At this stage, the free alcohol would be oxidized up to ketone 86 with the 
Dess Martin reagent. Subsequent reaction of 86 with a stoichiometric amount of 
functionalized Grignard reagent 96 should afford the corresponding 3° alcohol.42 The 
addition of the Grignard reagent is expected to occur from the more accessible convex 
face of the molecule leading to the desired stereochemistry at C-9. The synthesis of the 
functionalized Grignard reagent 96 from the corresponding cis-alkenyl bromide 99 is 
based on the extensive work from the Knochel group (Equation 1.2).42'43 
/ = \ /PrMgBr
 / = N 
B / C02Me *- BrMg7 C02Me Equation 1.2 
99 96 
The (Z)-alkenyl bromide functionality in 86 would not be expected to interfere 
with the Grignard addition step as such functionalized Grignard reagents were known to 
compatible with aryl halides present elsewhere in the reactive species. '44 Intramolecular 
lactonization of 97 was expected to occur spontaneously upon workup of the Grignard 
addition step. Should this not occur, the mixture would be treated with a base (e.g. NaH) 
to effect the lactonization to spirocyclic compound 98. Advanced intermediate 98, in 
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which then D-ring is established, would then set for the pivotal and last step in the 
proposed total synthesis: the intramolecular Heck cyclization.34'45 A successful reaction 
would directly provide the desired natural product (-)-securinine (1), thus completing the 
total synthesis. 
Examining possible routes towards synthesis of securinine (1), we settled on an 
approach starting from commercially available trans 4-hydroxy L-proline (51).36 The use 
of 51 satisfied two conditions simultaneously: it is cheap, and commercially available 
with the required stereochemistry at position C-2. Thus, esterification using methanol 
and thionyl chloride gave 4-hydroxy L-proline methyl ester hydrochloride 100 in 
quantative yield, which on reaction with benzyl chloroformate led to carbobenzyloxy 
protected derivative 90. The free 2° alcohol in 90 was then subsequently protected with 
TBSC1 to get compound 101 (Scheme 1.10). 
Scheme 1.10 Synthesis of Cbz-protected Proline Derivative (101) 
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The choice of the Cbz protecting group was based on the previous study of anodic 
oxidation of proline derivatives in the presence of MeOH. In 1985, Shono et al. reported 
that proline derivatives 102 (including many other carbamates) can be electrochemically 
oxidized in methanol in a regioselective manner to provide the corresponding a-
methoxycarbamates 103 (Equation 1.3). 
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CN/^C02Me 
-2e 
Cbz 
102 
MeOH 
78-83% 
\ - N / » < \ / " ^ M e O " ^ N / ^ c 0 2 M e Equation 1.3 
Cbz 
103 
However Barrett et al. also discovered that anodic oxidations of proline 
derivatives with substituents at carbon number 4 can be challenging.38 They speculated 
that poor yields were caused by the methanolysis of acetate (R3 = Ac)38 (Table 1.2). 
Table 1.2 Results Obtained by Electrolysis of 4-Substituted Proline Derivatives by 
Barrett et al. 
R3Q 
W 2 
5 - N p C 0 2 R 2 
C02R1 104 
-2e 
MeOH 
RJQ 
MeO •^. .^"•COoR2 N ^ 
C02R1 
105 
Entry 
1 
2 
3 
4 
5 
6 
R1 
Bn 
Bn 
Bn 
Bn 
Bn 
2-TMS-Et 
R1 
Bn 
Bn 
Bn 
Me 
Me 
Me 
R3 
Ac 
Piv 
Me 
Ac 
Ac 
Ac 
Yield (%) 
<5 
<10 
<5 
<19 
52 
66 
Barrett et al. theorized the cause of the low yields of some examples shown in 
Table 1.2 as due to the sensitivity of anodic oxidation at the electrode surface due to 
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steric hindrance. In case of entry 6, oxidation of 104 with a sterically less demanding 
carbamate groups (R ) gave a good chemical yield of 66%. 
Unfortunately, our attempts at oxidizing hydroxyl proline derivative 101 under 
Barrett's conditions were completely unsuccessful (Equation 1.4). Despite numerous 
attempts at modifying the reaction condition, we did not detect any of the desired 
products in the crude reaction mixture. 
TBSO^ TBSC\ 
C N > - C 0 2 M e < ] > < ^ » M e O ^ N ^ C 0 2 M e Equation 1.4 
Cbz M e 0 H Cbz 
101 106 
In view of the aforementioned failure, we decided to introduce the a-methoxy 
group chemically following a procedure reported by Xiaojun Zhang and collegues.39 4-
Hydroxypyrrolidine methyl ester 100 was converted to N-Boc pyrrolidine methyester 107 
and subsequent protection of the free secondary alcohol using TBSC1 afforded N-Boc 
protected proline derivative 108. 
HO,
 R n r „ n HO, TBSQ, 
r~\ B N V A TBSC1, r\ 
C/^COzMe ~ *- C M >^C0 2 Me i m i d a z o l e » l > ^ C 0 2 M e Equation 1.5 
H-HCI EtOAc 1 DMF, 7 
rt, 4 h Boc rt 14 h Boc 
Compound 108 was then subjected to oxidation with R11O2 (10 mol %) and NaIC>4 
(250 mol %) in ethyl acetate/water (2:1) at room temperature. In our initial attempt, 
R.UO2 black was mistakenly used instead of hydrated ruthenium (RUO2H2O). The other 
problem we discovered was that the NaI04 needed to be added portion wise and vigorous 
stirring was required. Fortunately, this problem proved relatively easy to avoid by 
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performing the reaction within an oversized flask (under nitrogen atmosphere) to increase 
the surface area and the vigorous stirring enabled the catalyst to remain in its active, 
oxidized form. The resulting amide 109 was reduced using LiBHEt3 to form aminal 110. 
110 was then converted to either methoxy derivative 111 or acetoxy derivative 112. 
Scheme 1.11 Synthesis of Methoxy and Acetoxy Derivative from Boc-protected Proline 
Derivative 
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_ ^ O' & N 
Boc 
109 
CQ2Me 
TBSO^ 
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LiBEt3H 
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HO N 
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Boc 
110 
C0 2 Me 
TBSO,, 
MeO N 
i 
Boc 
111 
C02Me 
pTsOH 
MeOH, rt, 16h 
i 
80% 
TBSO, i)(CH3CO)20 TBSO,, 
ii)Et3N 
H O ' -N ' C ° 2 M e CH 2 C l 2 , r t ,8h A c 0 
.XX 
Boc 
110 
87% 
over two steps 
^ J < ^ / " " » i 
N 
i 
Boc 
112 
C0 2Me 
The next proposed step in the synthesis was stereoselective addition of the alkenyl 
boronate to the iV-acyliminium ion 111 or 112. Nucleophilic additions of carbon-based 
nucleophiles to ./V-acyliminium ions have been well studied. In 1999, Batey et al. 
reported the additions of organoboronic acids or esters to iV-acyliminium ions. 5 The use 
of boronic acids or ester derivatives as nucleophiles have gained interest due to their 
enhanced stability in air and water. 
OH 
.—/ BF3-Et20, CH2CI2 
^ N 0 H -78 °C 82% 
Cbz 
113 OTBS 
114 
115 
i) p-TsCI, 
Et3N, Py ^ 
ii) H2, Pd/C, 
EtOH 40 °C 
Equation 1.6 
116 
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For example, Batey et al. showed that when diol 113 was treated with TBS-
protected boronic ester 114 and BF3-Et20, product 115 was obtained in 82% yield with 
attendant deprotection of the TBS group. The reaction most likely proceeds through an 
N-acyliminium ion. The boronate addition product was then subsequently converted to a 
fungal metabolite (li?*,8aR*)-l-hydroxyindolizidine 116 (Equation 1.6). 
In a similar manner, we anticipated that the stereoselective addition of boronate 
114 to the N-acyliminium species derived from aminal 111 would then be expected to 
lead to alkene 117 as the major addition product (Equation 1.7). 
TBSC\ BF3.Et20 CH2CI2 TBSO, 
M e O ^ K i ^ C O z M e ^ ~78 ° C H O ^ ^ ^ 5 ^ N C 0 2 M e E t J u a t i o n 1 - 7 
Boc \ A ^ B o c 
Not detected 
111 117 
The reaction did not work as anticipated despite many attempts. The likely reason 
for the failure is the presence of TBS protecting group. The lack of success forced us to 
change the strategy to construct ring A. An alternate construction of ring A by ring 
closing metathesis (RCM) was now envisaged. In the case of securinine, ring A is 6-
membered and in case of norsecurinine ring A is 5-membered. Construction of 6-
member rings via RCM could potentially require two allylic functionalities at C-5 and at 
N-l. A possible alternative is a homoallylic group at C-5 and a vinyl group at N-l (or 
vice versa). Towards this end, the Boc protecting group in 108 was easily removed 
simply by treatment with TFA at 0 °C in 77% yield. N-allylation was achieved by allyl 
bromide and triethylamine in DMF as shown in Scheme 1.12. 
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Scheme 1.12 Towards the Synthesis of Ring A of (-)-Securinine 
TBSOM 3 TBSO,, TBSO,, 
5 l . i . ^C0 2 Me J ^ , » C.. /^C02Me — *~ C.. /^C02Me 
N 2 CH2CI2 N E t 3 N N 
Boc 0 °C to rt DMF 
72 % 79% 
108 118 119 
Allylation at the C-5 of N-allylated derivatives was subsequently envisioned via 
preliminary chemical oxidation using Ru02. The oxidation reaction using RUO2H2O (10 
mol %) and NaIC>4 (250 mol %) in ethyl acetate/water at room temperature was 
unfortunately very low yielding probably due to the concomitant oxidation of the allyl 
group (Equation 1.8). 
T B S C \ Nal04 T B S° - - . f__A 
O - C 0 2 M e R U 0 2 ' H 2 ° » n X > - C 0 2 M e ° ! § ^ > ^ Equation 1.8 N 2 EtOAc/H20 ° N 2 T H F ^ ^ \ 
^^c/ low yielding 
119 120 
Subsequently, we decided to introduce the allyl group at C-5 prior to N-allylation. 
Nucleophilic addition of the allyl nucleophiles to the N-acyliminium ions has been shown 
to be reliable. In our system, however, there is an added issue of diastereoselectivity. In 
order to reach the targeted natural product (securinine), the resulting allylated product 
should have the (2S,4R,5R) stereochemistry at C-5 (i.e. compound 122 has the desired 
stereoisomer). 
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Table 1.3 Yields and Stereoselectivity of the Addition of Various Allyl Nucleophiles to 
Aminal(112) 
TBSO, 
AcO X> C02Me Lewis Acid 
Boc 
112 
Solvent 
Temperature 
TBSO. 
*D-+ / ^ C 0 2 M e 
Boc 
121 
TBSO. 
Allyl 
TBSO,, 
^•L../~*C02Me rfAM^-C02Me E ( 1 - 1 - 9 Nucleophile I N + f N 2 k Boc 
122 
i 
^ . Boc 
123 
Entry Lewis Acid Allylnucleophile Temperature 
(°C) 
d.r. 
(122:123) 
Yield (%) 
BF3-Et20 ,SiMe? Otort 2:1 71% 
BF3-Et20 ,SiMe? -78 to rt 4:1 88% 
TiCl4 ,SiMe, Otort 1:1 50% 
TiCL ,SiMe^ -78 to rt 2:1 55% 
SnCL ,SiMe? -78 to rt 1:1 55% 
BF3-Et20 .BF,K -78 to rt 2:1 67% 
Towards this end, numerous Lewis acids and allyl nucleophiles were screened in 
Equation 1.9. The results of which are shown in Table 1.3. The results from Table 1.3 
show that the best result we could obtain was a 4:1 diastereomeric ratio (in favor of the 
desired diastereomer) with the BF3-Et20 as the Lewis acid and an allyltrimethylsilane as 
the allyl nucleophile at -78 °C in THF (entry 2, Table 1.3). Unfortunately, the mixture of 
diastereomers (122:123) could not be separated at this stage using silica gel 
chromatography. The stereochemistry of the main diastereomer was, however, proven 
through X-ray analysis of an intermediate further down the synthetic pathway (vide 
infra). At this stage, the Boc protecting group was then subsequently removed using 
TFA. This mixture of diastereomers (124:125) was now separated at this stage via silica 
gel chromatography (Equation 1.10). 
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TBSC\ TBSC\ TBSC\ TBSQ,. 
, A N / ^ C 0 2 M e + > ^ N ) ^ C 0 2 M e T F A > N A N ) ^ C 0 2 M e ^ N > ^ C 0 2 M e E c l u a t i o n 1-10 
I l | i CH2CI2 I H + I H 
^ Boc ^ Boc 0 ° C t o r t 1 2 h ^ % 
68% 
122 123 from 112 124 125 
Compound 124 was then treated with freshly distilled allyl bromide and Et3N in 
DMF to afford 126, which was taken, as is, onto the RCM step. 
T B S C k ^ = ^ ^ B r TBSQ. 
i * A N / " * C 0 2 M e ll ^ X%A / ^ C 0 2 M e Equation 1.11 
I H DMF / N 
^ 0°Ctort , 12 h \ 
124 126 
At this stage, the intermediate 126 was ready for ring closing metathesis using 
Grubbs' 1st generation catalyst (127). Unfortunately, the reaction did not proceed even 
after refluxing the reaction mixture for 24 hours (Equation 1.12). 
Figure 1.3 Structure of Grubbs' 1st and 2nd Generation RCM Catalysts 
Ru=\ 
\ // C\' I Ph 
P 
Ru= 
cr 
Grubbs 1 s t generation Grubbs 2 n d generation 
127 128 
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T B S
° ^ Catalyst 127 - 0 T B S 
A ^ C 0 2 M e ^ > J T > Equation 1.12 
^ ) 40 °C, 12 h 
126 
To solve this problem, our immediate choice was to switch the RCM catalyst to 
the Grubbs' 2nd generation catalyst (128). With this switch, the reaction now proceeded 
smoothly in 93% yield over two steps (Equation 1.13). 
T B S 0
- Catalyst 128 " ° ™ S 
N Co2Me
 ( 5 m
°
l % )
 » (| T > Equation 1.13 
CH2CI2 
^ / 40 °C, 12 h 
93% 
126 from 124 
Palladium on charcoal with hydrogen gas then easily reduced the alkene double 
bond in (129) in quantitative yield after chromatographic purification. At this stage the 
AB ring framework had been synthesized. 
OTBS
 H OTBS 
10%Pd/C, H2 i / ^ " " \ Equation 1.14 
EtOAc, rt, 16 h 
C02Me quantitative yield C02Me 
129 130 
We next moved to the construction of either ring C or D. We decided first to 
construct the D ring (y lactone) of the securinine framework. Towards that end, we 
wanted to add a functionalized Grignard reagent to the ketone 86 using a strategy 
developed by Knochel.42 Thus TBS-protected 2° alcohol 130 was deprotected by 
tetrabutylammonium fluoride (TBAF) in THF at room temperature in quantitative yield. 
The free 2° alcohol (95) was oxidized using Swern oxidation conditions in very good 
yield. 
32 
DMSO 
H ? T B S H ? H (COCI)2 
TBAF (^\\ B s N 
N
- V THF, 60 °C, 12 h \ ^ N ~ V CH2CI2 ,-78 °C 
C02Me C02Me 76% 
130 95 
The addition of the Grignard reagent to 86 was expected to occur from the more 
accessible convex face of the molecule leading to the desired stereochemistry at C-9. 
Intramolecular lactonization of 131 was expected to occur spontaneously upon workup of 
the Grignard addition step. Thus, freshly prepared Grignard reagent 96 was added to 
ketone 86 under various reaction conditions (Equation 1.16). 
n BrMq C02Me 
4 // " 96 rv\ Equation 1.16 
C02Me THF, -20 °C C02Me 
86 131 
Unfortunately, the aforementioned strategy did not work as anticipated. 
Consequently, we immediately moved to construct the y lactone via ring closing 
metathesis using a strategy originally developed by March and co-workers22: (i) addition 
of vinyl magnesium bromide to ketone 86, followed by trapping of the intermediate 
alkoxide with acryloyl chloride to form diene 132, and (ii) RCM of 132 with 2nd 
generation Grubbs' catalyst.22'46 Thus, ketone 86 was added to vinyl magnesium 
bromide. The resulting tertiary alcohol 132 was isolated in 73% yield with presumed 
desired stereochemistry at C-9 as the Grignard reagent most likely attacked from the 
convex face of the molecule (d.r.= 95:5 ; please note that the relative stereochemistry was 
not unambiguously defined). The next step was to introduce the acrolyl functionality for 
subsequent y-lactonization. Thus tertiary alcohol 132 was deprotonated using NaH or 
MeMgBr and freshly distilled acryloyl chloride was added. After purification via column 
chromatography, 133 was isolated in 70% yield, which was ready for the pivotal ring 
closing metathesis reaction (Equation 1.17). 
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N ^ / THF * 
-20 °C to rt C02Me 
86 
C02Me 
CI 
o 
67% 
d.r. 95:5 
132 R=H 
132a R=MgBr 
H 9 
O 
r ^ ^ l - - V ^ Equat 
C02Me 
ion 1.17 
133 
In another trial, freshly distilled acryloyl chloride was added to the reaction flask 
after addition of vinylmagnesium bromide, but before quenching the reaction, thus 
trapping the intermediate alkoxide. This also led to the formation of the addition product 
diene 133 in 67% yield. Subsequently diene 133 was subjected to ring closing metathesis 
using Grubbs' 2nd generation catalyst (128) (Equation 1.18). 
O 
Catalyst 
128 
-
N
- - / CH2CI2, 40 °C 
C0 2 Me 72% 
133 
Equation 1.18 
C0 2 Me 
134 
The next step in the synthesis was to reduce the methyl ester in (134) to an 
aldehyde, and then use the Corey-Fuchs reaction/selective dehalogenation methodology 
to synthesize the requisite Z-halo alkene. Unfortunately, we observed that the y lactone 
was more readily reduced with DIBAL-H (1.0 M in PI1CH3) than the acyclic methyl ester. 
In hindsight, this development should have been anticipated given the expected greater 
reactivity of cyclic ketones/lactones compared to acyclic variants. Nevertheless, we 
moved forward while regarding the aforementioned exercise as a model study to 
construct the necessary y-lactone. Towards this end, we immediately changed strategy to 
first synthesize ring C. Thus, compound 130 was subjected to DIBAL-H in order to 
reduce the methyl ester to the corresponding aldehyde (Scheme 1.13). In a test reaction, 
the crude aldehyde product was subjected to silica column purification, but the 
purification was rather difficult and low yielding. Fortunately, 'H-NMR spectroscopy 
showed that crude aldehyde 135 was pure enough to use in the next step, eliminating the 
need for further purification of the crude reaction mixture. The next step was to construct 
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the Z-halo alkene. We considered two strategies to synthesize the Z-halo alkene: i) the 
Corey-Fuchs reaction followed by selective dehalogenation, and ii) the use of Stork's 
reagent. We tried both strategies as shown in Scheme 1.13. 
Scheme 1.13 Synthesis of a Z-halo Alkene by Two Different Methods 
OTBS 
H 
130 
OTBS QIBAL-H 
PhCH3 
-78 °C, 2 h 
C02Me 
OTBS 
C^ 
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36 
135 
137 138 
The use of the Corey-Fuchs reaction was problematic due to the difficulty in 
removing the excess phosphine and phosphine oxide by-products. Similarly, the 
reductive dehalogenation using Bu3SnH also suffered from similar issues with respect to 
removal of tin residues. Thus, we chose to instead proceed with the reaction of aldehyde 
135 with Pli3P=CHI according to the procedure developed by Stork. 7 The reaction 
proceeded smoothly to afford the desired Z-iodo alkene (136) in good chemical yield of 
80% (over two steps) and excellent stereochemistry. 
The next step in the synthesis was to deprotect the 2° alcohol in 136 with 
tetrabutyl ammonium fluoride (TBAF). To our surprise, significant decomposition of the 
substrate was observed under these conditions while reacting with TBAF in refluxing 
THF. When we attempted the reaction at room temperature, we observed an 
unanticipated dehydrohalogention of the appended (Z)-iodoalkene and concomitant 
removal of the TBS group to afford hydroxyalkyne 139 (Equation 1.19). a The structure 
and stereochemistry of 139 was confirmed by X-ray crystallography. Thus, the 
35 
stereochemistry of the major diastereomer of the initial allylation step (112-»122, 
Equation 1.9, vide supra) was also established by the X-ray structure of 139. 
H OTBS OH 
TBAF (2.2 equiv) 
^ / N - V | THF, rt 18 h 
• = / 75 % 
136 
&i 139 
Equation 1.19 
X - ray structure 
of 139 
The aforementioned discovery subsequently led to the development of a new 
methodology wherein a variety of terminal alkynes can be readily synthesized in high 
yields via dehydrohalogenation of the corresponding 1-iodo-l-alkenes using the mild and 
tolerant base tetrabutylammonium fluoride. In addition, the one-pot direct synthesis of 
terminal alkynes from aldehydes was also demonstrated, without the necessity of 
isolating the intermediate iodoalkene. 
Returning to the synthesis, we discovered through careful screening of the various 
reaction parameters that we were able to effect the deprotection of TBS group with TBAF 
in wet THF (5:1 mixture of THFiFFiO) (Equation 1.20). The presence of water seemed to 
considerably decrease the rate of the dehydrohalogenation reaction, and allowed us to 
isolate alcohol 140 in 79% yield. 
OTBS 
TBAF (1.1 equiv) 
• 
I THF:H20, (5:1), rt, 18 h 
79% 
OH 
140 
DMSO 
(COCI)2 
Et3N 
I CH2CI2, -78 °C 
94% 
Equation 1.20 
The subsequent oxidation of the secondary alcohol under Swern conditions 
afforded ketone 141 in high yield (94%). At this stage of the synthesis, the construction 
of the spirocyclic a,P-unsaturated y-lactone was warranted. The y-lactone (ring D) was 
synthesized via the previously mentioned two-step protocol. Thus ketone 141 was 
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subjected to addition of vinylmagnesium bromide, followed by trapping the intermediate 
alkoxide with freshly distilled acryloyl chloride to form triene 142 (80% isolated yield) as 
a single diastereomer (d.r. > 97:3) with the desired stereochemistry at the quaternary 
centre (Equation 1.21). 
141 
<=^MgBr 
THF, -30 °C to it 
o 
0 °C to rt 
80%, d.r. > 97:3 
Equation 1.21 
142 
Triene 142 was now set to be cyclized by RCM using 2nd generation Grubbs' 
catalyst. Unfortunately, no reaction was observed under these conditions. Fortunately, 
the RCM reaction did proceed using the 2nd generation Hoveyda-Grubbs' catalyst 143 to 
afford the required a, P-unsaturated y-lactone in 78% yield (Equation 1.22).22'46 
nd, Figure 1.4 Hoveyda-Grubbs' 2 Generation Catalyst 
O 
H 
•t 
Hoveyda-Grubbs 
2nd generation 
143 
143, 10mol% 
CH2CI2, 40 °C 
78% 
Equation 1.22 
142 144 
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The final step of the synthesis involved the intramolecular Heck cyclization of the 
(Z)-iodoalkene 144 onto the spirocyclic a,P-unsaturated y-lactone (Equation 1.23).22'49 
The reaction was conducted in the presence of the Herrmann-Beller catalyst 14550 to 
provide (-)-securinine (1) in 82% isolated yield. An X-ray structure of (1) was obtained 
and the NMR data also matched the data previously reported 51-53 
145, 10mol% 
»• 
"Bu4NBr 
NaOAc, 100 °C, 12 h 
82% 
144 
Equation 1.23 
The entire forward synthetic route for the total synthesis of securinine (1) is 
summarized in Scheme 1.14. 
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Scheme 1.14 The Complete Total Synthesis of (-)-Securinine (1) 
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a) SOCl2) MeOH 0 °C-m, 6 h; b) Boc20, Et3N, EtOAc, rt, 4 h; c) TBSCl, imidazole, DMF, RT, 14 h; d) 
NaI04, Ru02«H20, 2:1 H20/EtOAc, RT, 12 h, (96%, 4 steps); e) LiBEt3H, THF, -78 °C, 1 h; f) Ac20, Et3N, 
DMAP, rt, 8 h, (87%, 2 steps); g) BF3-Et20, allyltrimethylsilane, Et20, -78 °C^rt, l h, (88%, d.r.=4:l); h) 
TFA, CH2C12, 0 0C->rt, 10 h, (77%); i) allyl bromide, Et3N, DMF, rt, 16 h; j) Grubbs' 2nd generation 
catalyst, CH2C12, reflux (93%, 2 steps); k) 10% Pd/C, H2, EtOAc, rt, 18 h (quantitative); 1) DIBAL-H, 
PhCH3, -78 °C->-20 °C, 2 h, (98%); m) iodomethyltriphenylphosphonium iodide, NaHMDS, THF, -10 
°C-> -78 °C, 2 h, (80%, 2 steps); n) TBAF hydrate, 5:1 THF/H20, 0 °C, 10 h, (79%); o) DMSO, oxalyl 
chloride, Et3N, CH2C12, -78 °C, 1 h, (94%); p) vinylmagnesium bromide, THF, -78 °C-> -20 °C, 2 h, 
acryloyl chloride, rt, 2 h, (80%); q) Hoveyda-Grubbs' 2nd generation catalyst, CH2C12; 60 °C, 16 h, (78%); 
r) Herrmann-Beller catalyst, "Bu^NBr, NaOAc, DMA, 100 °C, 12 h, (82%). 
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1.3 Conclusion and Future work 
A flexible synthesis of (-)-securinine 1 was completed from trans-4-hydroxy-L-
proline 51 in 18 steps and 16% overall isolated yield.54'55 The highlights of the synthesis 
include an intramolecular Heck cyclization to complete the tetracyclic skeleton, and the 
highly diastereoselective preparation of the key spirocyclic a,P-unsaturated y-lactone 
intermediate. A flexible route to synthesize 1 not only provides additional quantities of 
this natural product for testing, but might also serve as basis for the synthesis of 
analogues with improved biological/medicinal properties. We anticipate that the 
synthetic route can be readily modified to access other securinega alkaloids (e.g. 
norsecurinine), and we are currently working towards this goal. 
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1.4 Experimental Procedures and Characterization Data 
General Information THF was dried and distilled over sodium/benzophenone ketal. 
DMF was dried and distilled over calcium hydride. All other solvents were dried over 
alumina in a series of Grubbs'-type columns. All other reagents were used as received 
(Aldrich, Acros). Silica gel (60 A, 230-400 mesh) was obtained from Silicycle and used 
as received. Melting points are uncorrected, and were measured on a Fisher-Johns 
melting point apparatus. Optical rotations were measured on a Perkin-Elmer 241 
polarimeter. 'H and 13C NMR spectra were recorded at 300 or 500 MHz and 75 or 125 
MHz respectively on a Bruker Spectrospin Avance 300 or 500 MHz spectrometer. 
Proton chemical shifts were internally referenced to the residual proton resonance in 
CDCI3 or CeD6 (5 7.26 and 7.16 respectively). Carbon chemical shifts were internally 
referenced to the deuterated solvent signals in CDC13 or C6D6 (5 77.00 and 128.06 
respectively). Infrared spectra were obtained on a Bruker VECTOR22 FT-IR 
spectrometer. HRMS-CI and HRMS-ESI were performed on a Waters/Micromass GCT 
time-of-flight mass spectrometer and a Waters/Micromass Q-TOF Global quadrupole 
time-of-flight mass spectrometer respectively. 
(25, 4^?)-4-Hydroxy-2-(methoxycarbonyl)pyrrolidinium chloride (100)57'39 
HO, 
CNXc02H 
H 
51 
To a stirred solution of trans 4-hydroxy-L-proline (12.00 g, 91.5 mmol) in MeOH (200 
mL) at 0 °C was added SOCI2 (6.68 mL, 91.5 mmol) dropwise over 20 min. The 
reaction mixture was then allowed to warm to rt stirred for a further 6 h at rt. All 
volatiles were removed in vacuo. 100 was obtained as a white, microcrystalline solid 
(16.62 g, quantitative). The crude material was used in the next step without further 
purification. 100: m.p. = 169-171 °C (MeOH). 
H 0
' , 
CN/^C02Me 
H-HCI 
100 
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(25, 4R)-l-tert-Butyl 2-Methyl 4-Hydroxypyrrolidine-l,2-dicarboxylate (107)39'58 
HO,, HO,, 
CN^C0 2Me *~ CN/^C02Me 
H
"
H C I
 Boc 
100 107 
To a solution of 100 (8.213 g, 45.2 mmol) in 1,4-dioxane/H20 (2:1, 80 mL) was added 
Et3N (9.45 mL, 67.8 mmol) and B0C2O (19.7 g, 90.4 mmol). The reaction mixture was 
stirred for 4 h at rt and all volatiles were evaporated in vacuo. The resulting solid residue 
was dissolved in EtOAc (250 mL), and then washed consecutively with HC1 (0.5 M, 25 
mL), sat. aq. NaHCC>3 (100 mL) and brine (100 mL). The organic extract was dried 
(MgS04), filtered and all volatiles were removed in vacuo to afford 107 as a white solid 
(11.074 g, quantitative), which was used directly in the next step. The spectral data of 
CO 
107 matched the previously reported data. 
(2S, 4R)-l-tert-Butyl 2-Methyl 4-(tert-Butyldimethylsilyloxy)pyrroIidine-l,2-
dicarboxylate (108)39'59 
HO, TBSO, 
COoMe COoMe N * N *• 
1 1 
Boc Boc 
107 108 
To a solution of 107 (9.503 g, 38.73 mmol) in DMF (80 ml), was added t-
butylchlorodimethyl silane (7.00 g, 46.48 mmol) and imidazole (5.27 g, 77.46 mmol). 
The reaction mixture was stirred at rt for 14 h. The solvent was removed in vacuo and 
Et20 (100 mL) was added. The mixture was washed with water (3 x 100 mL), brine (2 x 
100 ml), dried (MgS04), filtered and concentrated in vacuo to provide 108 as a viscous, 
straw-coloured oil (13.908 g, quantitative), which was used directly in the next step. The 
spectral data of 108 matched the previously reported data. 
43 
(25, 4R)-l-tert-Butyl 2-Methyl 4-(tert-Butyldimethylsilyloxy)-5-oxopyrrolidine-l,2-
dicarboxylate (109)39'60 
TBSO,, 
COoMe N 
i 
Boc 
108 
To a solution of NaI04 (8.900 g, 41.6 mmol) in distilled water (100 mL) was added 
Ru02#H20 (186 mg, 1.4 mmol). The resulting solution was stirred for 5 min at rt 
followed by addition of 108 (5.00 g, 13.91 mmol) in EtOAc (50 mL) in one portion. The 
reaction mixture was stirred for 12 h at rt. Small portions of NaI04 {ca. 500 mg) were 
added every 3 h during this period to ensure that Ru black did not form. EtOAc (100 mL) 
was subsequently added followed by sat. aq. NaHSCh, which immediately resulted in the 
precipitation of Ru black. The layers were separated and the organic extract was filtered 
through a pad of Celite®. The filtrate was then washed with brine (50 mL), dried 
(MgS04) and evaporated under reduced pressure. The resulting residue was subjected to 
silica gel chromatography (hexanes/EtOAc, 4:1) to afford 109 as a white, crystalline solid 
(4.984 g, 96%). 
109: m.p. = 55-56 °C (EtOAc); [a]D21 = +28.2 (c 0.10, CHC13), 'H NMR (CDC13, 300 
MHz) 5 4.59 (1H, dd, J= 10.0, 1.5 Hz), 4.43 (1H, dd, J= 10.0, 8.5 Hz), 3.80 (3H, s), 2.37 
( lH,dd , J= 13.0,8.5, 1.5 Hz), 2.21 (1H, dt, J= 13.0, 10.0 Hz), 1.51 (9H, s), 0.90 (9H, s), 
0.18 (3H, s), 0.13 (3H, s); l3C NMR (CDC13, 75 MHz) 5 171.96, 171.76, 149.51, 83.89, 
69.65, 54.96, 52.68, 31.83, 27.87, 25.66, 18.19, -4.47, -5.32; IR (KBr) 2956, 2931, 2887, 
2858, 1801, 1753, 1723 cm"1. 
TBSO,, 
**
 0 A N ^ C 0 2 M e 
1 
Boc 
109 
o~ 
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(25, 4R)-l-tert-Butyl 2-Methyl 5-Acetoxy-4-(te/-M)utyldimethylsilyloxy)pyrrolidine-
1,2-dicarboxylate (112) 
TBSO,, TBSO,, TBSO,, 
0 ^ N > - C 0 2 M e - H O A N > - C 0 2 M e * " A c O ^ N ^ C O 
i i i 
Boc Boc Boc 
109 110 112 
To a solution of 109 (1.000 g, 2.68 mmol) in THF (3.0 mL) at -78 °C was added LiBEt3H 
(1.0 M in THF, 2.70 mL, 2.70 mmol) dropwise. The reaction mixture was stirred for 1 h 
at -78 °C, and then quenched with sat. aq. NaHC03 (3.0 mL) at -78 °C. H202 (two drops) 
was added and the reaction mixture was allowed warmed to it. All volatiles were 
removed in vacuo. CH2CI2 (20 ml) was added followed by brine (10 mL). The mixture 
was stirred and the layers were separated. The organic phase was dried (MgS04), filtered 
and concentrated in vacuo. The resulting pale yellow oil was dissolved in CH2CI2 (10 
mL). Et3N (0.56 mL, 4.02 mmol), Ac20 (304 uL, 3.22 mmol) and cat. DMAP (20 mg) 
were then added successively. The reaction mixture was stirred at rt for 8 h prior to the 
addition of sat. aq. NaHC03 (5 mL). The layers were separated and the aqueous layer 
was extracted with CH2CI2 (10 mL). The combined organic extracts were washed with 
brine (10 mL), dried (MgS04), filtered and concentrated in vacuo. The residue was 
subjected to silica gel chromatography (hexanes:EtOAc = 4:1) to afford 112 as a clear, 
colourless oil (970 mg, 87%). 
112: *H NMR (CDC13, 300 MHz) 5 6.17 (1H, s), 4.53 - 4.38 (1H, m), 4.16 (1H, br s), 
3.77 (3H, s), 2.22 - 2.00 (5H, m), 1.45 (9H, s), 0.87 (9H, s), 0.14 (3H, s), 0.10 (3H, s); 
l3C NMR (CDC13, 75 MHz) 5 172.90, 172.54, 170.07, 169.82, 153.62, 153.26, 88.48, 
88.01, 81.46, 81.40, 74.66, 73.84, 59.03, 58.39, 52.24, 52.13, 36.76, 36.15, 28.21, 25.62, 
21.20, 17.91, -4.83, -5.09 (+ 4 overlapped signals); IR (film) 2955, 2932, 2859, 1751, 
1738, 1715 cm"1. 
45 
(25, 4R, 5R)-l-tert-Butyl 2-Methyl 5-AUyl-4-(tert-butyldimethylsilyloxy)pyrrolidine-
1,2-dicarboxylate (122)21"'39'61 
TBS(\ TBSO^ 
AcCT^N C ° 2 M e *" ^ A N ^ C 0 2 M e 
i i 
Boc Boc 
112 122 
To a solution of 112 (6.108 g, 14.6 mmol) in diethyl ether (100 mL) at -78 °C was added 
BF3Et20 (2.26 mL, 18.3 mmol) and allyltrimethylsilane (10.4 mL, 65.7 mmol). The 
reaction mixture was stirred for 15 min at -78 °C and then allowed to warm to it (1 h) and 
stirred for a further 2 h at rt. Sat. aq. NaHC03 (75 mL) was added and the layers were 
separated. The aqueous later was extracted with Et20 (2 x 50 mL) and the combined 
organic extracts were dried (MgS04), filtered and concentrated in vacuo. The residue 
was subjected to silica gel chromatography (hexanes:EtOAc=5:l) to afford 122 as a 4:1 
mixture of diastereomers (+ rotamers) (main diastereomer shown). 122 was isolated as a 
clear, colourless oil (5.112 g, 88%). 
122 (main diastereomer, rotamers): 'H NMR (CDC13, 300 MHz) 8 5.93-5.78 (1H, m), 
5.15-5.03 (2H, m), 4.60-4.40 (1H, m), 4.32^1.10 (1H, m), 3.88-3.62 (4H, m), 2.70-2.45 
(2H, m), 2.20-1.99 (2H, m), 1.47 (3H, s, rotamer), 1.45 (6H, s, rotamer), 0.86 (9H, s), 
0.07 (3H, s), 0.04 (3H, s); ,3C NMR (CDC13, 75 MHz) 5 174.04, 173.92 (rotamer), 
153.94, 153.40 (rotamer), 134.91, 117.28, 80.04 (br), 74.33 (rotamer), 73.37, 67.31 
(rotamer), 67.02, 59.78 (rotamer), 58.88, 52.18 (rotamer), 51.99, 37.83, 37.36 (rotamer), 
33.85 (rotamer), 33.04, 28.42, 28.26 (rotamer), 25.78, -4.37 (br), -4.76; IR (film) 3077, 
2954, 2934, 2859, 1754, 1704, 1641, 1439, 1391 cm"1; HRMS (ESI) m/z calcd. for 
C2oH38N05Si (MH+) 400.2519, found 400.2538 
46 
(2S, 4R, 5/f)-Methyl 5-Allyl-4-(ter^butyldimethylsilyloxy)pyrrolidiiie-2-carboxylate 
(124)21b 
TBSO^ TBSO,, 
Boc H 
122 124 
To a solution of 122 (6.205 g, 15.5 mmol) in CH2C12 (100 mL) at 0 °C was added TFA 
(11.5 mL, 155 mmol). The reaction mixture was stirred at it for 10 h. Sat. aq. NaHCC>3 
(100 mL) was carefully and slowly added at 0 °C. The layers were separated and the 
aqueous layer was extracted with CH2CI2 (2 x 50 mL). The combined organic extracts 
were dried (MgS04), filtered and concentrated in vacuo. The residue was subjected to 
silica gel chromatography (gradient, hexanes:EtOAc = 15:1 to 3:1) to afford 124 as a 
yellow oil (3.563 g, 77%). 
124: [a]D20 = -89.4 (c 1.50, CHC13); *H NMR (CDC13, 500 MHz) 8 5.90 - 5.75 (1H, m), 
5.10 (1H, d, J= 17.0 Hz), 5.04 (1H, d, J= 10.0 Hz), 4.25 - 4.20 (1H, m), 4.02 (1H, t, J = 
8.0 Hz), 3.72 (3H, s), 3.14 (1H, dt, J= 7.0, 2.0 Hz), 2.33-2.20 (3H, m), 2.13 (1H, ddd, J 
= 13.0, 8.0, 1.5 Hz), 2.04 (1H, ddd, J= 13.0, 8.0, 4.5 Hz), 0.90 (9H, s), 0.08 (3H, s), 0.07 
(3H, s); ,3C NMR (CDC13, 75 MHz) 8 175.87, 136.16, 116.51, 73.40, 63.48, 57.75, 
52.14, 39.88, 34.19, 25.92, 18.17, -4.37, -4.81; IR (film) 3352, 3077, 2954, 2932, 2899, 
2858, 1740, 1641 cm-1; HRMS (ESI) m/z calcd. for Ci5H3oN03Si (MH+) 300.1995, found 
300.1991. 
(IR, 3S, 8aif)-Methyll-(te^-Butyldimethylsilyloxy)-l,2,3,5,8,8a-hexahydroindolizine-
21b 3-carboxylate (129) 
TBSO, TBSO, H O T B S 
.o-^M^COzMe *" - * ^ A M ^ < 
H C02Me 
124 126 129 
47 
To a solution of 124 (3.004 g, 10.0 mmol) in DMF (65 mL) at rt was added allyl bromide 
and Et3N (3.48 mL, 25 mmol). The reaction mixture was stirred for 16 h at rt. Et^O (75 
mL) was then added and the organic layer was washed with sat. aq. NaHCCh (50 mL). 
The layers were separated and the aqueous later was extracted with diethyl ether (2 x 50 
mL). The combined organic extracts were dried (MgS04), filtered and concentrated in 
vacuo. The resulting pale, yellow oil 126 (3.40 g, 10.0 mmol) was dissolved in CH2CI2 
(100 mL) and the 2nd generation Grubbs' catalyst (425 mg, 0.5 mmol) was added. The 
reaction mixture was then refluxed for 8 h. All volatiles were then removed in vacuo and 
the residue was subjected to silica gel chromatography (hexanes:EtOAc = 4:1) to afford 
129 as a pale, yellow oil (2.894 g, 93% over two steps). 
129: [a]D20 = -85.0 (c 1.18, CHC13) 'H NMR (CDC13, 500 MHz) 5 5.85 - 5.78 (1H, m), 
5.68 - 5.60 (1H, m), 4.55 - 4.45 (1H, m), 3.92 (1H, dd, J = 9.0, 3.0 Hz), 3.70 (3H, s), 
3.33 - 3.20 (2H, m), 3.18 (1H, dt, J= 10.5, 5.0 Hz), 2.38 - 2.27 (2H, m), 2.06 (1H, ddd, J 
= 13.5, 9.0, 4.5 Hz), 1.91-1.84 (1H, m), 0.89 (9H, s), 0.06 (6H, s); 13C NMR (CDC13, 75 
MHz) 8 173.94, 125.10, 124.22, 72.12, 62.44, 59.17, 51.43, 47.42, 37.92, 25.84, 24.68, 
18.21, -4.77, -4.91; IR (film) 3034, 2954, 2931, 2891, 2857, 1748, 1672 cm-1; HRMS 
(ESI) m/z calcd. for Ci6H3oN03Si (MH+) 312.1995, found 312.2003. 
(IR, 3S, 8ai?)-Methyl-(ter^-Butyldimethylsilyloxy)octahydroindolizine-3-carboxylate 
(130)2,b 
H OTBS H OTBS 
CQ -C$ 
C02Me C02Me 
129 130 
To a solution of 129 (2.803 g, 8.99 mmol) in EtOAc (100 mL) was added 10% Pd/C (2.0 
g). The reaction mixture was stirred under an atmosphere of H2 for 18 h. The crude 
reaction mixture was then filtered through a pad of Celite®, and the pad was washed with 
EtOAc (3 x 25 mL). The filtrate was concentrated in vacuo to afford 130 as a pale, 
yellow oil (2.810 g, quantitative). 
48 
130: [a]D20 = -24.8 (c 0.77, CHC13) 'H NMR (CDCI3, 500 MHz) 5 4.42 - 4.34 (1H, m), 
3.90 (1H, d, J= 8.5 Hz), 3.03 (1H, d, J= 11.0 Hz), 2.80 - 2.73 (1H, m), 2.41 - 2.33 (1H, 
m), 2.30 (1H, ddd, J= 10.0, 7.5, 2.5 Hz), 2.01 (1H, ddd, J = 13.0, 9.0, 3.0 Hz), 1.86 -
1.79 (1H, m), 1.57 - 1.38 (4H, m), 1.30 - 1.20 (1H, m), 0.88 (9H, s), 0.05 (6H, s); 13C 
NMR (CDCI3, 75 MHz) 5 173.72, 73.03, 63.96, 62.58, 51.20, 48.50, 37.97, 25.95, 25.48, 
24.31, 23.76, 18.40, -4.78 (signal overlap); IR (film) 2933, 2857, 1736 cm '; HRMS 
(ESI) m/z calcd. for Cie^NOsSi (MH+) 314.2151, found 312.2169. 
(\R, 3S, 8a/?)-l-(tert-Butyldimethylsilyloxy)-3-((Z)-2-iodovinyl)octahydroindolizine 
(136) 
H OTBS H OTBS H OTBS 
C02Me CHO 
130 135 136 
To a solution of 130 (1.701 g, 5.41 mmol) in anhydrous PhCH3 (50 mL) cooled to -78 °C 
was added a solution of DIBAL-H (1.0 M in PI1CH3, 10.8 mL, 10.8 mmol) dropwise over 
15 min. The reaction mixture was stirred for a further 2 h at -78 °C. Anhydrous EtOH 
(15 mL) was then added and the mixture was allowed to warm to -20 °C. Potassium 
sodium tartrate (1M in H2O, 50 mL) was added and the biphasic mixture was vigorously 
stirred for 1 h while warming to rt. The layers were separated and the aqueous later was 
extracted with Et20 (3 x 25 mL). The combined organic extracts were dried (MgS04), 
filtered and concentrated in vacuo to afford 135 as a pale, yellow oil (1.50 g, 98%). 135 
was prone to decomposition at rt over several hours and was hence immediately reacted 
as shown below 
To a suspension of iodomethyltriphenylphosphonium iodide (3.60 g, 6.80 mmol) in 
anhydrous THF (20 mL) at -10 °C was added NaHMDS (1.0 M in THF, 6.8 mL, 6.8 
mmol). The mixture was stirred for 15 min at -10 °C. The reaction mixture was then 
cooled to -78 °C and a solution of the aldehyde (1.50 g, 5.27 mmol) in anhydrous THF (5 
CQ , 
49 
mL) was added. The mixture was stirred for 30 min at -78 °C, and another 1.5 h at -10 
°C. Hexanes (15 mL) was then added, and the solids were filtered off. The solid residue 
was rinsed with hexanes (2x15 mL). The combined organic filtrate was dried (MgS04), 
filtered and concentrated in vacuo. The dark yellow residue was subjected to silica gel 
chromatography (hexanesracetone = 9:1) to afford 136 (1.752 g, 80% over two steps) as a 
yellow oil. 
136: [a]D20 = -100.7 (c 1.00, CHC13) 'H NMR (CDC13, 500 MHz) 5 6.31 (1H, d, J= 7.5 
Hz), 6.15 (1H, t, J= 7.5 Hz), 4.34 (1H, dt, J= 9.0, 3.5 Hz), 2.9 - 2.90 (1H, m), 2.65 -
2.57 (1H, m), 2.46 ( lH,d t , J = 13.5, 1.5 Hz), 2.11 (1H, ddd, J= 13.5, 9.0, 3.5 Hz), 1.94-
1.80 (2H, m), 1.61 (1H, tq, J= 13.0, 4.0 Hz), 1.53 - 1.43 (3H, m), 1.31-1.20 (1H, m), 
0.89 (9H, s), 0.05 (6H, s); l3C NMR (CDC13, 75 MHz) 5 141.12, 83.01, 72.86, 64.67, 
62.88, 47.42, 39.80, 26.04, 24.23, 23.02, 23.22, 18.43, -4.63, -4.75; IR (film) 3070, 2932, 
2856, 2794, 1602 cm"1; HRMS (ESI) m/z calcd. for C,6H3,INOSi (MH+) 408.1220, found 
408.1220. 
(IR, 3S, 8afl)-3-Ethynyloctahydroindolizin-l-ol (139) 
H OTBS H OTBS 
O^, 
136 139 
To a solution of 136 (204 mg, 0.5 mmol) in THF (1 mL) at rt was added TBAF (1.0 M in 
THF, 1.1 mL, 1.1 mmol). The reaction mixture was stirred for 18 h at rt. All volatiles 
were then removed in vacuo. The residue was subjected to silica gel chromatography 
(hexanes:acetone = 3:1) to afford 139 as a clear, colourless crystalline solid (62 mg, 
75%). X-ray quality crystals of 139 were grown via slow evaporation of a solution of 
139 in EtOAc. 
50 
139: m.p. = 62-63 °C (EtOAc); [a]D20 = -18.9 (c 0.64, CHC13); 'H NMR (CDCI3, 300 
MHz) 8 4.20 - 4.10 (1H, m), 4.03 (1H, d, J = 8.5 Hz), 2.95 - 2.88 (1H, m), 2.51 (1H, dt, 
J= 11.5, 3.0 Hz), 2.42 - 2.30 (2H, m), 2.27 (1H, d, J = 2.0 Hz), 2.10 (1H, dd, J= 14.0, 
8.5 Hz), 1.92 - 1.63 (4H, m), 1.61 - 1.40 (2H, m), 1.34 - 1.20 (1H, m); 13C NMR 
(CDCI3, 75 MHz) 5 82.51, 73.12, 72.44, 63.64, 52.29, 48.93, 42.02, 25.43, 25.33, 23.66; 
IR (KBr) 3359, 3305, 2932, 2856, 2190 cm"1; HRMS (ESI) m/z calcd. for C10Hi6NO 
(MH+) 166.1232, found 166.1246. 
(17?, 3S, 8atf)-3-((Z)-2-Iodovinyl)octahydroindolizin-l-ol (140) 
u OTBS u OH 
136 140 
To a solution of 136 (204 mg, 0.5 mmol) in THF/H20 (5:1, 2 mL) at 0 °C was added 
TBAF hydrate (144 mg, 0.55 mmol). The reaction mixture was stirred for 10 h at 0 °C. 
All volatiles were then removed in vacuo. The residue was subjected to silica gel 
chromatography (hexanes:acetone = 4:1) to afford 140 as a white solid (116 mg, 79%). 
140: m.p. = 49-51 °C (EtOAc); [a]D2° = -100.2 (c 0.33, CHCI3) 'H NMR (CDCI3, 500 
MHz) 5 5.93 (1H, d, J= 7.5 Hz), 5.62 (1H, dd, J= 8.5, 7.5 Hz), 4.09 (1H, dt, J= 9.0, 3.5 
Hz), 3.85 - 3.78 (1H, m), 2.85 - 2.79 (1H, m), 2.16 (1H, dt, J= 9.0, 3.5 Hz), 2.09 - 2.00 
(1H, m), 1.96 (1H, ddd,J= 13.5, 9.0, 3.5 Hz), 1.73 (1H, br s), 1.70-1.61 (1H, m), 1.55-
1.30 (5H, m), 1.05 - 0.93 (1H, m); 13C NMR (CDCI3, 75 MHz) 5 140.76, 83.30, 72.97, 
64.80, 63.69, 48.03, 40.33, 25.78, 25.50, 24.38; IR (KBr) 3350, 3060, 2933, 2856, 1578 
cm"1; HRMS (ESI) m/z calcd. for C10H17INO (MH+) 294.0355, found 294.0364. 
51 
(35,8ai?)-3-((^)-2-iodovinyl)hexahydroindolizin-l(5if)-one(141) 
u PH 
140 141 
To a solution of DMSO (87 uL, 1.2 mmol) in CH2C12 (5 mL) at -78 °C was added a 
solution of oxalyl chloride (62 uL, 0.71 mmol) in CH2CI2 (2 mL). The reaction mixture 
was stirred for 15 min at -78 °C prior to the addition of a solution of 140 (181 mg, 0.61 
mmol) in CH2CI2 (2 mL) was added. The mixture was stirred for an additional 35 min at 
-78 °C. Et3N (43 uL, 3.0 mmol) was then added dropwise and the mixture was stirred for 
10 min at -78 °C and another 1 h while warming to rt. Sat. aq. NaHCCh (10 mL) was 
added and the layers were separated. The aqueous phase was extracted with CH2CI2 (2 x 
10 mL). The combined organic extracts were dried (MgSCU), filtered, and concentrated 
in vacuo. The resulting residue was subjected to silica gel chromatography 
(hexanes:EtOAc = 85:15) to afford 141 as a pale yellow oil (169 mg, 94%). 
141: [a]D20 = -45.0 (c 0.32, CHC13) !H NMR (C6D6, 500 MHz) 8 5.93 (1H, d,J= 7.5 Hz), 
5.55 (1H, dd, J= 8.5, 7.5 Hz), 4.06 (1H, dt, J= 8.5, 3.5 Hz), 2.80 - 2.72 (1H, m), 2.48 
(1H, dd, J= 11.5, 3.5 Hz), 2.30 (1H, dd, J= 11.5, 3.5 Hz), 2.23 (1H, dt, J= 12.0, 3.0 Hz), 
1.77 (1H, dd, J= 18.5,3.5 Hz), 1.75- 1.70 (lH,m), 1.55- 1.48 (1H, m), 1.37 (1H, tq, J 
= 13.0, 4.0 Hz), 1.18 - 1.09 (2H, m), 0.91 (1H, tq, J= 13.0, 4.0 Hz); 13C NMR (C6D6, 75 
MHz) 5 211.75, 138.85, 84.49, 64.36, 61.10, 47.62, 41.65, 25.33, 24.00, 23.76; IR (film) 
3062, 2936, 3855, 1754, 1638, 1613 cm"1; HRMS (ESI) m/z calcd. for Ci0H15INO (MH+) 
292.0198, found 292.0208. 
Ol 
52 
(15, 35, 8aif)-3-((Z)-2-Iodovinyl)-l-vinyloctahydroindolizin-l-yl acrylate (142) 
O 
141 142 
To a solution of 141 (146 mg, 0.50 mmol) in THF (2.0 mL) at -78 °C was added freshly 
prepared vinyl magnesium bromide (0.7 M in THF, 786 uL, 0.55 mmol). The reaction 
mixture was stirred for 30 min at -78 °C and another 30 min at -20 °C. The reaction 
mixture was then cooled to -78 °C prior to the addition of freshly distilled acryloyl 
chloride (163 uL, 2.00 mmol). The mixture was stirred for 2 h while warming to rt. Sat. 
aq. NH4CI (5 mL) and EtOAc (10 mL) were added and the layers were separated. The 
aqueous layer was extracted with EtOAc (5 mL). The combined organic extracts were 
dried (MgS04), filtered, and concentrated in vacuo. The resulting residue was subjected 
to silica gel chromatography (gradient, hexanes:EtOAc = 90:10 to 80:20) to afford 142 as 
a pale yellow oil (150 mg, 80%). 
142: [a]D20 = -27.8 (c 1.00, CHC13) 'H NMR (CDCI3, 500 MHz) 8 6.42 - 6.35 (2H, m), 
6.20-6.11 (2H, m), 5.98 (1H, dd, J= 17.5, 11.0 Hz), 5.79 (1H, dd, J= 11.0, 1.5 Hz), 
5.18 (1H, d, J= 11.0 Hz), 5.11 (1H, d,J= 17.5 Hz), 3.15 - 3.07 (2H, m), 2.73 (1H, dd, J 
= 15.0, 7.5 Hz), 2.15 ( lH,dd,J = 15.0, 9.5 Hz), 1.99 (1H, dd ,J= 11.0, 1.5 Hz), 1.95 (1H, 
dd, J= 11.0, 2.5 Hz), 1.92 - 1.85 (1H, m), 1.80 - 1.65 (3H, m), 1.55 - 1.48 (1H, m), 1.28 
- 1.20 (1H, m); I3C NMR (CDC13, 75 MHz) 5 165.18, 141.14, 138.58, 130.47, 129.39, 
113.77, 86.53, 84.19, 74.23, 68.52, 52.33, 42.31, 24.93, 24.05, 23.78; IR (film) 3120, 
2936, 2857, 2786, 1724, 1636, 1617, 1441 cm '; HRMS (ESI) m/z calcd. for C5H21INO2 
(MH+) 374.0617, found 374.0625. 
53 
(l'S, 3'S, Sa'Ryy-iW-l-lodoYinyiyy&f'S'&M'-hexahydro-VH, 5i/-spiro[furan-
2, lMndolizinl-5-one (144) 
142 144 
To a solution of 142 (51 mg, 0.137 mmol) in CH2CI2 (2 mL) in a pressure tube was added 
2nd generation Hoveyda-Grubbs' catalyst (9 mg, 10 mol%). The tube was sealed and the 
heated at 60 °C for 16 h. The tube was then unsealed, the solvent was blown off under a 
stream of nitrogen, and the residue was directly subjected to silica gel chromatography 
(hexanes:EtOAc = 4:1) to afford a 144 as a yellow oil (37 mg, 78%) 
144: [a]D2° = -98.7 (c 1.00, CHCI3); *H NMR (CDC13, 500 MHz) 5 7.54 (1H, d, J= 5.5 
Hz), 6.44 (1H, d,J= 7.5 Hz), 6.22 (1H, dd, J= 8.5, 7.5 Hz), 6.03 (1H, d, J= 5.5 Hz), 
3.29 (1H, dd, J = 9.0, 8.5 Hz), 3.24 (1H, d, J= 10.5 Hz), 2.59 (1H, dd, J= 11.5, 2.5 Hz), 
2.46 (1H, dd, J= 14.0, 9.0 Hz), 2.24 (1H, dd ,J= 14.0, 7.5 Hz), 2.10 (1H, dt, J= 11.5, 3.0 
Hz), 1.83 - 1.75 (1H, m), 1.72 - 1.62 (2H, m), 1.58 - 1.45 (2H, m), 1.20 - 1.03 (2H, m); 
,3C NMR (CDCI3, 75 MHz) 5 172.38, 158.30, 141.39, 119.90, 92.36, 83.79, 69.10, 64.52, 
52.33, 36.06, 26.09, 24.65, 23.38; IR (film) 3103, 2983, 2920, 2857, 1751, 1680 cm"1; 
HRMS (ESI) m/z calcd. for C,3HI7IN02 (MH+) 346.0304, found 346.0295. 
(-)-Securinine (1) 
144 
(-)-securinine 
1 
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A degassed solution of 144 (62 mg, 0.180 mmol), anhydrous NaOAc (17 mg, 0.200 
mmol), "Bu4NBr (12 mg, 20 mol%) and /r<ms-di(u-acetato)-bis[o-(di-o-
tolylphosphino)benzyl]-dipalladium (II) (Herrmann-Beller catalyst)50 (17 mg, 10 mol%) 
in DMA (1 mL) was heated at 100 °C for 12 h. The reaction mixture was then directly 
subjected to silica gel chromatography (hexanes:EtOAc = 4:1) to afford 1 as a yellow 
solid (32 mg, 82%). X-ray quality crystals were grown by slow evaporation of a solution 
ofl inMeOH. 
1: m.p. = 142-144 °C (MeOH); [a]D20 = -1085 (c 1.00, CHC13); !H NMR (CDC13, 500 
MHz) 8 6.55 (1H, d,J= 9.0 Hz), 6.36 (1H, dd, J= 9.0, 5.5 Hz), 5.48 (1H, s), 3.76 (1H, t, 
J= 4.5 Hz), 2.91 (1H, dt, J= 10.5, 3.5 Hz), 2.43 (1H, dd, J= 9.0, 4.0 Hz), 2.36 (1H, ddd, 
J= 10.5, 7.0, 6.5 Hz), 2.04 ( lH ,dd , J= 11.0,2.5 Hz), 1.81 (1H, d of pentet, J= 13.5,3.5 
Hz), 1.71 (1H, d, J = 9.0 Hz), 1.62 - 1.40 (4H, m), 1.25 - 1.08 (1H, m); 13C NMR 
(CDC13, 75 MHz) 5 173.49, 170.02, 140.13, 121.26, 104.87, 89.35. 62.84, 58.63, 48.59, 
42.16, 27.13, 25.75, 24.37; IR (KBr) 2946, 2819, 1739, 1627 cm"1; HRMS (ESI) m/z 
calcd. forC13H,6N02(MH+)218.1181,found218.1189. 
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Chapter 2 Acyclic Diaminocarbene: Simple, Versatile Ligand 
for Cross-Coupling Reaction 
2.1 Introduction 
The design and development of ligands for transition metal catalysis continues to 
have a significant impact on the field of synthetic organic chemistry.1 The catalytic 
properties of transition metal-ligand complexes can be customized to perform very 
specific reactions by careful ligand design. Over the past decade, numerous ligands have 
been developed that provide good catalysts for various organic reactions. Two important 
parameters that impact ligand properties include steric and electronic effects. In recent 
times, the use of carbenes as ligands in transition metal catalysis has changed the field of 
catalysis and transition metal chemistry.1 Carbenes with the general formula RR'C: (both 
singlet and triplet) are very reactive and short lived species due to the six valence electron 
carbon center.2 Carbenes are classified into singlet and triplet according to the electronic 
spins they acquire (Figure 2.1). Singlet carbenes having total electronic spin of zero 
possess two electrons in the sp2 orbital while on the other hand triplet carbenes having 
electronic spin of one have two unpaired electrons, one in sp2 orbital and the other in the 
p orbital.2 
Figure 2.1 Carbene Electronics 
Singlet carbene 
(Fischer carbene) 
Triplet carbene 
(Schrock carbene) 
146 147 
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Carbenes can be stabilized by complexation with transition metals. Most carbenes 
used in transition metal complexes are divided into either Fischer carbene (singlet 
carbene) (146) or Schrock carbene (triplet carbene) (147). Fischer carbene complexes 
having singlet carbenes are generally formed with late transition metals having low 
oxidation state and 7i-electron acceptor ligands. On the other hand, Schrock carbene 
complexes or triplet carbene complexes are derived from early transition metal with high 
oxidation state and 7r-donor ligand. These two class of complexes exhibits different 
chemical reactivity. The Fischer complexes are electrophilic at the carbene carbon while 
Schrock complexes are generally nucleophilic at the carbene carbon e.g. alkylidene 
transition metal complexes.3 Some of the examples of Fischer (146a, 146b) and Schrock 
(147a, 147b) carbene complexes are shown in Figure 2.2. 
Figure 2.2 Examples of Fischer and Shrock Carbene Complexes 
W(CO)6 Cr(CO)fi X H 2 
IT X Cp2Taf Np3Ta=CH(t-Bu) 
M e ^ OMe P h ^ P h ^ M e 
146a 146b 1473 147b 
In the past few years a new class of carbene called N-heterocyclic carbenes (NHC) 
has been introduced into the field of catalysis. NHC's are a type of carbene displaying 
particular stability despite also being a reactive intermediate. NHC carbenes have been 
found to have many applications as ligands in organometallic chemistry and as 
organocatalysts.4 NHC are strong o-donors and have reactivities similar to other classical 
2e" donors like phosphines, amines, and ethers.4 
Various stable carbenes have been isolated or synthesized to date are shown in 
Figure 2.3. Preparation of persistent triplet diarylcarbenes6 148 and isolation of various 
heteroatom-substituted singlet carbenes7 (149-161) have developed the field of carbene 
chemistry significantly. 
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Figure 2.3 Examples of Different Types of Stable Carbenes 
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Guy Bertrand and co-workers isolated the first stable phosphinosilyl carbene in 
1988.8 Encouraged by the results of the Bertrand group, and following Wanzlick's earlier 
work on the attempted synthesis of the stable cyclic diamino carbenes, 9 Arduengo and 
co-workers produced a crystalline carbene (Equation 2.1) 10 
Equation 2.1 Synthesis of the first stable N-Heterocycle Carbenes (NHC) by Arduengo 
etal 10 
NK N 
©y 
H C I 0 
NaH (1 equiv. 
DMSO (Cat.) 
THF -Q + H2 + NaCI 
162 163 
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In recent times, the attractive properties of NHC have led to the replacement of 
phosphines ligands with NHC.11 Specifically, NHC have come to replace phosphines in 
many transition metal catalyzed reactions. NHC have comparable or superior activity 
relative to phosphines such as (i) they are easy to synthesize on a large scale, and (ii) the 
corresponding carbene precursors do not decompose in air/moisture. Phosphines, on the 
other hand, degrade at high temperatures and, in certain cases, oxidize upon exposure to 
air. 
2.1.1 General Synthesis of NHC12 
The most common method to synthesize NHC is via deprotonation of the 
corresponding imidazolium and imidazolinium salts with bases such as NaH, LDA, or 
KO'Bu (Equation 2.2). 13~15 The popularity of this route stems from the ease of synthesis 
of the corresponding formamidium salts. 
FT^Y^R B a s e »
 R . N x / N . R + B X Equation 2.2 
X 0 H Base = NaH, KOfBu or LDA 
164 165 
The second most common method is via the desulfurization of thiourea 
derivatives with potassium. This method is usually preferred over the previous methods 
for substrates that are susceptible to strong bases (Equation 2.3).15'16 
f=\
 K / = \ 
R~N IVUR ^ F T N ^ N ~ R Equation 2.3 
I] THF, A 
s 
R='Pr, 'Bu, Ar 
166 167 
In addition to the above methods, the reaction of chloroamidinium salts 168 with 
Hg(SiMe3)2 also affords the corresponding diaminocarbene 169 (Equation 2.4). The 
advantages of using this method are that fewer side reactions occur than when alkali 
1 7 
metals are employed, and it is more efficient due to the mild conditions employed. 
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ci-
RN J ^ © R Hg(SiMe3)2 ' ^ M ^ ^ N T * Equation 2.4 ?' R ^ R 
.,^K © R Hg(SiMe3)2 N N ^ ^ M - K 
N ^ N » • / R I THF, -78 °C R R 
R =
'
P r
 168 169 
2.1.2 Synthesis of Azolium/Imidazolinium Salts 
Azolium salts are attractive precursors of NHC due to their synthesis from readily 
available cheap starting materials. The symmetrically substituted imidazolinium salts are 
typically synthesized through a one pot three component reaction of formaldehyde, 
glyoxal and two equivalents of the appropriate primary amines (Equation 2.5).n'18 The 
dissymmetrically substituted imidazolinium salts are synthesized in the same manner as 
described above except that one equivalent of the primary amine is used. The N-
monosubstituted imidazole derivatives are then subsequently alkylated with other 
electrophiles (Equation 2.6).19 The imidazolinium salts can also be synthesized via a 
stepwise alkylation of imidazole.20 
O H . ^ 0 i.PhCH3 
II r^ 0-40 °C ' * 
A + f + 2 H2N-R «- R ^ ^ N - R Equation 2.5 
H H
 H ^ O ii.HCI ® e 
cr 
1 Y + U M P N H 4 C I f X> R 'X N M S I Equat ions 
A , + L H2N-R »• I L ^ »• R ' l ^ N - R ' 
R x 3 
H H H ^ S D N ® 
In contrast, imidazolinium salts are successfully synthesized by reacting 1,2-ethyl-
7 1 
diamine derivatives with orthoformate (Equation 2.7). This methodology also allows 
for variation in the heterocyclic precursor by easily changing the substitution of different 
alkyl chain of the starting diamine derivative. 
66 
H2N NH2 R , _x R'—NH NH-R' ur<nt=t\ 1—\ r- . „ - , 
\—f _____ HC(OEt)3 / \ Equation 2.7 
R R R R NH4BF4 R 0 ^ 
BF4 
2.1.3 Synthetic Utility of NHC in Synthetic Organic Chemistry 
NHC act as nucleophiles since the p-orbital of the carbon is mostly filled due to 
the lone pair of electron present on the neighboring nitrogen atoms. For example NHC 
reacts with CS2 and CO2 to give zwitterionic salts 170. Incidentally, NHC/CO2 
complexes regenerate the free NHC upon heating, a fact that makes these complexes 
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attractive precursors to NHC in a variety of settings. 
NHC are reactive compounds which readily react with a variety of reagents. 
Thus, NHC adducts 171, which form upon reaction of the free NHC with water, amine, 
and chloroform, have properties similar to zwitterionic salts 170. Carbene adducts 171 
are typically air stable but do undergo the reverse reaction upon vacuum pyrolysis to 
reform the NHC. In the field of organocatalysis, adduct 172 has been known to 
participate in benzoin type condensation in which it acts as a metal free catalyst.24 With 
increasing numbers of publications on NHC in the field of organometallic chemistry and 
organocatalysis, new adducts continue to be synthesized, such as 173 and 176.25' 26 
Presently, adduct 174 formed from carbene is used as reducing agent.27 Moreover, 
carbenes can also undergo Michael addition and forms adducts such as 175.28 In 
addition, carbenes are so reactive that when they come in to contact with O2 or H2O they 
form cyclic ureas 177 and compounds such as 171 respectively. 
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Scheme 2.1 Synthetic Utility of NHC 
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2.1.4 NHC as Organocatalysts 
Today, NHC's have become an important class of organocatalysts. In 1943, Ugai 
and coworker reported the thiamine catalyzed reaction of benzaldehyde to produce 
benzoin as shown in scheme 2.2. Some years later, Breslow proposed mechanism for 
benzoin condensation and found that reaction proceeded through the thiamine carbene.29 
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Scheme 2.2 NHC-catalyzed Benzoin condensation 29 
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Another use of an NHC in organocatalysis was reported by Stetter and 
coworkers. 30 
Scheme 2.3 NHC-catalyzed Stetter reaction 30 
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They have extended the concept of benzoin condensation in which compound 183 
acts as a catalyst for the reaction of an aldehyde (e.g. 184) with a class of Michael 
acceptor substrates such as 185 to afford 1,4-dicarbonyl compounds such as 186 (Scheme 
2.3). The mechanism of Stetter reaction is shown in Scheme 2.4.30 
Scheme 2.4 Proposed Mechanism of Stetter reaction 
OMe 
186 
There are various natural products that have been synthesized using the Stetter 
reaction. In 1999, Tius synthesized rosephillin31(187) (Scheme 2.5) and later in 2007 
Nicolau synthesized platensimycin32(188), (Scheme 2.6) both via a Stetter reaction. 
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Scheme 2.5 Synthesis of Roseophilin using the Stetter reaction 31 
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Scheme 2.6 Synthesis of Platensimycin using the Stetter reaction 32 
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2.1.5 NHC-transition Metal Complexes and Catalysts 
NHC's have been complexed to a variety of metals, thereby acting as ligands. 
Many of these organometallic complexes are air and moisture stable, thus making them 
promising candidates for catalysis. Specifically, NHC have been found to form robust 
complexes with nearly every transition metal (e.g., Rh, Pd, Pt, Cu, Ru, Ni, Ag and Au). ' 
34
 In 1997, the first NHC-Metal complexes were synthesized by Herrmann et al.34 The 
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researchers used the newly synthesized Rh-NHC complexes for hydrosilylation of 
acetophenone derivatives.35 (Equation 2.8) 
H3C ,—\ ?ioH8 
C 1 0 H 8 * J _ N N - ^ - C H 3 
O Hs H 192 OSiHPh2 H Y H 
P h - \ Ph'SkPh -30°C,THF * P h ^ - " ^ - C l Equation 2.8 
189 190 191 
192 
Prior to Herrmann's work, there were many reactions that employed transition 
metals in conjunction with NHC, but most of these catalysts were generated in situ via 
deprotonation of azolium salts.35 
Stable NHC-metal complexes having very robust metal-NHC bonds are generally 
formed from either isolated NHC or in situ generated NHC. There are various routes for 
the synthesis of transition metal-NHC complexes. Among the various routes, 
transmetallation with Ag-NHC complexes is widely used because the requisite Ag-NHC 
complexes can be easily synthesized from the corresponding azolium salts and silver 
oxide and the transmetallation step avoids the handling of free reactive NHC (Scheme 
2.7).36 
Scheme 2.7 Synthesis of Pd-NHC 195 via transmetallation36 
M e s - N ^ % e s CH2CI2 
Br 93% 
193 
194 195 
Though there are certain cases reported where the NHC dissociates from the 
37-42 
metal, " in general NHC are stable transition metal ligands. NHC are two electron a 
43-46 donors with little to no 7r-back-donation. " Two adjacent nitrogen atoms contributes to 
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^--donation to the empty p-orbital so little or no ^--donation from the transition metal 
center is required for enhanced stability. The aforementioned electronic feature makes 
for robust metal-NHC bonds, which are often referred to as inert.47 
In addition, the steric bulkiness of NHC substituents ultimately affects the metal-
NHC bond dissociation energies.47 More bulky substituents makes the metal-NHC bond 
weaker as there will be less orbital interaction, and that leads to lengthening of metal-
NHC bond. For instance, the bulkier 1,3-diadamanthylimidazolylidene 196a has a 
relative BDE of 6.8 kcal/mol due to the steric hindrance of the bulky adamantyl groups.47 
On the other hand, the ruthenium complex of 1,3-dimestylimidazolylidene 196b has a 
BDE of 15.6kcal/ mol and the corresponding phosphine complexes 197a and 197b have 
BDE of 9.4 and 10 kcal/mol respectively. This example shows that sterically bulky 
substituents have a dramatic effect on bond dissociation energy of metal-NHC 
complexes. 
X I Ru V;R i% Ru' 
196a R: adamantyl 197a R': isopropyl 
196b R: mesityl 197b R': cyclohexyl 
NHC are better c-electron donating ligands than phosphines. This hypothesis can 
be evaluated using the IR stretching frequencies of the CO ligand in corresponding NHC 
or phosphine containing metal-carbonyl complexes. The main idea of evaluating the CO 
stretching frequencies is that the stronger a-donating ligands increase the electron density 
at the transition metal so there will be more 7r-back bonding on carbonyl ligands. As this 
electron density is pushed into the x* orbitals of CO, the bond order of CO is reduced and 
the CO stretching frequency is lowered. When CO stretching frequencies of complex 
198 and 199 was evaluated it was found to be in range between 2052.2 cm"1 and 2050.7, 
whereas the frequencies of 200a and 200b are 2056.1 and 2056.4 cm"1, respectively 
(Figure 2.4). From these results, it is apparent that NHC are thus better a-electron 
donating ligands than even the so-called "electron rich" trialkyl phosphines.48' 49 The 
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stronger electron donating ability of NHC is thus an advantage in catalysis where an 
electron rich metal center is frequently required (e.g. in cross-coupling reactions). 
Figure 2.4 Comparision of IR Stretching Frequencies of Ni-NHC and Ni-Phosphine 
Complexes 
R-N N-R. R-NyN-R PR"3 
Ni Ni Ni 
o' I \ o" l \
 0-' 1 \ 
OC coCO 0C" COCO 0 C COCO 
198a R: 2,6-diisopropyl 199a R: 2,6-diisopropyl 200a R": t-butyl 
198b R: mesityl 199b R: mesityl 200b R": cyclohexyl 
In addition to that, NHC-metal complexes are more stable than phosphine metal 
complexes. The enhanced stability of this complex makes it useful in transition metal 
catalysis reaction because higher turnover number can be achieved and less catalyst can 
be used. In 1995, Herrmann et al. were also the first research group to use an NHC-metal 
complex in transition metal catalysis as shown in Equation 2.9.50 The Heck cross-
coupling reaction was carried out at 130 °C for 36 hours with 0.1% mol of catalyst 201. 
Several other examples of the use of transition metal-NHC complexes in cross-coupling 
reactions are shown in Scheme 2.8 (the Buchwald-Hartwig cross-coupling)51 and Scheme 
2.9 (the Sonogashira cross-coupling). 52 
<^ - N -CH 3 
H 3 C Pck, 
N—\ 
02N 
N~CH3 
201 
O 
201 (0.1mol%) n-^ //—((
 r ±. „ „ 
v
 // \ /J \ Equation 2.9 02N 
36 h, 130 °C, quant. 
[N(A7-C4H9)4]Br 
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Scheme 2.8 Palladium-NHC Complex Catalyzed Amination of Aryl Halides51 
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Scheme 2.9 NHC-catalyzed Sonogashira Cross-Couplings52 
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One of the most important applications of NHC in the field of metal catalysis is 
almost certainly the development of the Grubbs' 2n generation ring-closing metathesis 
catalyst. The blockbuster ruthenium metathesis catalyst 203, which is widely used, was 
developed by Robert Grubbs in 1999 and contains an Af-heterocyclic carbene (NHC) as a 
ligand. The structure of the catalyst 128 is shown in Figure 2.5. 
Grubbs and co-workers reported their first molecularly well-defined ruthenium-
carbene complex RuCl2(PR3)(=CH-CH=CPh2)] (203, R=Ph) in 1992. The complex was 
active for the polymerization of norbornene and was stable in the presence of protic 
solvents.53 Several years later in 1995, Grubbs reported new molecularly-well-defined 
catalysts [Ru(=CHPh)Cl2(PR3)2], R=Ph or Cy (cyclohexyl) (127, R=Ph or Cy)54a'b having 
structural similarity to complex 203. 
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Figure 2.5 Structures of Various Grubbs' and Hoveyda-Grubbs' Catalysts 
Ruthenium-carbene complex Grubbs' 1s t generation catalyst 
203 127 
r^ r^ 
^ Y ^ ^ ^ N y N ^ 
Grubbs' 2nd generation catalyst 
128 
Hoveyda-Grubbs' 2nd generation catalyst 
143 
Catalyst (127) is sold commercially as the so-called first-generation Grubbs' 
catalyst for alkene metathesis. After thorough study of its reaction mechanism, it was 
concluded that the first step of the reaction pathway is the dissociation of one of the 
phosphines to produce the reactive ruthenium intermediate.55 To improve catalytic 
properties, Grubbs replaced one of the phosphines with a NHC ligand. 55 
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nd Equation 2.10 Synthesis of Grubbs' 2  Generation catalyst 
/ ^ 
0.01 M C6H6/THF 
80 °C, 15-30 min 
127 128 
The new more reactive catalyst 128 was synthesized as shown in Equation 2.10 
and subsequently commercialized. 128 is commonly referred to as the "second 
generation Grubbs catalyst". Catalyst 128 is currently the most widely used catalyst for 
efficient cross-metathesis reactions as it has greater thermal stability than any of its 
predecessors.56 Hoveyda has also modified Grubbs' 1st and 2nd generation catalysts by 
removing the 2nd phosphine ligand and installing an appropriate alkylidene that contains a 
stabilizing ethereal ligand. The resulting complexes are referred to as the Hoveyda-
Grubbs' 1st or 2nd generation catalyst (Figure 2.5). 
The alkene-metathesis reaction has become one of the most important carbon-
carbon bond-forming reactions that is presently available to the synthetic organic 
chemist. It is a rare to find a total synthesis of a complex natural product that does not 
involve the use of ring-closing metathesis (RCM) reaction. For example, during the 
course of pochonin C synthesized by Paquette and coworker, an advanced intermediate 
containing several alkenes 204 nevertheless smoothly undergoes a RCM reaction 
catalyzed by 128 to afford the desired product in 87% yield (Scheme 2.10).57 
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Scheme 2.10 The use of NHC Based Ru Catalyst in the Total Synthesis of Pochonin C57 
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Another example of the importance of catalysts (128) and (143) is demonstrated 
by their use in the synthesis of the securigena family of alkaloids58, as show in Equations 
1.11 and 1.16 in chapter 1. 
2.1.6 Acyclic Diaminocarbenes 
Acyclic diaminocarbenes (ADC) (207)59'60 on the other hand, have not attracted 
the same degree of attention as NHCs, despite several appealing characteristics. In 1997, 
Alder et al. reported the first isolation of a stable acyclic diaminocarbene, 207a, by 
deprotonation of the corresponding formamidinium salt with lithium diisopropylamide 
(LDA) as shown in Equation 2.11,59 
R 
R^ 
i 
R2 
-•V 
207 
207a: R1=R2=i-pr 
207b: R1=t-Bu, R2=Me 
207c: R1=R2=(CH2)4 
207d: R1=R2=(CH2)5 
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CI 0 
208 
LDA 
THF 
,NL ^N, 
207a 
+ HCI Equation 2.11 
ADC are easily synthesized from formamidinium salt precursors and are more 
basic compared to similar NHC.59 Alder showed that the pKa value of N,N-
dialkylformamidinium ions is ~ 24 in DMSO and based on calculated proton acidity, he 
estimated the pKa value of acyclic diaminocarbene to be approximately 2 to 6 pKa units 
higher than imidazolylidenes 59 
Wolfgang Herrmann and co-workers have studied the basic properties of ADC 
synthesized by deprotonation of the formamidinium salts with NaH in liquid NH3 at low 
temperatures.61 Successful reports of acyclic diaminocarbene formation enabled the 
synthesis of complexes of ADC with a variety of transition metals. For example, 
Hermann et al. successfully synthesized monocarbene rhodium(I) and iridium(I) 
complexes of free acyclic diaminocarbenes with the corresponding COD-metal 
chlorides 59,60 
Scheme 2.11 Synthesis of Acyclic Diaminocarbenes Rhodium(I) and Iridium(I) 
Complexes by Herrmann and Co-workers 59,60 
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However, the researchers were unable to synthesize bis-ADC metal complexes. 
The reason for this is likely due to the broadened NCN angle, and thus greater "steric 
size" of the ADC. Hermann and co-workers also reported that acyclic diaminocarbenes 
have evidently stronger electron donating effects as compared with their cyclic 
counterparts (NHC). 59,60 
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r ^ 
Carbene 
Rh 
CO 
NCI 
„ „ Carbene 
ocx / 
Rh 
O C / \ \ 
Carbene = 
209 
Equation 2.12 
The same researchers also examined the physical properties of several 
ADC/NHC-complexes as shown in Table 2.1. The requisite metal complexes were 
synthesized as shown in Equation 2.12. The v(CO)vibrations of cis-dicarbonyl carbene 
rhodium complexes 209 when complexed to ADC occurred at lower wavenumber 
compare to when 209 was complexed to NHC. In addition, chemical shifts for the 13C-
signals of the carbene carbon for ligand 207a also appear further downfield which 
confirms the greater of the s-character of the carbene atom of the ADC (Table 2.1). 
Table 2.1 Comparison of Physical Properties of Several ADC/NHC Complexes 
Carbene 
Y Y 
' 207a ' 
210 
211 
5 Carbene 
(C-atom) ppm 
255.5 
244.5 
211.14 
NCN 
Angle 
121.0 
104.7 
102.2 
v(CO) I 
cm"1 
2057 
2081 
2076 
v(CO) II 
cm"1 
1984 
1996 
2006 
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Based upon the results from the Table 2.1, it is clear that ADC ligands are more 
electron donating than the corresponding NHC. Therefore, it would be interesting to 
synthesize ADC complexes with a diverse range of metals in order to compare and 
contrast their properties with NHC-metal complexes. 
Towards this end, Furstner et al. have reported the synthesis and characterization 
of a series of ADC-metal complexes, and applied some of these catalysts in Heck cross-
coupling reactions (Scheme 2.12).62 
Scheme 2.12 ADC-metal Complex Catalyzed Heck Cross-coupling Reactions 62 
-,© 
Ph3P-Pd-PPh3 
i 
CI 
212 
PF? 
I I 
Ph3P-Pd-CI 
CI 
213 
R O Catalyst 212/213 
OBu 
OBu 
R=l, Br 
81 
2.2 Results and Discussion 
Concurrent to all the aforementioned studies, we were working towards 
evaluating the utility of ADC (207a-d) as potential ligands in the Suzuki-Miyaura 
reaction. Towards that end, we chose to investigate the cross-coupling between 2-bromo-
1,3-dimethylbenzene and 2-methylphenylboronic acid.63 
Figure 2.6 Examples of ADC and NHC 
R1 R1 /=\ n n 
i i 
R 
,N_NL ,
 D - N N . 2 ' " ' \ / , , , - R 2 d&b 207a: R1 = R2 = /-Pr 214: R = 2,6 disiopropylphenyl 
207b: R1 = t-Bu, R2 = Me 215: R = 2,4,6 trimethylphenyl
 216 
207c: R1 = R2 = (CH2)4 
207d: R1 = R2 = (CH2)5 
A number of ADC (207a-d) were screened as ligands. It is important to note that 
NHC such as (214-216) have been previously shown to be very effective ligands in a 
variety of cross-coupling reactions.64"66 Several reaction parameters were initially varied 
including the palladium source, base, solvent, and other additives. 
Table 2.2 Effect of the Nature of the Palladium Source on the Suzuki-Miyaura Coupling 
of 2-Bromo-l,3-dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as 
Ligand 
B(OH)2 P d s o u r Ce (x mol %) 
207a (1.25 mol %) 
"Bu4NBr (2.5 mol %) 
1.1equiv. Cs2C03(2eq.) 
PhCH3/THF, rt, 16 h 
82 
Entry Pd source(mol%) Yield(%) 
Pd2(dba)3/0.5 89 
Pd(OAc)2/1.0 62 
[Pd(allyl)Cl]2/0.5 80 
4 PdCl2(CH3CN)2/1.0 79 
207a prepared in situ via deprotonation of the corresponding formamidinium salt 
The first parameter screened was the source of the palladium. We found it to be 
optimal if 207a was allowed to pre-mix with the palladium catalyst before the addition of 
the other reagents. We suggest that this observation is due to the fact that once the ADC 
is bound to the metal center, the resulting catalyst species is more robust and less likely to 
degrade to palladium black during the course of the reaction. If 207a was added at the 
same time as the other reagents, lower conversions were observed probably due to the 
earlier appearance of palladium black in the reaction mixture. These studies showed that 
Pd2(dba)3 was the palladium source of choice. 
Table 2.3 Effect of Additives on the Suzuki-Miyaura Coupling of 2-Bromo-l,3-
dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 
1.1 equiv. 
Pd2(dba)3 (0.5mol%) 
207a (1.25 mol %) 
additives ( x mol %) 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16 h 
83 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
Additive 
None 
LiBr 
NH4Br 
"Bu4NBr 
"BU4NI 
"Bu4NBr 
"BmNBr 
"Bu4NBr 
Mol(%) 
-
5 
5 
5 
5 
2 
1 
1.25 
Yield(%) 
62 
65 
60 
90 
89 
90 
84 
89 
We next sought to investigate the effect of various additives in the 
aforementioned cross-coupling reaction (Table 2.3). Subsequent to these studies, we next 
look at the effect of the base on the Suzuki cross-coupling reaction catalyzed by ADC 
207a (Table 2.4). It should be noted that the use of nBu4NBr is precedented in NHC 
catalyzed Suzuki-Miyaura couplings.67 We found that the use of nBu4NBr allowed the 
palladium catalyst to remain homogenous and soluble for a longer period of time (i.e. 
palladium black formation was delayed until near full conversion was achieved) 
Table 2.4 Effect of the Nature of the Base on the Suzuki-Miyaura Coupling of 2-Bromo-
1,3-dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 
1.1 equiv. 
Pd2(dba)3 (0.5mol%) 
207a (1.25 mol %) 
"Bu4NBr (2.5 mol %) 
Base (x mol%) 
PhCH3/THF, rt, 16 h 
84 
Entry Base Equiv. Yield(%) 
1 None - <2 
2 Cs2C03 2.0 89 
3 ''Pr2NEt 2.0 <10 
4 CsF 2.0 85 
5 KOMe 5.0 78 
6 Na2C03 5.0 19 
7 NaOH 2.0 <10 
8 Cs2C03 1.5 85 
9 Cs2C03 1.1 77 
In addition, further optimization studies were carried out to determine the best 
solvent (Table 2.5), palladium to ligand (207a) ratio (Table 2.6), palladium loading 
(Table 2.7), stoichiometry of the boronic acid (Table 2.8), reaction time (Table 2.9), and 
temperature (Table 2.10) for Suzuki cross-coupling reaction using ADC 207a as the 
ligand. 
Table 2.5 Effect of the Solvent on the Suzuki-Miyaura Coupling of 2-Bromo-l,3-
dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 Pd2(dba)3 (0.5 mol %) 
207a (1.25 mol %) 
"Bu4NBr (1.25 mol %) 
1.1 equiv. Cs2C03(2eq.) 
Solvent/THF, rt, 16 h 
85 
Entry Solvent Yield(%) 
1 THF 70 
2 PhCH3 89 
3 DME 73 
4 DMA 80 
5 CH2C12 24 
6 Benzene 85 
Table 2.6 Effect of Pd:207a Ratio on the Suzuki-Miyaura Coupling of 2-Bromo-l,3-
dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 Pd2(dba)3 (0.5 mol %) 
207a (x mol %) 
"Bu4NBr (1.25 mol %) 
Hequ iv . Cs2C03(2eq.) 
PhCH3/THF, rt, 16 h 
Entry (207a)(mol%) Yield(%) 
1 0.5 43 
2 1.0 79 
3 1.25 89 
4 1.5 85 
86 
2.0 80 
4.0 61 
Table 2.7 Effect of Pd2(dba)3 Loading on the Suzuki-Miyaura Coupling of 2-Bromo-l,3-
dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 
1.1 equiv. 
Pd2(dba)3 (x mol %) 
207a (2.5 mol %) 
"Bu4NBr (2.5 mol %) 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16 h 
Entry Pd2(dba)3(mol%) Yield(%) 
1.5 95 
2 
3 
4 
5 
6 
1.0 
0.5 
0.3 
0.2 
0.1 
90 
89 
82 
59 
31 
87 
Table 2.8 Effect of the Stoichiometry of the Boronic Acid on the Suzuki-Miyaura 
Coupling of 2-Bromo-l,3-dimethylbenzene with 2-Methylphenylboronic Acid Using 
ADC 207a as Ligand 
B(OH)2 
x equiv. 
Pc 
"BL 
J2(dba)3 (0.5 mol %) 
207a (1.25 mol %) 
j4NBr (1.25 mol %) 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16 h 
Entry 
1 
2 
3 
4 
5 
6 
ArB(OH)2(equiv.) 
2.0 
1.5 
1.3 
1.2 
1.1 
1.0 
fl ^ 
\ ^ \ 
^ Y ^ i T ^ 
^ / 
Yield(%) 
96 
90 
89 
85 
89 
81 
Table 2.9 Effect of Reaction Time on the Suzuki-Miyaura Coupling of 2-Bromo-l,3-
dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 
1.1 equiv. 
Pd2(dba)3 (0.5 mol %) 
207a (1.25 mol %) 
> 
"Bu4NBr (1.25 mol %) 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, X h 
88 
Entry Time(h) Yield(%) 
1.0 47 
6.0 70 
12.0 84 
16.0 89 
24.0 88 
Table 2.10 Effect of Temperature on the Suzuki-Miyaura Coupling of 2-Chloro-l,3-
dimethylbenzene with 2-Methylphenylboronic Acid Using ADC 207a as Ligand 
B(OH)2 Pd2(dba)3 (0.5 mol %) 
207a (1.25 mol %) 
"Bu4NBr (1.25 mol %) 
1.1equiv. Cs2C03(2eq.) 
PhCH3/THF, temperature, 16 h 
Entry Temperature(°C) Yield(%) 
rt 22 
30 47 
45 81 
60 87 
80 95 
89 
After extensive screening of all the aforementioned parameters, the following set 
of standard reaction conditions were established with respect to the aryl/alkenyl halide: 
0.5 mol% Pd2(dba)3, 1.25 mol% (207a), 1.25 mol% "Bu4NBr,67 1.1 equiv. ArB(OH)2 and 
2 equiv. CS2CO3 in toluene-THF. The requisite ADC were synthesized in situ through 
deprotonation (LDA) of the corresponding formamidinium salts62 as originally reported 
by Alder et al. Bis(diisopropylamino)carbene (207a) was found to be the ligand of 
choice affording the desired tri-ortho-substituted biaryl (217a) in 89% isolated yield.68 
There was very little difference in efficacy when isolated carbene (207a) was used in 
CO 
place of the in situ generated variant. The room temperature Suzuki-Miyaura reaction 
was extended to a variety of other substrates, the results of which are shown in (Table 
2.11). 
Table 2.11 Room Temperature Suzuki-Miyaura Coupling of Aryl/Alkenyl Bromides 
Using ADC Ligand (207a) 
Pd2(dba)3(0.5mol%) 
207a (1.25 mol%)
 D D 
F^-Br + R2-B(OH)2 *" K1 K2 
1.1 equiv. "Bu4NBr (1.25 mol%) 217 
Cs2C03 (2 equiv.) 
PhCH3/THF,rt,16 h 
Entry 
1 
2 
3 
Ri-Br 
& 
V 
S^Br 
R2-B(OH)2 
, / ^ B ( O H ) 2 cc 
^ ^ B ( O H ) 2 
^ ^ B ( O H ) 2 
Yield(%) 
86 (217a) 
85 (217b) 
89 (217c) 
90 
4 
5 
6 
7 
8 
9 
10 
M e 2 N ^ ^ 
& 
& 
& 
rB' 
P h
^ B r 
6" 
cc 
TBSOCH2CH2 
N
^
X B ' 0 
6J> 
B(OH)2 
/ W B ( 0 H ) 2 17 
N 
^L/B(OH)2 
OMe 
A^B(OH)2 u 
J^-B(OH)2 
79 (217d) 
93 (217e) 
89 (217f) 
91 (217g) 
88 (217h) 
93 (217i) 
95 (217k) 
As the results in Table 2.11 show, the coupling was effective for sterically 
hindered aryl bromides (entries 5-7), heterocyclic bromides (entries 2,3) and alkenyl 
bromides (entries 8,9). The scope of the reaction was also established with a number of 
sterically demanding (entries 1—4) and electron rich boronic acids (entry 9). The nature 
of the boronic acid was also expanded to include alkenyl (entries 5,6) and heterocyclic 
variants (entry 7). 
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Table 2.12 Suzuki-Miyaura Coupling of Aryl/Alkenyl Chlorides Using ADC Ligand 
Pd2(dba)3 (0.5 mol%) 
207a (1.25 mol%)
 D D 
Ri-CI + R2-B(OH)2 *" K1 K2 
1.1equiv. nBu4NBr (1.25 mol%) 2 1 7 
Cs2C03 (2 equiv.) 
PhCH3/THF,45°C,16h 
Entry Ri-Cl R2-B(OH)2 Yield(%) 
CI / ^ B ( O H ) 2 cc 81 (217a) 
OHC - \ / - c i 
B(OH)2 89(217j) 
B(OH)2 80 (217a) 
B(OH)2 86 (217k) 
CI 
B(OH)2 
COCH3 
88 (2171) 
Me2N 
CI OMe 
A^B(OH)2 u 85 (217m) 
OMe 
CI ^ . B ( O H ) 2 u 92(217n) 
92 
B(OH)2 89(217i) 
A significant improvement to the cross-coupling process would be to enable the 
use of aryl chlorides in the Suzuki-Miyaura reaction. Initial optimization studies 
involving 2-chloro-l,3-dimethylbenzene and 2-methylphenylboronic acid revealed that 
the coupling reaction, when conducted under the conditions reported in Table 2.11, 
proceeded rather sluggishly (22% isolated yield of 217a). Fortunately, elevating the 
reaction temperature from rt to 45 °C resulted in a much more facile reaction (80% 
isolated yield of 217a). A variety of aryl chlorides and boronic acids were then subjected 
to the cross-coupling reaction using ADC ligand (207a) (Table 2.12). As before, the 
desired products were obtained in good yields. 
To round off the studies into the efficacy of using ADC as ligands in a variety of 
cross-coupling reaction, we explored the use of 207a in the Sonogashira reaction.6 
Before proceeding with the actual cross-coupling of various alkynes, we sought to 
investigate the effect of various parameters on the Sonogashira reaction using ADC 207a 
as the ligand. Towards this end, we looked at the effect of the palladium source and 
loading (Table 2.13), the stoichiometry of the palladium pre-catalyst and 207a (Table 
2.14), the stoichiometry of the alkyne (Talbe 2.15), and the various additives on the 
Sonogashira cross-coupling reaction. 
Table 2.13 Effect of the Palladium Source and Loading on the Room Temperature 
Sonogashira Coupling of Aryl Bromides Using Ligand 207a 
+ Phr 
1.1 equiv. 
Pd Source (x mol %) 
207a (1.33 mol %) 
5 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16 h 
Ph 
93 
Entry Pd source Mol(%) Yield(%) 
1 Pd2(dba)3 1.5 70 
2 Pd(OAc)2 1.5 51 
3 [Pd(allyl)Cl]2 1.5 80 
4 PdCl2(CH3CN)2 1.5 71 
5 [Pd(allyl)Cl]2 1.0 65 
6 [Pd(allyl)Cl]2 0.5 49 
207a prepared in situ via deprotonation of the corresponding formamidinium salt 
Table 2.14 Effect of the Ratio of [Pd(allyl)Cl]2:207a on the Room Temperature 
Sonogashira Coupling of Aryl Bromides Using Ligand 207a 
Ph 
[Pd(allyl)CI2](1.5mol%) 
207a (x mol %) 
+ P h — = 
1.1 equiv. 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16 h 
Entry (207a)(mol%) Yield(%) 
1 1.5 49 
2 3.0 73 
3 4.0 80 
4 5.0 81 
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Table 2.15 Effect of the Stoichiometry of Alkyne on the Room Temperature 
Sonogashira Coupling of Aryl Bromides Using Ligand 207a 
Ph 
+ Ph-
x equiv. 
[Pd(allyl)CI2](1.5mol%) 
207a (4 mol %) 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16h 
Entry Alkyne(equiv.) Yield(%) 
2.0 84 
1.5 80 
1.1 81 
Table 2.16 Effect of the Additives on the Room Temperature Sonogashira Coupling of 
Aryl Bromides Using Ligand 207a 
Ph 
+ Prr 
x equiv. 
[Pd(allyl)CI2](1.5mol%) 
207a (4 mol %) 
- 1 
additive (x mol%) 
Cs2C03 (2 eq.) 
PhCH3/THF, rt, 16 h 
Entry Additive Mol(%) Yield(%) 
1 none 80 
2 "Bu4NBr 1.25 80 
3 "Bu4NBr 4.0 75 
95 
The optimized copper-free protocol, which turned out to be similar to one 
previously reported by Soheili et al.,70 is as follows: aryl halide (1 equiv.), alkyne (1.1 
equiv.), [Pd(allyl)Cl]2 (1.5 mol%), (207a) (4 mol%), Cs2C03 (2 equiv.), PhCH3/THF, rt, 
16 h. A variety of aryl halides were subjected to the conditions reported above, the 
results of which are shown in Table 2.17. The room temperature Sonogashira reaction 
worked well with both aromatic (entries 1, 2, 4-6) and aliphatic alkynes (entries 3, 7). A 
range of sterically hindered- (entry 1), electron rich- (entries 2-4) and heterocyclic aryl 
bromides (entries 6, 7) were employed as coupling partners. The resulting products were 
consistently obtained in good isolated yields. 
Table 2.17 Room Temperature Sonogashira Coupling of Aryl Bromides Using ADC 
Ligand 
[Pd(allyl)CI]2(1.5mol%) 
D1 D D3 — 207a(4mol%) R i — R 3 R1-Br + R 3 ^ ^ *• K — K 
1.1 equiv. nBu4NBr (1.25 mol%) 218 
Cs2C03 (2 equiv.) 
PhCHVTHF, rt,16h 
Entry 
1 
2 
3 
4 
R'-Br 
& : 
M e O ^ ^ ^ 
OMe 
6-* 
R3 = 
P h ^ = 
P h — ^ 
HO 
\ — 
Ph-HEEE 
Yield(%) 
80 (218a) 
87 (218b) 
80 (218c) 
91 (218d) 
96 
5 
6 
7 
& 
O* 
erf 
Ph 
i n — 
P h ^ = 
HO 
\ — 
89 (218e) 
90 (218f) 
81 (218g) 
Finally, to conclude the studies into the applicability of ADC as ligands in cross-
coupling reactions, we also briefly examined the use of ADC 207a in intermolecular 
Heck reactions.71 Several initial optimization studies were carried out to investigate the 
effect of various reaction parameters on the intermolecular Heck cross-coupling reaction, 
the results of which are shown in Tables 2.18 and 2.19. 
Table 2.18 Effect of Temperature, Time and Solvent on the Heck Reaction of Aryl 
Bromides Using ADC 207a as Ligand 
O (1.5 equiv.) 
NOMe 
Pd2(dba)3 (0.5 mol %) 
Br 207a (1.25 mol %) 
• 
"Bu4NBr (1.25 mol %) 
Cs2C03 (2 eq.) 
Solvent, THF, temperature 
OMe 
97 
Entry Solvent Temperature(°C) Time(h) Yield(%) 
1 PhCH3 110 8 39 
2 DMF 110 8 73 
3 
4 
5 
6 
DMA 
DMA 
DMA 
DMA 
110 
110 
90 
50 
8 
16 
8 
8 
78 
80 
62 
17 
Table 2.19 Effect of Palladium Source and Additives on the Heck Reaction of Aryl 
Bromides Using ADC 207a as Ligand 
O 
II (1.5equiv.) 
^ ^ T > M e 
Pd Source (x mol %) 
Br 207a (1.25 mol %) 
>• 
additive (x mol %) 
Cs2C03 (2 eq.) 
Solvent, THF, temperature 
Entry Palladium Source(mol%) Additive(mol%) Yield(%) 
1 Pd2(dba)3(0.5) None 61 
2 Pd2(dba)3(0.5) "Bu4NBr(1.25) 78 
3 Pd2(dba)3(0.25) "Bu4NBr(0.65) 38 
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R 
4 
5 
6 
7 
Jr 
Pd(OAc)2(1.0) 
Pd(OAc)2(1.0) 
[Pd(allyl)Cl]2(0.5) 
PdCl2(CH3CN)2(1.0) 
0 
II (1.5equiv.) 
Pd2(dba)3 (0.5 mol%) 
207a (1.25 mol %) 
nBu4NBr(1.25mol%) RJ 
Cs2C03 (2 equiv.) 
DMA/THF, 110°C, 8h 
None 
"Bu4NBr(1.25) 
"Bu4NBr(1.25) 
"Bu4NBr(1.25) 
O 
219a R = F, 85% 
219b R= H, 78% 
22 
32 
73 
61 
Equation \ 
After the initial optimization studies were conducted, two aryl bromides were 
coupled to an electron deficient alkene (methyl acrylate) in good yields as shown in 
Equation 2.32. The corresponding aryl chlorides, however, were poor substrates for the 
Heck reaction (35% and 29% isolated yields of 219a and 219b respectively) under the 
otherwise identical conditions shown in Equation 2.32. 
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2.3 Conclusion and Future Work 
In summary, we demonstrated for the first time that ADC are useful ligands for 
the Suzuki, Sonogashira and Heck reactions, affording the desired products in good to 
excellent yields. Due to its likely greater electron-donating properties, ADC can be 
appropriately substituted for NHC in typical cross-coupling reactions. We also anticipate 
further applicability of ADC in prototypical organocatalyzed reaction (e.g. Stetter, 
benzoin condensation). Ultimately, the goal, which we are already working towards, is 
the development of an entire platform of chiral ADC for use in important enantioselective 
transformations. Perhaps it would be a good idea to compare the results obtain with ADC 
207a to the literature results obtained using NHC-Pd 221 in the Suzuki reaction by 
Michael Organ et al 72 
V 
220 221 
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2.4 Experimental procedures and characterization data 
General information is the same as Chapter 1 except toluene and 7V,iV-dimethylacetamide 
(DMA) were dried and distilled over calcium hydride. THF, toluene and DMA were 
also degassed (freeze-pump-thaw) just prior to use. Cesium carbonate was dried under 
vacuum (60 °C, 1 mmHg) just prior to use. Aryl and alkenyl halides in liquid form were 
distilled prior to use. Methyl acrylate was distilled just prior to use. All the requisite 
formamidinium salts were prepared as previously described by Alder et al, and without 
any modifications.74 
2.4.1 General Procedure for Suzuki Couplings of Aryl Bromides/Chlorides (Tables 
2.11-2.12) 
A 1.25 M solution of carbene 207a was made as follows74: To a solution of 
diisopropylaminomethylidene(diisopropyl)ammonium tetrafluoroborate (1.500 g, 5.00 
mmol) in anhydrous THF (2.33 mL) cooled to -20 °C was added a freshly prepared 
solution of LDA (3.0 M in THF, 1.67 mL, 5.00 mmol). The reaction mixture was stirred 
for 30 min at -20 °C prior to the next step. 
To a solution of Pd2(dba)3 (9.0 mg, 0.010 mmol) in anhydrous THF (0.25 mL) cooled to 
-20 °C was added carbene 207a (1.25 M in THF, 20 mL, 0.025 mmol). The reaction 
mixture was stirred for 30 min at -20 °C, and another 5 min at rt. Anhydrous toluene 
(2.50 mL) was then added followed by cesium carbonate (1.30 g, 4.00 mmol), tetra-n-
butylammonium bromide (8.0 mg, 0.025 mmol), aryl/alkenyl halide (2.00 mmol) and 
boronic acid/ester (2.20 mmol) in that particular order. For aryl/alkenyl bromides (Table 
2.11)-the reaction mixture was subsequently stirred for 16 h at rt. For aryl chlorides 
(Table 2.12)-the reaction was subsequently stirred for 16 h at 45 °C. The reaction 
mixture was next diluted with EtOAc/hexanes (1:1, 30 mL), filtered and concentrated in 
vacuo. The residue was then subjected to silica gel chromatography. Please note that the 
reactions with the aryl chlorides were carried out at half-scale (i.e. 1 mmol of the aryl 
chloride was employed). 
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2,2',6-Trimethylbiphenyl (217a) 
Chromatographic purification by hexanes (Rf = 0.3). 217a (330 mg, 86%) was isolated as 
a clear, colorless oil : !H NMR (CDC13, 500 MHz) 5 7.32 - 7.25 (3H, m), 7.22 - 7.11 
(3H, m), 7.07 - 7.02 (1H, m), 2.00 (3H, s), 1.98 (6H, s); 13C NMR (CDCI3, 125 MHz) 5 
141.08, 140.53, 135.84, 135.60, 129.95, 128.83, 127.20, 126.98, 126.89, 126.03, 20.31, 
19.37. 
3-(2,6-Dimethylphenyl)pyridine(217b)76 
Chromatographic purification by hexanes:EtOAc (9:1) (Rf = 0.2). 217b (311 mg, 85%) 
was isolated isolated as a clear, colorless oil: [H NMR (CDC13, 500 MHz) 8 8.47 (1H, d, 
J= 3.5 Hz), 8.31 (1H, s), 7.50 (1H, dt, J= 7.5, 2.0 Hz), 7.35 (1H, dd, J= 7.5, 5.0 Hz), 
7.21 (1H, dd, J= 8.0, 7.0 Hz), 7.13 (2H, d, J= 7.5 Hz), 2.02 (6H, s); 13C NMR (CDCI3, 
125 MHz) 8 149.55, 147.61, 137.59, 136.89, 136.14, 127.81, 127.44, 125.84, 123.36, 
20.78. 
2-(2,6-Dimethylphenyl)thiophene (217c) 
Chromatographic purification by hexanes (Rf = 0.4). 217c (334 mg, 89%) was isolated as 
a clear, colorless oil: !H NMR (CDC13, 300 MHz) 8 7.40 (1H, dd, J = 5.0, 1.0 Hz), 7.24 -
7.10 (4H, m), 6.85 (1H, dd, J= 3.0, 1.0 Hz), 2.18 (6H, s); 13C NMR (CDCI3, 125 MHz) 8 
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141.31, 138.42, 134.04, 128.04, 127.22, 127.02, 126.23, 125.26, 20.78; IR (film) u 3141, 
3066, 3021, 2953, 2922, 2855, 1582, 1463, 1441, 1377, 1253, 1237, 1194, 1039, 951, 
848, 830, 771, 731, 695 cm '; HRMS (CI) m/z calcd. for Ci2Hi2S (M+) 188.0660, found 
188.0654. 
(2'6'-Dimethylbiphenyl-4-yl)dimethylamine (217d) 
Chromatographic purification by hexanes:EtOAc (8:2) (Rf = 0.1). 217d (354 mg, 79%) 
was isolated as a clear, colorless crystalline solid: m.p. = 75-77 °C (CHCI3); *H NMR 
(CDCI3, 500 MHz) 8 7.18 - 7.11 (3H, m), 7.05 (2H, d, J= 8.5 Hz), 6.82 (2H, d, J= 8.5 
Hz), 3.02 (6H, s), 2.10 (6H, s); l3C NMR (CDC13, 125 MHz) 5 149.07, 141.99, 136.80, 
129.69, 129.09, 127.14, 126.54, 112.35, 40.60, 20.99; IR (KBr) u 3156, 2918, 2852, 
2794, 1830, 1612, 1524, 1465, 1441, 1376, 1340, 1223, 1193, 1165, 1123, 1096, 1060, 
1030, 946, 822, 767 cm"1; HRMS (CI) m/z calcd. for Ci6H20N (MH+) 226.1596, found 
226.1599 
(E)-tert-Butyl [4-(2,6-dimethylphenyl)but-3-enyloxy] dimethylsilane (217e) 
OTBS 
Chromatographic purification by hexanes (Rf = 0.4). 217e (542 mg, 93%) was isolated as 
a clear, colorless oil: "H NMR (CDC13, 500 MHz) 5 7.03 - 7.00 (3H, m), 6.39 (1H, d,J = 
16.0 Hz), 5.69 (1H, dt, J= 16.0, 7.0 Hz), 3.77 (2H, t,J= 7.0 Hz), 2.47 (2H, dq, J= 7.0, 
1.0 Hz), 2.30 (6H, s), 0.92 (9H, s), 0.60 (6H, s); l3C NMR (CDC13, 125 MHz) 5 137.56, 
135.93, 132.25, 129.19, 127.56, 126.18, 63.11, 37.14, 25.95, 20.93, 18.33, 5.28; IR (film) 
v 3111, 2954, 2929, 2857, 1670, 1471, 1379, 1361, 1255, 1097, 1006, 971, 940, 836, 768 
cm '; HRMS (CI) m/z calcd. forC,8H3|OSi (MH+) 291.2144, found 291.2137. 
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l,3-Dimethyl-2-[CE)-2-phenyl-l-ethenyl]benzene(217f) 
Chromatographic purification by hexanes (Rf= 0.3). 217f (370 mg, 89%) was isolated as 
a clear, colorless crystalline solid: m.p. = 33-35 °C (CHC13); 'H NMR (CDC13, 300 MHz) 
5 7.52 (2H, q,J= 7.5 Hz), 7.39 (2H, d, J= 7.5 Hz), 7.37 - 7.26 (1H, m), 7.13 (1H, d, J = 
16.5 Hz), 7.12 - 7.08 (3H, m), 6.62 (1H, d, J= 16.5 Hz), 2.39 (6H, s); 13C NMR (CDC13, 
75 MHz) 5 137.67, 137.02, 136.31, 134.04, 128.73, 127.94, 127.64, 127.01, 126.77, 
126.35,21.13. 
1 -(1,2-Diisopropylpenta-1,4-dienyl)-2-methylbenzene (217g) 
Chromatographic purification by hexanes (Rf = 0.25). 217g (428 mg, 91%) was isolated 
as a clear, colorless oil: 'H NMR (CDC13, 500 MHz) 5 7.20 - 7.09 (3H, m), 6.95 (1H, dd, 
J =7.0, 1.5 Hz), 5.67 - 5.58 (1H, m), 4.92 - 4.83 (2H, m), 2.52 - 2.39 (3H, m), 2.31 -
2.23 (1H, m), 2.18 (3H, s), 2.12 - 2.02 (2H, m), 1.57 - 1.45 (2H, m), 1.42 - 1.23 (2H, m), 
0.99 (3H, t, J= 7.5 Hz), 0.89 (3H, t, J= 7.5 Hz); 13C NMR (CDC13, 125 MHz) 8 142.92, 
137.14, 136.40, 135.32, 133.50, 129.74, 129.37, 126.13, 125.08, 114.95, 37.47, 35.66, 
32.30, 21.85, 21.44, 19.42, 14.31 (one overlap); IR (film) v 3120, 3059, 3014, 2959, 
2871, 1677, 1635, 1485, 1455, 1378, 1119, 1092, 1042, 910, 767, 758, 733 cm '; HRMS 
(EI) m/z calcd. for C18H26 (M+) 242.2035, found 242.2038. 
l-Methoxy-2-[(£)-2-phenyl-l-ethenyl]benzene(217h)78 
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Chromatographic purification by hexanes:EtOAc (95:5) (Rf = 0.3). 217h (389 mg, 88%) 
was isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 5 7.61 (1H, dd, J = 
7.5, 1.5 Hz), 7.55 (2H, d, J= 7.5 Hz), 7.50 (1H, d, J= 16.5 Hz), 7.36 (2H, t,J= 7.5 Hz), 
7.28 - 7.23 (2H, m), 7.13 (1H, d, J - 16.5 Hz), 6.98 (1H, t,J= 7.5 Hz), 6.91 (1H, d,J = 
8.0 Hz), 3.90 (3H, s); 13C NMR (CDC13, 125 MHz) 5 156.91, 137.96, 129.09, 128.64, 
128.56, 127.33, 126.55, 126.44, 126.40, 123.49, 120.73, 110.93, 55.51; HRMS (CI) m/z 
calcd. for C15Hi40 (M+) 210.1045, found 210.1054. 
2,2'-DimethyIbiphenyl (217i)79 
Chromatographic purification by hexanes (Rf = 0.25). 217i (347 mg, 93%) was isolated 
as a clear, colorless oil: 'H NMR (CDC13, 500 MHz) 5 7.38 - 7.30 (6H, m), 7.23 - 7.20 
(2H, m), 2.17 (6H, s); 13C NMR (CDC13, 125 MHz) 5 141.55, 135.73, 129.76, 129.23, 
127.11, 125.50,19.79. 
5-(2,6-Dimethylphenyl)furan-2-carbaldehyde (217j) 
OHC^ 0 >VS 
Chromatographic purification by hexanes:EtOAc (8:2) (Rf= 0.3). 217j (179 mg, 89%) 
was isolated as a clear, colorless crystalline solid: m.p. = 143-145 °C (CHCI3) 'H NMR 
(CDCI3, 500 MHz) 5 9.67 (1H, s), 7.36 (1H, d, J= 3.5 Hz), 7.24 (1H, t,J= 7.5 Hz), 7.11 
(2H, d, J= 7.5 Hz), 6.52 (1H, J= 3.5 Hz), 2.12 (6H, s); 13C NMR (CDC13, 125 MHz) 5 
177.56, 158.90, 152.29, 138.23, 129.64, 129.22, 127.70, 121.96, 112.49, 20.43; IR (KBr) 
D 3102, 2965, 2847, 1666, 1640, 1526, 1468, 1384, 1278, 1231, 1172, 1023, 964, 922, 
812, 771 cm"1; HRMS (CI) m/z calcd. for Ci3Hi202 (M+) 200.0837, found 200.0836. 
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2,6-Dimethyl-4 '-methylsulfanylbiphenyl (217k) 
Chromatographic purification by hexanes (Rf = 0.2). 217k (196 mg, 95%) was isolated as 
a white solid: m.p. = 48-50 °C (CHC13) !H NMR (CDC13, 300 MHz) 5 7.41 - 7.33 (2H, 
m), 7.24 - 7.09 (5H, m), 2.57 (3H, s), 2.09 (6H, s) ;13C NMR (CDC13, 75 MHz) 5 141.14, 
137.77, 136.47, 136.12, 129.50, 127.26, 127.03, 126.49, 20.81, 15.73; IR (KBr) u 3115, 
3056, 2917, 2853, 1870, 1675, 1464, 1438, 1388, 1183, 1164, 1109, 1090, 964, 822, 77, 
753 cm"1; HRMS (CI) m/z calcd. for Ci5Hi6S (M+) 228.0973, found 228.0975. 
l-(2',4',6'-Trimethylbiphenyl-3-yl)ethanone(2171) 
Chromatographic purification by hexanes:Et20 (9:1) (Rf= 0.3). 2171 (210 mg, 88%) was 
isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 5 7.94 (1H, dt, J= 8.0, 1.0 
Hz), 7.75 (1H, t, J= 1.5 Hz), 7.52 (1H, t,J= 8.0 Hz), 7.36 (1H, dt,J= 7.5, 1.5 Hz), 6.96 
(2H, s), 2.61 (3H, s), 2.34 (3H, s), 1.99 (6H, s); 13C NMR (CDCI3, 125 MHz) 5 198.20, 
145.51, 137.85, 137.32, 137.05, 135.78, 134.14, 129.33, 128.73, 128.19, 126.53, 26.70, 
20.99, 20.72; IR (film) v 3120, 3040, 2919, 1686, 1613, 1599, 1579, 1474, 1433, 1356, 
1286, 1230, 1034, 851, 799, 704 cm"1 HRMS (CI) m/z calcd. for C17H,80 (M+) 238.1358, 
found 238.1361. 
(2 '-Methoxybiphenyl-4-yl)dimethylamine (217m) 
MeCX ^ - \ 
I 
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Chromatographic purification by hexanes:EtOAc (8:2) (Rf = 0.2). 217m (193 mg, 85%) 
was isolated as a yellow solid: m.p. - 45-46 °C (CHC13); *H NMR (CDCI3, 300 MHz) 5 
7.45 (2H, dd, J= 9.0, 2.0 Hz), 7.32 (1H, dd, J= 7.5, 2.0 Hz), 7.26 (1H, dt, J= 8.5, 1.5 
Hz), 7.04 - 6.94 (2H, m), 6.80 (2H, d, J= 8.5 Hz), 3.82 (3H, s), 2.99 (6H, s); I3C NMR 
(CDCI3, 75 MHz) 8 156.44, 149.51, 130.75, 130.42, 130.13, 127.51, 126.62, 120.72, 
112.17, 111.05, 55.46, 40.61; IR (KBr) u 3062, 2932, 2833, 1678, 1613. 1526, 1489, 
1462, 1353, 1297, 1261, 1239, 1198, 1166, 1120, 1057, 1029, 947, 819, 803, 752 cm '; 
HRMS (CI) m/z calcd. for C,5H17NO (M+) 227.1310, found 227.1313. 
2-Methoxy-2 '-methylbiphenyl (217n)80 
OMe f^\ 
Chromatographic purification by hexanes:EtOAc (95:5) (Rf = 0.3). 217n (183 mg, 92%) 
was isolated as a clear, colorless crystalline solid: m.p. = 42-44 °C (CHCI3) *H NMR 
(CDCI3, 500 MHz) 8 7.34 - 7.26 (6H, m), 7.01 (2H, d, J = 8.0 Hz), 3.89 (3H, s), 2.33 
(3H, s); 13C NMR (CDCI3, 125 MHz) 8 158.48, 141.52, 135.44, 134.33, 130.27, 130.22, 
129.88, 126.95, 125.74, 113.45, 55.22, 20.53 (two overlap). 
2.4.2 General Procedure for Sonogashira Couplings of Aryl Bromides (Table 2.17) 
A 1.25 M solution of carbene 207a was made as follows73: To a solution of 
diisopropylaminomethylidene(diisopropyl)ammonium tetrafluoroborate74 (1.500 g, 5.00 
mmol) in anhydrous THF (2.33 mL) cooled to -20 °C was added a freshly prepared 
solution of LDA (3.0 M in THF, 1.67 mL, 5.00 mmol). The reaction mixture was stirred 
for 30 min at -20 °C prior to the next step. 
To a solution of [Pd(allyl)Cl]2 (5.5 mg, 0.015 mmol) in anhydrous THF (0.25 mL) cooled 
to -20 °C was added carbene 207a (1.25 M in THF, 32 uL, 0.04 mmol). The reaction 
mixture was stirred for 30 min at -20 °C, and then for 5 min at rt. Anhydrous toluene 
(1.00 mL) was then added followed by cesium carbonate (652 mg, 2.00 mmol), aryl 
bromide (1.00 mmol) and acetylene (1.10 mmol) in that particular order. The reaction 
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mixture was subsequently stirred for 16 h at rt. The mixture was then diluted with Et20 
(20 mL), filtered through celite, and the filtrate concentrated in vacuo. The resulting 
residue was purified by silica gel chromatography. 
2,6-Dimethyl-l-(phenylethynyl)benzene(218a)70 
Chromatographic purification by hexanes (Rf = 0.25). 218a (160 mg, 80%) was isolated 
as a clear, colorless oil: *H NMR (CDC13, 300 MHz) 5 7.61 - 7.55 (2H, m), 7.43 - 7.34 
(3H, m), 7.20 - 7.08 (3H, m), 2.56 (6H, s); 13C NMR (CDC13, 75 MHz) 8 140.23, 131.37, 
128.34, 128.07, 127.45, 126.67, 123.79, 122.92,97.80,87.10,21.11. 
3-Methyl-4-(phenylethynyl)anisole(218b)81 
MeO 
Chromatographic purification by hexanes:EtOAc (8:2) (Rf = 0.3). 218b (193 mg, 87%) 
was isolated as a white solid: m.p. = 78-79 °C (CHC13); 'H NMR (CDC13, 500 MHz) 5 
7.56 (2H, d, J= 8.0 Hz), 7.47 (1H, d, J= 8.5 Hz), 7.42 - 7.32 (3H, m), 6.81 (1H, d, J = 
2.5 Hz), 6.75 (1H, dd, J= 8.5, 2.5 Hz), 3.83 (3H, s), 2.54 (3H, s); 13C NMR (CDC13, 125 
MHz) 5 159.50, 141.94, 133.11, 131.29, 128.27, 127.80, 123.80, 115.23, 115.06, 111.19, 
91.89,88.34,55.17,20.99. 
3-(4-Methoxy-2-methylphenyl)prop-2-yn-l-ol(218c) 
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Chromatographic purification by hexanes:CH2Cl2 (8:2) (Rf = 0.25). 218c (106 mg, 80%) 
was isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 5 7.33 (1H, d, J= 8.5 
Hz), 6.73 (1H, d, J= 2.0 Hz), 6.67 (1H, dd, J= 8.5, 2.5 Hz), 4.52 (2H, s), 3.79 (3H, s), 
2.41 (3H, s), 1.71 (1H, br s); l3C NMR (CDC13, 125 MHz) 8 159.66, 142.09, 133.45, 
115.04, 114.59, 111.21, 89.56, 84.59, 55.20, 51.81, 20.90; IR (film) u 3424, 2213, 1643, 
1497, 1234, 1163, 1120, 1039 cm '; HRMS (CI) m/z calcd. for C11H12O2 (M+) 176.0837, 
found 176.0837. 
2-(Phenylethynyl)anisole(218d)82 
Ph 
Chromatographic purification by hexanes:EtOAc (9:1) (Rf = 0.25). 218d (189 mg, 91%) 
was isolated as a clear, colorless oil: !H NMR (CDC13, 500 MHz) 8 7.62 (2H, dd, J= 8.0, 
1.5 Hz), 7.56 (1H, dd, J= 7.5, 1.5 Hz), 7.41-7.31 (4H, m), 6.98 (1H, t, J= 7.5 Hz), 6.93 
(1H, d, J= 8.5 Hz), 3.94 (3H, s); 13C NMR (CDC13, 125 MHz) 8 159.81, 133.47, 131.56, 
129.70, 128.17, 128.03, 123.45, 120.38, 112.28, 110.57, 93.34, 85.67, 55.69. 
2-(Phenylethynyl)toluene (218e) 
Chromatographic purification by hexanes (Rf = 0.5). 218e (171 mg, 89%) was isolated as 
a clear, colorless oil: *H NMR (CDCI3, 300 MHz) 8 7.60 - 7.50 (3H, m), 7.41 - 7.33 (3H, 
m), 7.26 - 7.16 (3H, m), 2.54 (3H, s); 13C NMR (CDC13, 75 MHz) 8 140.15, 131.80, 
131.48, 129.43, 128.32, 128.28, 128.14, 125.55, 123.50, 122.98, 93.31, 88.30, 20.73. 
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3-(Phenylethynyl)pyridine (218f) 
Chromatographic purification by hexanes:EtOAc (9:1) (Rf = 0.2). 218f (162 mg, 90%) 
was isolated as a white solid: m.p. = 48-50 °C (CHC13); 'H NMR (CDC13, 500 MHz) 5 
8.77 (1H, d, J= 1.0 Hz), 8.53 (1H, dd, J= 4.5, 1.0 Hz), 7.79 (1H, dt, J= 8.0, 2.0 Hz), 
7.57 - 7.52 (2H, m), 7.38 - 7.33 (3H, m), 7.28 (1H, dd, J = 8.0, 5.0 Hz); 13C NMR 
(CDCI3, 125 MHz) 5 152.10, 148.42, 138.30, 131.56, 128.69, 128.33, 122.92, 122.36, 
120.32,92.53,85.83. 
3-Quinolin-3-ylprop-2-yn-l-ol(218g)84 
Chromatographic purification by 2% MeOH/CH2Cl2 (Rf = 0.25). 218g (149 mg, 81%) 
was isolated as a white solid: m.p. = 121-123 °C (CHCI3); 1H NMR (CD3OD, 500 MHz) 
5 8.78 (1H, d, J= 1.5 Hz), 8.33 (1H, s), 7.98 (1H, d, J= 8.5 Hz), 7.85 (1H, d, J= 8.0 Hz), 
7.74 (1H, dt, J= 8.0, 1.5 Hz), 7.59 (1H, t, J = 8.0 Hz), 4.76 (2H, s) (OH not detected); 
13C NMR (CD3OD, 75 MHz) 5 152.75, 147.36, 140.34, 131.77, 129.15, 129.04, 128.81, 
128.75, 118.57, 92.85, 82.15, 51.17. 
2.4.3 General Procedure for Heck Couplings of Aryl Bromides (Equation 2.32) 
A 1.25 M solution of carbene 207a was made as follows73: To a solution of 
diisopropylaminomethylidene(diisopropyl)ammonium tetrafluoroborate74 (1.500 g, 5.00 
mmol) in anhydrous THF (2.33 mL) cooled to -20 °C was added a freshly prepared 
solution of LDA (3.0 M in THF, 1.67 mL, 5.00 mmol). The reaction mixture was stirred 
for 30 min at -20 °C prior to the next step. 
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A solution of Pd2(dba)3 (9.1 mg, 0.010 mmol) in anhydrous THF (0.25 mL) in a sealed 
tube equipped with a septa was cooled to -20 °C. To this solution was added carbene 
207a (1.25 M in THF, 20 uL, 0.025 mmol). The reaction mixture was stirred for 30 min 
at -20 °C, and another 5 min at rt. Anhydrous AfJV-dimethylacetamide (2.50 mL) was 
then added followed by cesium carbonate (1.30 g, 4.00 mmol), tetra-«-butylammonium 
bromide (8.1 mg, 0.025 mmol), aryl bromide (2.00 mmol) and methyl acrylate (270 uL, 
3.00 mmol) in that particular order. The septa was then removed and the tube sealed. 
The sealed tube was subsequently heated at 110 °C for 8 h. After cooling to room 
temperature, the contents of the tube were diluted with Et20 (25 mL) and washed with 
H2O (25 mL). The organic phase was dried (Na2S04), filtered and concentrated in vacuo 
to afford a yellow oil. The desired cross-coupled product was isolated by silica gel 
chromatography. 
O f 
Methyl frans-4-Fluorocinnamate (219a) 
£T* 
O 
OMe 
Chromatographic purification by hexanes:EtOAc (8:2) (Rf = 0.3). 219a (154 mg, 85%) 
was isolated as a clear, colorless crystalline solids: m.p. = 48-49 °C (CHCI3); 'H NMR 
(CDCI3, 300 MHz) 5 7.61 (1H, d, J= 16.0 Hz), 7.49 - 7.39 (2H, m), 7.07 - 6.95 (2H, m), 
6.32 (1H, d, J= 16.0 Hz), 3.75 (3H, s); ,3C NMR (CDC13, 75 MHz) 8 166.24 (d, J = 126 
Hz), 162.08, 143.34, 130.48, 129.79 (d, J = 8.5 Hz), 117.40, 115.86 (d , J= 22 Hz), 51.51. 
Methyl frans-Cinnamate (219b)86 
O 
I l l 
Chromatographic purification by hexanes:EtOAc (8:2) (Rf = 0.25). 219b (126 mg, 78%) 
isolated as a clear, colorless crystalline solid: m.p. = 37-38 °C (CHC13); *H NMR (CDC13, 
300 MHz) 8 7.68 (1H, A, J = 16.0 Hz), 7.52 - 7.44 (2H, m), 7.39 - 7.30 (3H, m), 6.43 
(1H, d, J= 16.0 Hz), 3.78 (3H, s); 13C NMR (CDC13, 75 MHz) 8 167.33, 144.79, 134.32, 
130.22, 128.82, 128.00, 117.74, 51.60. 
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Chapter 3 Diastereoselective Allylation and Crotylation of N-
unsubstituted Imines Derived from Ketones 
3.1 Introduction 
Homoallylic amines have attracted significant attention from the scientific 
community over the last decade.1 In fact, numerous biologically active compounds 
contain the homoallylic amine subunit (Figure 3.1). For example, anticancer agent 
eponemycin (222) has shown significant activity against B16 melanoma cells. In 
addition, cryptophycin 337 (223) is an analogue of a potent anti-tumor compound 
cryptophycin (224), which is produced by cyanobacteria species of the genus Nostoc 
(Figure 3.1). 
Figure 3.1 Biologically Active Compounds Containing a Homoallylic Amine 
Subunit 
cryptophycin 337 cryptophycin 
223 224 
Crytophycins are the most active stabilizers of microtubule dynamics, and are 
known for depolymerising microtubules at higher concentrations. They also deactivate 
the Bcl2 protein and produce apoptotic response faster at considerably lower 
concentrations than clinically utilized compounds. " In fact, Cryptophycin is currently in 
phase 1 clinical trials, and the design, synthesis and SAR study of novel analogues of 223 
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and 224 are also of great interest. In addition, scientists have already been studying 
derivatives of cryptophycin and many of them are currently under clinical investigations.2 
3.1.1 Synthetic Utility of Homoallylic Amines 
Homoallylic amines are particularly important since they are excellent synthons 
for the synthesis of several nitrogen containing derivatives found in Nature. For 
example, the alkaloid desoxoprosopinine (226), which is derived from the Prosopis 
Africana plant, was synthesized using advanced homoallylic amine intermediate 225 
(Scheme 3.1).7 
Scheme 3.1 Synthesis of Desoxoprosopinine from an Advanced Homollylic Amine 
Intermediate 
OBn OBn 
225 
HO,,,, 
"n 
f ^ £ f **C12H25 
OH H 
desoxoprosopinine 
226 
Another example comes from the synthesis of vancomycin (227) from an 
aminosugar intermediate 230, which in turn is synthesized from homoallylic amine 229 
(Scheme 3.2).8 
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Scheme 3.2 Synthesis of Vancomycin from a Homoallylic Amine Subunit 
Me HO p H 
u ^ /~°\ / \ OH 
HO""Y V-O" ' 
HOOC 
vancomycin 
227 
O 
Me 
OR 
R=iPr3Si 
228 
OEt 
^ 227 
vancomycin 
homoallylic amine 
229 
Yet another example of the synthetic utility of homoallylic amines is shown in the 
synthesis of the spirocyclic alkaloid halichlorine (232). 232 was prepared from advanced 
homoallylic intermediate (231) as shown in Scheme 3.3.9 
Scheme 3.3 Synthesis of halichlorine using homoallylic amine 
^SMe 
H2N" "C02H H,N 
OBn 
homoallylic amine 
231 
CI OH 
halichlorine 
232 
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Piperidine alkaloids are an important class of alkaloids. For example, several 
piperidine alkaloids have been isolated from Sedum and other species, and have shown 
biological activity in the treatment of cognitive disorders, specifically piperidine alkaloid 
(234) has been synthesized from homoallyic amine (233) after a series of transformations. 
(Scheme 3.4).10 
Scheme 3.4 Synthetic Approach to Piperidine Alkaloids from Homoallylic Amines 
homoallylic amine 
233 234 
The synthetic utility of homoallylic amines is not restricted to natural product 
synthesis. Homoallylic amines can also be easily converted into many different 
functional groups such as P-and y-amino acids, y-lactams, amino alcohols, and y-amino 
alcohols." Enantiomerically pure p-amino alcohols play a significant roles in both the 
treatment of a wide variety of human disorders, and as chiral auxiliaries in organic 
synthesis. For example, P-peptide based antibiotics have been investigated as alternative 
drugs designed to avoid antibiotic resistance since P-peptides, in general, do not appear 
in nature (e.g. P-alanine is the only naturally occurring p-amino acid). Scheme 3.5 
summarizes the various synthetic applications of homoallylic amines. 
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Scheme 3.5 Synthetic Applications of Homoallylic Amines 
C02Et 
FT " N ' 
H 
pyridine derivative 
natural products 
e.g. pinnaic acid 
J3- amino acids 
2-allylpyrrolidine 
ex- amino acids 
3.1.2 Synthesis of homoallylic amines 
The primary literature reveals a plethora of methods for the synthesis of 
homoallylic amines. Among these possible alternatives, the addition of allyl 
organometallics to N-substituted imines is the most commonly used approach.12 
However, the majority of research in this area has focused on the addition of these 
organometallics to aldimines. Specifically, the nuleophilic addition of organometallic 
allyl reagents derived from numerous elements such as Sn, Zn, Si, Mg, Sm, Li, Ce, Cr or 
B to an N-substitued imine derived from aldehyde affords the desired homoallylic amines 
(Equation 3.1). 
N' R 2 
R 1 ^ H 
IVU 
M= Sn, Zn, Mg, Si, 
Sm, Li, , Ce, CrorB 
Equation 3.1 
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The main disadvantage in the use of allyl magnesium (M=Mg) or lithium (M=Li) 
reagents is that they easily deprotonate at the a-proton in non-branched (enolizable) 
imines due to their strongly basic nature. Consequently, less basic allyltin reagents are 
widely used as organoallyl reagents for the synthesis of homoallylic amines.13"16 If 
needed, the nitrogen substituent in the resulting homoallylic amines can be removed by 
various different methods to afford the corresponding primary amine.13"16 
It is recognized that aldehydes are more reactive towards organometallic 
nucleophiles, such as allyl Grignard and allyllithium reagents, than the corresponding 
1 7 
imines. Therefore, when imines are employed as substrates, Lewis acids such as TiCU 
and BF3OEt2 have typically been used to increase the electrophilicity of the imine. Keck 
and Enholm have reported the use of both TiCU and BF3'OEt2 catalyzed allylation and 
crotylation of the imine derived from aldehyde and benzylamine in toluene.17 The 
chemical yields obtained were moderate to good (48-84%) for the addition of both 
crotyltri-n-butylstannane and allyltri-n-butylstannane (Equation 3.3 and 3.2 
respectively). A 3:1 ratio of the syn:anti diastereomers was obtained for the addition of 
crotyltri-n-butylstannane (Equation 3.3). 
N^Ph HN^Ph 
H ^^SnBu 3 ( f ^ T ^ ^ ^ Equation 3.2 
Lewis acid \ s s ^ 
yield: 53-73% 
yield: 85%, d.r.=3:1 
The disadvantage of using pre-formed imines is that the synthesis of the 
aforementioned can be quite cumbersome, especially for aldehydes containing a-protons. 
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Furthermore, such imines will readily hydrolyze in the presence of water and their 
isolation/purification can be difficult. Therefore, imines are often generated in situ from 
an aldehyde and amine, and further treated with the appropriate allyl reagent. In these 
situations, water sensitive Lewis acids cannot be used as water is formed during the 
condensation step. Lanthanide triflates, however, are unique Lewis acids that are stable 
in water and can catalyze many useful synthetic reactions.1 Thus, Kobayashi and co-
workers have reported the Sc(OTf)3-catalyzed three-component reactions of an aldehyde, 
primary amine and allyltributylstannane in micellar systems.19 The results of these 
studies are summarized in Equation 3.4. 
9 Sc(OTf)3 (0.2 equiv.) 
, i ^ u + R2"NH2+ . ^ ^ S n B u 3 R 1 ^ H * K - N H 2 + ^ ^ o „ D u 3 SDS (0.2 equiv.) R 1 ^ ^ ^ . Equation 3.4 
H20, rt, 20 h 
R
„
= A r
 Yield: 67-90% 
R-aryl, a, p-unsaturated cycloalkyl 
In a further extension, Yamamoto and co-workers used a Pd(II) catalyst for the 
enantioselective synthesis of homoallylic amines. They reported that chiral homoallylic 
imines can be synthesized by reaction of allylstannanes with imines using Pd(II) catalyst 
as shown in Equation 3.5. In this case, the researchers found that imines has been 
allylated chemoselectively by the formation n-allylpalladium chloride dimer catalyst 
complex (235) as shown in Scheme 3.6.20 
R ^ 1 
R l - ^Y^SnBu 3 N- 4 PdCI2(PPh3)2 ^ Kz^K^> Equation 3.5 
R3 ^ THF
 4.NH R2 
R4 
72-98% 
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Scheme 3.6 Reaction Mechanism of the Allylation Reaction Catalyzed by Pd(II) 
Catalyst .20 
"SnBu3 + PdCI2(PPh3)2 
1 
Ph3P CI 
| | + Bu3SnCI 
<-Pd + PPh3 
PPh3 
235 
^ - — SnBu3 Bu3SnCI 
rPd^)+ 2PPh3 ^ (-Pd + PPh3 
PPh3 
Copper catalysis has also been used to promote allylation of imines. Phukan and 
colleagues have described the Cul-catalyzed three component reaction for the synthesis 
of homoallylic amines as shown in Equation 3.6. In this process the imine was 
generated in situ. Both electron-donating and electron-withdrawing functional groups on 
the phenyl ring were investigated. The chemical yields observed were good for most of 
the substrates examined. The advantage of this process is that unlike lanthanide triflates, 
Cul is a much more economical catalyst. 
o 
fT^lf H [ f ^ ^ N 1 ^ ^ -^s^SnBua Cul (0.15 mmol) rj 
A ^ Kj?
 D M F , rt, 24 h • ' 
Equation 3.6 
yield: 55-88% 
3.1.3 Stereoselective Allylation of Imines 
Enantioselective addition of allyl organometallics to N-substituted aldimines is a 
known procedure for the synthesis of chiral homoallylic amines. The synthesis of chiral 
homoallylic amines (i.e. diastereoselective approach) is generally achieved by substrate-
control. The reagent controlled enantioselective achiral amines have only recently been 
investigated. For example, Yamamoto and co-workers were the first to demonstrate 
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diastereoselective allylation of an imine by allyl organometallic reagents in the presence 
of a Lewis acid. 22 
More recently, Schaus and co-workers reported the use of BINOL-derived 
catalysts for enantioselective allylboration of JV-acyl aldimines. Various BINOL 
ligands were examined and the ligand 238 afforded the best results. Using n B NMR, the 
authors showed that the reaction proceeds via ligand exchange by the BINOL ligand. In 
the presence of an electrophilic imine 237, the ligand exchange between the BINOL 
ligand 239 and allylboronate 236 was accelerated to form the complex 239. The results 
from these investigations are shown in Equation 3.7. 
O-iPr 
'
B
^0-iPr 
236 
1 
R- H 
237 
Rn = aryl, alkyl 
R2 = aryl, alkyl 
238 
15mol% 
3AMS 
Toluene, rt 
239 
yield: 80-94% 
e.r. > 95:5 
Equation 3.7 
3.1.3.1 Diastereoselective allylation of imines 
Scott E. Schaus and co-workers have used their strategy outlined above to 
synthesize Maraviroc (242), a CCR5 entry inhibitor as an anti-HIV drug. Imine 240 was 
treated with allylboronate and BINOL ligand 238 to give the homoallylic amide 241 in 
75% chemical yield and good enantioselectivity (e.r. = 95.5:4.5). Subsequent oxidation 
of the alkene produced a terminal aldehyde, and subsequent reductive amination afforded 
Maraviroc (242) as shown in Scheme 3.7. 
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Scheme 3.7 Synthesis of Maraviroc 242 via Asymmetric Allylation of 
Difluorocyclohexane Carboximide Imine 240 
O-iPr 
^ - • V i P r 
238, 15mol% 
! 
3AMS 
Toluene, rt 
240 
. ^ N ^ N 
Maraviroc 
242 
Itsuno and colleagues have also demonstrated substrate controlled 
diastereoselective allylation using N-chiral imine 243.24 Their study revealed that 
prenylzinc reagents afford homoallylic amines 244 with (S,S) stereoconfiguration while 
allylboron reagents afford the corresponding (i?,5)-homallylic amines 245. The chiral 
imines were synthesized via the condensation of the chiral auxiliary (5)-valine methyl 
ester with benzaldehyde as shown in Scheme 3.8. The stereochemical outcome was 
rationalized by the transition stepts shown in Figure 3.2. 
Scheme 3.8 Diastereoselective Allylation of Amines Using Different Allylmetal Species 
(S,S) 
244 
Zn powder 
CeCI3-7H20 
THF, 25 °C 
MeOoC N 
* • 1 1 
( ^ B 
Phr H 
243 
BF3-OEt2 
THF, 0 °C 
Me02C NH 
(S,R) 
245 
Figure 3.2 Proposed Transition States in the Synthesis of Homoallylic Amines by Itsuno 
etal. 
Ph 
Br. 
246 
Vc7/ 
n ~N H 
MeO J 
247 
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In other studies, Ellman and co-workers have used Af-ter/-butanesulfinylimines 
(248) for substrate controlled allylation by taking advantage of the enhanced stability of 
these imines.25 The sulfinyl group also activates the imine, and the configurationally 
stable sulfur stereocenter enables diastereofacial selectivity in a subsequent nucleophilic 
addition reaction. Moreover, the sulfinyl group is readily removed by brief treatment 
with acid. The requisite imines (248) are easily synthesized from readily available N-
tert-butanesulfinamide and the appropriate aldehyde or ketone. 
Scheme 3.9 Diastereoselective Allylation to N-tert-butanesulfinyl Imines in Two 
Different Systems 
NH 
^ 
Zn powder
 R ^ ^ / ^ s . Z n powder 
ln(OTf)3 HMPA 
THF, 25 °C H20,25 °C (S-R) 
248 250 
The addition of allylzinc and allylindium to chiral TV-terf-butanesulfinyl imines 
248 is proposed to proceed via a six-membered chair-like transition state (Figure 3.3). 
Three different transition states have been proposed. In transition state 251 the R group 
of the imine assumes a pseudoaxial position as the allylmetal coordinates to the sulfinyl 
oxygen. The 57-face addition will be favoured to yield the (5)-amine as the major product 
when (i?)-Ar-tert-butanesulfinyl imine is used. In transition state 252, the (R)- allylamine 
product would be formed as the allyl nucleophile addition occurs through the less-
hindered i?e-face of the imine. Acyclic transition state 253 would be expected to 
predominate in the presence of a strong Lewis acid. Coordination of the Lewis acid with 
the sulfinyl oxygen and nitrogen in the imine would lead the allyl nucleophile to attack 
predominately from the £7-face to provide the (S)-amine. Transition state 251 and 253 
both gave equally the same result at room temperature. 
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Figure 3.3 Three Probable Transition States in the Allylation of N-tert-Butanesulfinyl 
Imines 
M R - S I V I - — • - - , 
x s 
Transition State 1 Transition State 2 Transition State 3 
251 252 253 
3.1.3.2 Enantioselective allylations of imines 
Shinichi Itsuno and co-workers have also examined the utility of chirally modified 
allylboron reagents 254-257.26 The imines used in the reaction were prepared via partial 
reduction of nitrile with either boranes or borohydrides. Partial reduction of nitriles with 
BH3 and subsequent addition of allylboron reagents afforded the product, however, with 
poor yields. Fortunately, the partial reduction of nitriles with Super-Hydride (LiEt/sBH) 
followed by the addition of allylboron reagents was a much more effective protocol. 
Figure 3.4 Different Types of Allylboron Reagents for Asymmetric Allylboration 
^ - ^ Y V T >^ 
Ts 
Brown's reagent 
254 255 256 257 
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Scheme 3.10 Asymmetric Allylboration of N-silylimines using Chiral Reagent 254 
LiEt3BH 
Ar-CSN THF, 0 °C 
1 h 
N A 
„BEt3Li 
A r H 
254 
THF, 5 h 
rt 258 
-78 °C: 63%,82% ee, 
0°C:61%,82%ee 
RT:71%, 81%ee 
Various nitriles were subjected to the above synthetic strategy. In the case of an 
aliphatic nitrile (V-Bu), the chemical conversion and enantiomeric excess were very poor. 
On the other hand, the use of aromatic nitriles resulted in adequate chemical yields and 
stereoselectivity. Hoffmann's reagent 259 has also been used for the enantioselective 
synthesis of homoallylic amines. Kobayashi's group examined the use of reagent 259 but 
the found ee of 258 was very poor (Equation 3.8).28 
Ph 
O 
J 
Equation 3.8 
Brown et al. have also reported stereoselective allylation of JV-silyl or N-
aluminoimines using reagent 254 (Scheme 3.II).27 The Af-aluminoimines were 
synthesized via reduction of aromatic nitriles using DIBAL-H. Af-silylimines on the other 
hand were synthesized via the reaction of aromatic aldehyde and LiHMDS. Interestingly, 
one full equivalent of water or methanol was used in each reaction. With the inclusion of 
water, the homoallylic amines were isolated in improved yields, higher 
enantioselectivities, and shortened reaction times. It is believed that water removes the 
silyl/aluminyl group on the nitrogen atom (i.e. remove the Al(iBu)2 or SiMe3 substituents) 
to produce the N-unsubstituted imine, which is then believed to react quickly with chiral 
reagent (254). 
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Scheme 3.11 Asymmetric Allylboration of Aldimines with Chiral Reagent 254 in the 
Presence of 1.0 Equivalent of Water 
Ar -CEN 
J 
DIBAL-H 
THF, 0° C 
1 h 
|| LiN(SiMe3)2 
P h
 Et02, -50° C 
1 h 
N,AI(/Bu)2 
A r ^ H 
254 
H20 LOequiv 
THF, -78° C 1 h 
N ' H 
A r ^ H 
N 
SiMe-, 
Ar H 
254 
258 
60-80%, 
ee = 81-92% 
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3.2 Results and Discussion 
The majority of the above discussion has focused on the research of the addition of 
allyl organometallics to imines derived from aldehydes. Until recently, the growth of the 
substrate scope to include imines derived from ketones has received limited 
consideration29,30 
Scheme 3.12 Diastereoselective Allylation and Crotylation of in situ Generated 
Ketimines 
O 
R 1 ^ R 2 
NH, 
MeOH, rt 
NH 
R1"^R2 
260 
R\ M 
261 
As part of a separate total synthesis project, a tertiary carbinamine (262) was 
required. We anticipated that 262 could be synthesized through crotylation of an N-
unsubstituted ketimine 260—a previously unknown reaction. As this work was 
progressing, Kobayashi and co-workers described the use of ammonia in the direct 
synthesis of homoallylic amines (Equation 3.9).31 Three-component reactions of 
aldehydes, ammonia, and allylboronates, were found to afford primary homoallylic 
amines in high chemo selectivities and good yields. 
O 
R ^ H 
+ NH3 + Equation 3.9 
69-92% 0-12% 
Inspired by the elegant report of aminoallylation of aldehydes, the development of 
a robust methodology for the diastereoselective allylation and crotylation of N-
unsubstituted imines derived from ketones was investigated (Scheme 3.12). After a brief 
survey of a number of methods to synthesize and isolate the requisite substrate 260, it 
was concluded that a three-component reaction of the ketone, excess ammonia and the 
allyl organometallic (261) was the most efficient and effective protocol to generate the 
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desired homoallylic amines. As one of the most ubiquitous and inexpensive nitrogen 
sources, ammonia plays a critical role in the chemical reaction. The condensation of 
ammonia with the carbonyl group allows for the incorporation of nitrogen into the 
substrate thereby making the process economically attractive. Thus, ketimine (260) is 
formed by reacting the appropriate ketone with excess ammonia. We suggest that N-
unsubstituted ketimine (260) is formed in situ prior to its reaction with the 
allylorganometallic but this hypothesis needs further detailed validation. 
A series of allyl organometallics were screened for addition to the in situ 
generated ketimine (260) (R1=4-BrC6H4, R2=Me). The allylboron class of reagents were 
noticeably superior in terms of reactivity and chemoselectivity.32'34 A more detailed 
investigation of a range of allylboron compounds was undertaken in order to determine 
the reagent of choice. 
Table 3.1 Addition of Allylboron Reagents to N-Unsubstituted Ketimines 
H2N Me 
NH3 (ca. 10equiv.) 
MeOH, rt, 16 h 263 
Entry 
Allylboron 
Reagent 
Number Yield of 263 (%) 
3 
4 
^ \ ^ B ( O H ) 2 
264 
265 
266 
267 
268 
35 
29 
43 
70 
79 
137 
As anticipated, the more reactive allylboron reagents, 267 and 268 displayed the 
highest efficacy in terms of isolated yields of homoallylic amine 263 ( Table 3.1, entries 4 
and 5). A major issue of concern in all these reactions—chemoselectivity of imine versus 
ketone addition—was addressed by analyzing the organic extracts from the acid-base 
workup of 263 (entries 4,5). It was determined that the corresponding homoallylic 
alcohol of (263) was formed in minor amounts (<5%). It was decided to continue the 
studies with allylboronic acid 268 due to its ease of preparation and the simple 
purification of the resulting products. 4 A series of ketones were then reacted with 
reagent 268 in methanolic ammonia (Table 3.2). Aliphatic (Table 3.2, entries 1-4), 
electron rich aromatic (entry 5), electron deficient aromatic (entries 6 and 7), unsaturated 
(entry 8), cyclic (entries 9 and 10) and heterocyclic substituted (entries 11 and 12) 
ketones were successfully allylated under the standard conditions. The resulting 
homoallylic amines 269 were easily isolated in high yields through simple acid-base 
extraction, and in all cases but one, did not require any further purification. 
Table 3.2 Addition of Allylboronic acid to N-Unsubstituted Ketimines 
^ ^ B ( O H ) 2 268 
(1.6equiv.) H2N R2 
•
 R 1 ^ ^ . 
NH3 (ca. 10 equiv.) 
MeOH, rt, 16 h 2 6 9 
Entry 
1 
2 
3 
Ketone 
0 
0 
H
° N A 
"•JL 
Product 
HlH\C 
H2N ^ 
H2N /—y 
^ ^ Ph 
Yield (%) 
73 (269a) 
80(269b) 
78 (269c) 
o 
R 1 ^ R 2 
138 
4 
5 
6 
7 
8 
9 
10 
11 
12 
0 
0 2 N ^ 
o 
o 
Bn-N \ = 0 
0 
o 
H 
H 2 N ^ — " 
H 2 N ^ 
H 2 N ^ — 
H 2 N ^ 
0 2 N ^ ^ 
H2N y—" 
Ph/^X 
H 2 N ^ / 
CA3 
/—\ NH2 Bn-N K . 
H2N ^ 
H2N / ' 
H 
85 (269d) 
72 (269e) 
80 (269f) 
87 (269g) 
70 (269h) 
78 (269i) 
92 (269j) 
75(269k) 
80 (2691) 
A variety of functional groups are tolerated in the reaction sequence including the 
nitro (entry 7), cyano (entry 6), unprotected hydroxy (entry 2) and amino groups (entry 
12). However, it was not possible to extend the substrate scope to include ketones that 
are either sterically hindered (e.g. pinacolone) or contain active methylene groups (e.g. 
ethyl acetoacetate) under the current conditions. 
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The next step was to investigate the allylation of ketones containing a pre-existing 
stereocenter. The substrates were subject to the standard set of reaction and work-up 
conditions, the results of which are shown in Table 3.3. Good to excellent yields of the 
resulting tertiary carbinamines (269m-p) were obtained while the observed 
diastereoselectivities, as determined by *H NMR spectroscopy, varied from modest for 
the reaction of 4-tert-butylcyclohexanone (269m), norcamphor (269n), and benzoin 
(269o), respectively to excellent for verbenone (269p).35 
Table 3.3 Addition of Allylboronic acid to Ketones Containing Pre-existing 
Stereocenters in the Presence of Methanolic Ammonia 
Furthermore, crotylation of a select number of ketones was examined under a 
slightly modified set of conditions (2.0 equiv. of 268, 10 equiv. of NH3, rt, 24 h) (Table 
3.4). Excellent diastereoselectivities (d.r. > 96:4) were obtained with acetophenone 
derivatives (Table 3.4, entries 1-6). 
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Table 3.4 Addition of Crotylboronic acid to N-unsubstituted Ketimines in the Presence 
of Methanolic Ammonia 
O 
R 1 ^ R 2 
R 3 \ ^ ^ B ( O H ) 2 
R4 (2.0 equiv.) 
270a: R3 =Me, R4 =H 
270b: R3 =H, R4 = Me 
• 
NH3 (ca. 10 equiv.) 
MeOH, rt 
H,N R2 n2 
R1 
R3 R4 
262 
Entry Ketone 
Crotyl 
reagent 
Reaction 
time (h) 
Product 
Yield 
(%) 
FSC 
H2N c 
CH, 270a 24 
F,C 
80 
(262a) 
F,C 
H2N ^ 
CH-, 270b 24 
F,C 
73 
(262b) 
FSC 
H2N CONH2 
CONH2 270a 24 
95 
(262c) 
F,C 
H2N CONH, 
CONH2 270b 24 
92 
(262d) 
O H2N c 
CH, 270a 24 
50 
(262e) 
O x 
H3C CONH2 
270a 24 
H2N CONH2 88 
(262f) 
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The anti diastereomer (262a/c) was formed when (E)-crotylboronic acid (270a) 
was employed as the reagent, while (Z)-crotylboronic acid (270b) afforded the syn 
diastereomer (262b/d). The stereochemistry of the crotylated products (262) were 
assigned based upon the reaction of crotyl reagent (270a) with acetophenone (entry 5) 
which afforded the previously known anti diastereomer (262e) in moderate yield and 
excellent diastereoselectivity (d.r. = 97:3). Crotylation of methylpyruvate (entry 6), on 
the other hand, was not diastereoselective likely due to the similar steric sizes of the 
methyl and methylformate groups. The results from entries 3, 4 and 6 also constitute a 
convenient route to a-allylated amino acid derivatives. 
142 
3.3 Conclusion and Future Work 
In summary, an easily executable three component methodology for allylation of 
N-unsubstituted imines derived from a diverse range of ketones has been presented. The 
resulting homoallylic amines were isolated in good to excellent yields through simple 
acid-base extraction. More importantly, the crotylation of N-unsubstituted ketimines was 
also shown to be highly diastereoselective. We are currently striving to ameliorate the 
described methodology by expanding the substrate scope and developing enantioselective 
variants. 
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3.4 Experimental procedures and characterization data 
General considerations are the same as chapter 1 except all ketones in liquid form were 
distilled prior to use. All ketones in solid form were used as received. MeOH was dried 
over magnesium methoxide and distilled prior to use. 2 M solutions of allyl, (E)- and 
(Z)-crotylboronic acid in anhydrous MeOH were prepared just prior to use (exact 
molarities were confirmed by titration with benzaldehyde). 
3.4.1 General procedure for allylation of N-unsubstituted imines derived from 
ketones (Table 3.2, Table 3.3) 
To the ketone (0.5 mmol) was added a solution of ammonia in methanol {ca. 7M in 
MeOH, 0.75 mL, ca. 10 equiv.). The resulting solution was stirred for 15 min at rt. A 
freshly prepared solution of allylboronic acid (2M in MeOH, 0.4 ml, 0.8 mmol) was then 
added dropwise over 5 min. The reaction mixture was subsequently stirred for 16 h at rt. 
All volatiles were removed in vacuo and the residue re-dissolved in Et^ O (15 mL). The 
desired amine was then extracted with IN HC1 (15 ml). The acidic aqueous extract was 
washed with Et20 (3 x 15 mL). The aqueous extract was next made alkaline by addition 
of solid NaOH (ca. 5 g). The alkaline aqueous layer was then extracted with 
dichloromethane (3 x 15 mL). The combined organic extracts were dried (Na2S04), 
filtered and concentrated in vacuo to afford the desired amine. 
3.4.2 General procedure for crotylation of N-unsubstituted imines derived from 
ketones(Table 3.4) 
As above, except a freshly prepared solution of either (£)- or (Z)-crotylboronic acid 
(270a or 270b) (2M in MeOH, 0.5 mL, 1.00 mmol) was used. 
l-(4-Bromophenyl)-l-methy!but-3-enylamine(263) 
Me NH2 
263 isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 5 7.44 (2H, d,J= 8.5 
Hz), 7.35 (2H, d, J= 8.5 Hz), 5.55 (1H, dddd, J= 18.0, 9.5, 8.0, 7.0 Hz), 5.09-5.04 (2H, 
m), 2.53(1 H, dd, J = 13.5, 7.0 Hz), 2.38 (1H, dd, J= 13.5, 8.0 Hz), 1.49 (2H, br s), 1.44 
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(3H, s); 13C NMR(CDC13, 125 MHz) 5 147.79, 133.89, 131.14, 127.26, 120.12, 118.81, 
54.45, 49.64, 30.93; IR (film) u 3423, 1638 cm"1; HRMS (CI) m/z calcd. for CnHi5BrN 
(MH+) 240.0388, found 240.0395. 
l,l-Diethylbut-3-enylamine(269a) 
269a (73%) isolated as a clear, colorless oil: *H NMR (CDC13, 300 MHz) 5 5.77 (1H, ddt, 
J= 16.0, 11.0, 7.5 Hz)), 5.04 (1H, d, J= 11.0 Hz), 5.03 (1H, d, J= 16.0 Hz), 2.03 (2H, d, 
J = 7.5 Hz), 1.32 (4H, q, J= 7.5 Hz), 1.18 (2H, br s), 0.81 (6H, t, J= 7.5 Hz); 13C NMR 
(CDCI3, 75 MHz) 5 134.44, 117.69, 53.36, 43.85, 31.66, 7.70; IR (film) v 3420, 1636 cm 
'; HRMS (ESI) m/z calcd. for C8Hi8N (MH+) 128.1439, found 128.1444. 
2-Amino-2-methylpent-4-en-l-ol (269b) 
269b (80%) isolated as a clear, colorless oil: !H NMR (CDCI3, 300 MHz) 5 5.79 (1H, 
ddt, J= 16.5, 10.5, 7.5 Hz), 5.12 - 5.01 (2H, m), 3.30 (1H, d, J= 10.5 Hz), 3.25 (1H, d, J 
= 10.5 Hz), 2.45 (3H, br s), 2.11 (2H, d, J= 7.5 Hz), 1.01 (3H, s); 13C NMR (CDC13, 75 
MHz) 5 133.77, 118.51, 68.07, 52.70, 44.28, 24.53; IR (film) u 3345, 3157, 1639 cm"1; 
HRMS (CI) m/z calcd. for C6H,4NO (MH+) 116.1075, found 116.1072. 
l-Benzyl-l-phenylbut-3-enylamine (269c) 
269c (78%) isolated as a clear, colorless oil: [H NMR (CDC13, 300 MHz) 5 7.38 - 7.08 
(8H, m), 6.90 - 6.84 (2H, m), 5.53 (1H, dddd, J= 17.0, 10.0, 8.5, 5.5 Hz), 5.15 - 5.00 
(2H, m), 3.12 (1H, d, J= 13.0 Hz), 2.97 (1H, d, J= 13.0 Hz), 2.86 (1H, dd, J= 13.5, 5.5 
Hz), 2.44 (1H, dd, / = 13.5, 8.5 Hz), 1.50 (2H, br s); 13C NMR (CDC13, 75 MHz) 5 
146.52, 137.09, 134.08, 130.68, 128.07, 127.86, 126.46, 126.30, 126.19, 118.81, 57.97, 
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50.54, 47.62; IR (film) \> 3401, 1677 cm"1; HRMS (ESI) m/z calcd. for Ci7H20N (MH+) 
238.1596, found 238.1585. 
l-Methyl-l-(3-methylbutyl)but-3-enylamine(269d) 
Me NH2 
269d (85%) isolated as a clear, colorless oil: 'H NMR (CDC13, 300 MHz) 8 5.74 (1H, 
ddt, J = 17.0, 10.0, 7.5 Hz), 5.05 - 4.93 (2H, m), 2.00 (2H, d, J = 7.5 Hz), 1.40 (1H, 
septet, J = 6.5 Hz), 1.29 - 1.20 (2H, m), 1.19 - 1.03 (4H, m), 0.95 (3H, s), 0.80 (6H, d, J 
= 6.5 Hz); 13C NMR (CDC13, 75 MHz) 5 134.50, 117.77, 51.14, 47.15, 40.36, 32.82, 
28.45, 27.71, 22.53; IR (film) u 3385, 1636 cm1; HRMS (ESI) m/z calcd. for C10H22N 
(MH+) 156.1752, found 156.1745. 
l-Ethyl-l-(4-Methoxyphenyl)but-3-enylamine(269e) 
Et NH? 
269e (72%) isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 5 7.31 (2H, d, J 
= 9.0 Hz), 6.86 (2H, d, J= 9.0 Hz), 5.53 (1H, dddd, J= 17.5, 10.0, 8.5, 6.0 Hz), 5.06 (1H, 
d, J= 17.5 Hz), 5.03 (1H, d, J= 10.0 Hz), 3.80 (3H, s), 2.59 (1H, dd, J= 13.5, 6.0 Hz), 
2.36 (1H, dd, J= 13.5, 8.5 Hz), 1.85 (1H, dq, J= 14.0, 7.5 Hz), 1.66 (1H, dq, J= 14.0, 
7.5 Hz), 1.52 (2H, br s), 0.71 (3H, t, J= 7.5 Hz); 13C NMR (CDCI3, 75 MHz) 5 157.72, 
138.66, 134.32, 126.93, 118.34, 113.27, 57.06, 55.16, 48.37, 36.05, 8.04; IR (film) v 
3420, 1638, 1610, 1511, 1248 cm '; HRMS (CI) m/z calcd. for Ci3H20NO (MH+) 
206.1545, found 206.1565. 
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4-(l-Amino-l-methylbut-3-enyl)benzonitrile(269f) 
Me NH2 
269f (80%) isolated as a clear, colorless oil: *H NMR (CDC13, 300 MHz) 8 7.57 (4H, 
apparent s), 5.55 - 5.40 (1H, m), 5.07 - 4.97 (2H, m), 2.51 (1H, dd, J= 13.5, 6.5 Hz), 
2.36 (1H, dd ,J= 13.5, 8.0 Hz), 1.46 (2H, br s), 1.43 (3H, s); 13C NMR (CDC13, 75 MHz) 
8 154.26, 133.32, 131.99, 126.36, 119.37, 119.03, 110.05, 54.94, 49.50, 30.85; IR (film) 
v 3499, 2228, 1639 cm"1; HRMS (CI) m/z calcd. for Ci2H,5N2 (MH+) 187.1235, found 
187.1235. 
l-Methyl-l-(4-nitrophenyI)but-3-enylamine (269g) 
Me NH2 
0?N 
269g (87%) isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 8 8.16 (2H, d, J 
= 9.0 Hz), 7.66 (2H, d, J= 9.0 Hz), 5.53 (1H, dddd, J= 17.0, 10.5, 8.0, 7.0 Hz), 5.07 (1H, 
d, J= 10.5 Hz), 5.06 (1H, d, J= 17.0 Hz), 2.57 (1H, dd, J= 13.5, 7.0 Hz), 2.42 (1H, dd, J 
= 13.5, 8.0 Hz), 1.54 (2H, br s), 1.50 (3H, s); l3C NMR (CDC13, 125 MHz) 8 156.28, 
146.47, 133.13, 126.45, 123.30, 119.43, 55.01, 49.55, 30.92; IR (film) v 3375, 1639, 
1526, 1351 cm"1; HRMS (CI) m/z calcd. for CnHi5N202 (MH+) 207.1134, found 
207.1132. 
1 -Methyl-LE-styrylbut-3-enylamine (269h) 
NH2 
147 
269h (70%) isolated as a clear, colorless oil: *H NMR (CDC13, 300 MHz) 5 7.45 - 7.15 
(5H, m), 6.46 (1H, d,J= 16.0 Hz), 6.28 (1H, d, J= 16.0 Hz), 5.87 - 5.72 (1H, m), 5.18 -
5.05 (2H, m), 2.31 (1H, dd, J= 16.5. 7.5 Hz), 2.23 (1H, dd , J = 16.5, 8.0 Hz), 1.41 (2H, 
br s), 1.27 (3H, s); ); 13C NMR (CDC13, 75 MHz) 5 138.42, 137.22, 133.95, 128.39, 
128.27, 127.06, 126.14, 118.45, 52.96, 48.00, 28.57; IR (film) u 3545, 1638 cm"1; HRMS 
(CI) m/z calcd. for Ci3Hi8N (MH+) 118.1439, found 118.1449. 
9-Allyl-9iy-fluoren-9-ylamine(269i) 
269i (78%) isolated as a clear, colorless oil: 'H NMR (CDC13, 500 MHz) 5 7.66 (2H, d, J 
= 7.5 Hz), 7.51 (2H, d, J= 7.0 Hz), 7.38 - 7.30 (4H, m), 5.57 (1H, ddt, J= 17.0, 10.0, 7.5 
Hz), 5.01 (1H, dd, J= 17.0, 1.5 Hz), 4.96 (1H, d, J= 10.0 Hz), 2.70 (2H, d, J= 7.5 Hz), 
1.81 (2H, br s); l3C NMR (CDC13, 125 MHz) 5 150.86, 139.28, 133.22, 128.00, 127.53, 
123.26, 119.85, 118.60, 64.71, 45.46; IR (film) u 3360, 1640 cm"1; HRMS (ESI) m/z 
calcd. for Ci6H16N (MH+) 222.1283, found 222.1278. 
4-Allyl-l-benzylpiperidin-4-ylamine (269j) 
Bn 
269j (92%) isolated as a clear, colorless oil: !H NMR (CDCI3, 300 MHz) 5 7.32 - 7.15 
(5H, m), 5.81 (1H, ddt, J= 17.0, 10.0, 7.5 Hz), 5.12 - 5.01 (2H, m), 3.48 (2H, s), 2.58 -
2.48 (2H, dq, J= 12.0, 4.0 Hz), 2.30 (2H, dt, J= 11.0, 3.0 Hz), 2.09 (2H, d, J= 7.5 Hz), 
1.61 (2H, ddd, J= 13.0, 10.5, 4.0 Hz), 1.41 - 1.31 (2H, m), 1.08 (2H, br s); 13C NMR 
(CDCI3, 75 MHz) 5 138.43, 133.51, 128.88, 127.95, 126.69, 118.29, 63.08, 49.39, 48.67, 
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47.60, 37.83; IR (film) i) 3422, 1639 cm"1; HRMS (ESI) m/z calcd. for C15H23N2 (MH+) 
231.1861, found 231.1862. 
l-Phenyl-l-thiophen-2-ylbut-3-enylamine (269k) 
269k (75%) isolated as a clear, colorless oil: *H NMR (CDCI3, 500 MHz) 8 7.49 (2H, dt, 
J= 7.5, 1.0 Hz), 7.33 (2H, t, J= 8.0 Hz), 7.27 - 7.17 (2H, m), 6.94 (1H, dd, J = 5.0, 3.5 
Hz), 6.90 (1H, dd, J= 3.5, 1.0 Hz), 5.62 (1H, ddt, / = 17.0, 10.0, 7.0 Hz), 5.19 (1H, d, J = 
17.0, 1.5 Hz), 5.13 (1H, ddd, J= 10.0, 1.5, 1.0 Hz), 3.08 (1H, dd, J= 14.0, 7.0 Hz), 3.01 
(1H, dd, J= 14.0, 7.5 Hz), 2.09 (2H, br s); 13C NMR (CDC13, 75 MHz) 8 154.78, 147.10, 
133.63, 128.15, 126.77, 126.50, 126.01, 124.22, 123.64, 119.55, 59.32,49.15; IR (film) u 
3410, 1639 cm"1; HRMS (CI) m/z calcd. for d4Hi6NS (MH+) 230.1003, found 230.1017. 
l-(l//-Indol-3-yl)-l-methylbut-3-enylamine(2691) 
H2N Me 
CO 
H 
2691 (80%) isolated as a clear, colorless oil: *H NMR (CDC13, 500 MHz) 8 8.03 (1H, br 
s), 7.84 (1H, d, J= 8.0 Hz), 7.37 (1H, d,J= 8.0 Hz), 7.19 (1H, dt, J= 7.5, 1.0 Hz), 7.12 
(1H, dt, J= 7.5, 1.0 Hz), 7.07 (1H, d, J = 2.5 Hz), 5.65 (1H, ddt, J= 17.5, 10.0, 7.5 Hz), 
5.06 (1H, d, J= 17.5 Hz), 5.03 (1H, d, J= 10.0 Hz), 2.79 (1H, dd, J= 13.5, 7.5 Hz), 2.63 
(1H, dd, J= 13.5, 7.5 Hz), 1.85 (2H, br s), 1.61 (3H, s); I3C NMR (CDC13, 75 MHz) 5 
137.30, 134.93, 125.20, 124.74, 121.77, 120.91, 120.51, 119.21, 117.92, 111.35, 52.39, 
48.20, 30.00; IR (film) u 3205, 1639 cm '. 
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l-AUyl-4-terf-butylcyclohexylamine (269m) 
269m (95%) isolated as a clear, colorless oil (d.r. = 87:13). The diastereomeric ratio was 
determined by !H NMR of the crude sample. Main diastereomer: !H NMR (CDC13, 300 
MHz) 5 5.83 (1H, ddt, J= 17.0, 10.5, 7.5 Hz), 5.08 - 4.98 (2H, m), 2.02 (2H, d, J= 7.5 
Hz), 1.60 - 1.40 (4H, m), 1.34 - 1.00 (6H, m), 0.90 - 0.83 (1H, m), 0.83 (9H, s); 13C 
NMR (CDCI3, 75 MHz) 5 134.26, 117.87, 50.16, 49.94, 48.11, 38.43, 32.30, 27.50, 
22.42; IR (film) v 3368, 1638 cm '; HRMS (CI) m/z calcd. for Ci3H26N (MH+) 196.2065, 
found 196.2068. The stereochemistry of 6n (axial NH2) was confirmed by converting it 
(allylbromide, 'Pr2NEt, CH2CI2; 49%) to the previously known compound JV-Allyl-1-
Allyl-4-tert-butylcyclohexylamine (axial NHCH2CH=CH).37 
2-AIIyl-bicyclo[2.2.1]hept-2-ylamine (269n) 
NH2 
269n (91%) isolated as a clear, colorless oil (d.r. = 94:6). The diastereomeric ratio was 
determined by *H NMR of the crude sample. Main diastereomer: *H NMR (CDCI3, 300 
MHz) 5 5.78 (1H, ddt, J = 17.0, 10.5, 7.5 Hz), 5.08-4.97 (2H, m), 2.10 (2H, d, J= 7.5 
Hz), 1.88 (1H, d, J= 3.5 Hz), 1.78 (1H, ddt, J= 12.5, 9.0, 3.0 Hz), 1.60 - 1.42 (3H, m), 
1.24 - 1.08 (6H, m), 0.82 (1H, dd, J= 12.5, 3.0 Hz); 13C NMR (CDC13, 75 MHz) 5 
134.57, 117.95, 57.99, 47.41, 46.69, 46.48, 38.30, 37.54, 28.43, 22.92; IR (film) v 3400, 
1638 cm"1; HRMS (CI) m/z calcd. for Ci0H,8N (MH+) 152.1439, found 152.1435. 
2-Amino-l,2-diphenylpent-4-en-l-ol (269o) 
H2N V 
ph>YPh 
OH 
- S 7 \ CM » 
let ,•<:« 
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269o (81%) isolated as a clear, colorless crystalline solid. The diastereomeric ratio (d.r. = 
88:12) was determined by *H NMR of the crude sample. Main diastereomer: m.p. = 85-
86 °C (CH2C12); *H NMR (CDCI3, 300 MHz) 5 7.30 - 7.06 (8H, m), 6.90 - 6.85 (2H, m), 
5.56 - 5.40 (1H, m), 5.12 (1H, d, J = 17.0 Hz), 5.00 (1H, d, J= 10.0 Hz), 4.74 (1H, s), 
2.95 (1H, dd, J= 14.0, 5.5 Hz), 2.65 (1H, dd, J= 14.0, 9.0 Hz), 2.08 (3H, br s); I3C NMR 
(CDCI3, 75 MHz) 8 142.54, 140.02, 133.74, 127.62, 127.42, 127.24, 127.10, 126.71, 
126.50, 118.96, 79.91, 61.70, 43.45; IR (film) v 3422, 1638 cm"1; HRMS (CI) m/z calcd. 
for C17H20NO (MH+) 254.1545, found 254.1543. The stereochemistry of 269o was 
confirmed by X-ray crystallography. 
(15'*,2/?*,5i?*)-2-Allyl-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-ylamine(269p) 
269p (84%) isolated as a clear, colorless oil (d.r. = 97:3). The diastereomeric ratio was 
determined by *H NMR spectrum of the crude sample. *H NMR (CDCI3, 300 MHz) 5 
5.85 (1H, ddt, J = 17.5, 10.5, 7.5 Hz), 5.13 - 5.02 (3H, m), 2.36 (1H, dt, J = 9.0, 5.5 Hz), 
2.20 (1H, dd,J= 13.5, 7.0 Hz), 2.13 ( lH,dd , J= 13.5, 8.0 Hz), 1.98 - 1.88 (2H, m), 1.68 
(3H, d, J= 1.5 Hz), 1.60 - 1.35 (3H, m), 1.33 (3H, s), 1.05 (3H, s); 13C NMR (CDC13, 75 
MHz) 5 143.51, 133.89, 124.42, 118.23, 57.24, 52.84, 47.64, 45.88, 41.87, 33.78, 27.36, 
23.85, 22.77; IR (film) v 3410, 1713, 1681, 1623 cm"1; HRMS (ESI) m/z calcd. for 
C13H22N (MH+) 192.1752, found 192.1756. 
(15'*,25*)-l,2-Dimethyl-l-(4-trifluoromethylphenyl)but-3-enylamine(262a) 
262a (80%) isolated as a clear, colorless oil (d.r. = 97:3). The diastereomeric ratio was 
determined by 'H NMR of the crude sample. 'H NMR (CDC13, 300 MHz) 5 7.60 (2H, d, 
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J= 9.0 Hz), 7.56 (2H, d, J= 9.0 Hz), 5.66 - 5.53 (1H, m), 5.10 - 5.00 (2H, m), 2.53 (1H, 
pentet, J = 7.0 Hz), 1.49 (2H, br s), 1.46 (3H, s), 0.91 (3H, d, J = 7.0 Hz); 13C NMR 
(CDC13, 75 MHz) 8 152.45, 139.63, 128.52 (q, J = 30 Hz), 126.37, 124.79 (q, J = 3.5 
Hz), 124.64 (q, J= 270 Hz), 116.45, 55.96, 48.82, 27.13, 14.30; IR (film) v 3378, 1636 
cm"1; HRMS (ESI) m/z calcd. for C,3Hi7F3N (MH+) 244.1313, found 244.1305. 
(15'*,2^*)-l,2-Dimethyl-l-(4-trifluoromethylphenyl)but-3-enylamine(262b) 
H2N .c-
F3C 
262b (73%) isolated as a clear, colorless oil (d.r. = 96:4). The diastereomeric ratio was 
determined by *H NMR spectrum of the crude sample. *H NMR (CDC13, 300 MHz) 5 
7.56 (4H, apparent s), 5.75 (1H, ddd, J= 18.5, 10.5, 8.0 Hz), 5.13 - 5.03 (2H, m), 2.53 
(1H, pentet, J = 7.5 Hz), 1.58 (2H, br s), 1.43 (3H, s), 0.78 (3H, d, J = 7.5 Hz); 13C NMR 
(CDCI3, 75 MHz) 5 152.10, 139.46, 128.02 (q, J = 30 Hz), 126.23, 125.83 (q, J = 270 
Hz), 124.73 (q, J= 3.5 Hz), 116.34, 55.56, 48.65, 29.51, 14.51; IR (film) v 3390, 1637 
cm '; HRMS (ESI) m/z calcd. for Ci3Hi7F3N (MH+) 244.1313, found 244.1304. 
(2S ,3S )-2-Amino-3-methyl-2-phenylpent-4-enoic acid amide (262c) 
H2N CONH2 
262c (95%) isolated as a clear, colorless, crystalline solid (d.r. = 97:3): m.p = 90 °C 
(CH2CI2); 'H NMR (CDCI3, 300 MHz) 5 7.65 - 7.58 (2H, m), 7.35 - 7.18 (4H, m), 6.20 
(1H, br s), 5.46 (1H, ddd, J= 17.5, 10.0, 6.5 Hz), 5.05 - 4.95 (2H, m), 3.59 (1H, pentet, J 
= 6.5 Hz), 1.59 (2H, br s), 1.08 (3H, d,J= 6.5 Hz); l3C NMR (CDC13, 75 MHz) 5 176.99, 
141.60, 138.23, 128.16, 127.04, 125.64, 116.69, 65.54, 42.58, 12.27; IR (film) v 3441, 
3207, 1710, 1620, 1637 cm"1; HRMS (CI) m/z calcd. for C,2H17N20 (MH+) 205.1341, 
found 205.1332. 
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(2£*,3^*)-2-Amino-3-methyl-2-phenylpent-4-enoic acid amide (262d) 
H2N CONH2 
262d (92%) isolated as a clear, colorless, crystalline solid (d.r. = 96:4): m.p = 136 °C 
(CH2C12); 'H NMR (CDC13, 500 MHz) 5 7.64 - 7.60 (2H, m), 7.35 - 7.24 (4H, m), 6.02 
(1H, ddd, J= 17.5, 10.5, 5.0 Hz), 5.59 (1H, br s), 5.26 (1H, dt, J = 10.5, 1.5 Hz), 5.17 
(1H, dt, J= 17.5, 1.5 Hz), 3.76 - 3.69 (1H, m), 1.63 (2H, br s), 0.73 (3H, d, J= 7.0 Hz); 
13C NMR (CDCI3, 125 MHz) 5 177.15, 141.16, 139.07, 128.24, 127.06, 125.54, 117.21, 
65.47, 41.87, 10.97; IR (film) v 3432, 3170, 1715, 1633 cm"1; HRMS (CI) m/z calcd. for 
Ci2Hi7N20 (MH+) 205.1341, found 205.1337. 
(15*,25*)-l,2-Dimethyl-l-phenylbut-3-enylamine(262e)30a 
262e (50%) isolated as a clear, colorless oil (d.r. = 97:3). The diastereomeric ratio was 
determined by 'H NMR of the crude sample. 'H NMR (CDC13, 300 MHz) 5 7.42 - 7.10 
(4H, m), 5.65 -5.55 (1H, m), 4.96 - 5.02 (2H, m), 2.45 (1H, dq, J= 7.0 Hz), 1.50 (2H, br 
s), 1.38 (3H, s), 0.83 (3H, d, J= 7.0 Hz); 13C NMR (CDC13, 75 MHz) 5 148.22, 140.30, 
127.87, 126.13, 125.79, 115.90,56.81,49.02,26.68, 14.49. 
2-Amino-2,3-dimethylpent-4-enoicacid amide (262f) 
H2N CONH2 
262f (88%) isolated as a clear, colorless oil (d.r. = 60:40). The diastereomeric ratio was 
determined by *H NMR of the crude sample. Main diastereomer: *H NMR (CDCI3, 300 
153 
MHz) 8 7.41 (1H, br s), 5.95 - 5.60 (2H, m), 5.15 - 5.05 (2H, m), 2.81 (1H, pentet, J = 
6.5 Hz), 1.28 (3H, s), 1.26 (2H, br s), 0.99 (3H, d, J = 6.5 Hz); 13C NMR (CDC13, 75 
MHz) 5 180.06, 139.33, 116.28,59.62,43.29,25.10, 11.88; IR (film) u 3444, 3250, 1691, 
1654, 1557 cm '; HRMS (CI) m/z calcd. for C7HI4N20 (MH+) 143.1184, found 143.1186. 
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